GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: April 13, 2004, 09:22:17; Search time 43.6226 Seconds

(without alignments)

2202.208 Million cell updates/sec

Title: US-10-021-121-4

Perfect score: 1850

Sequence: 1 MGPPHSGPGGVRVGALLLLG.....PVYIVQDGPPQSPPNIYYKV 340

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: A Geneseq 29Jan04:*

1: geneseqp1980s:*

2: geneseqp1990s:*

3: geneseqp2000s:*

4: genesegp2001s:*

5: geneseqp2002s:*

6: geneseqp2003as:*

7: genesegp2003bs:*

8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

			8				
]	Result		Query				
	No.	Score	Match	Length	DB	ID	Description
	1	1850	100.0	340	2	AAW31544	Aaw31544 Human cyt
	2	1850	100.0	340	2	AAW33699	Aaw33699 AL-2-shor
	3	1850	100.0	340	2	AAW10637	Aaw10637 NLERK2 li
	4	1850	100.0	340	6	ABU07845	Abu07845 Human eph
	5	1844	99.7	340	2	AAW17081	Aaw17081 EPH famil
	6	1841	99.5	455	2	AAW33698	Aaw33698 AL-2-long
	7	1836	99.2	340	2	AAW46615	Aaw46615 Human tra
	8	1780	96.2	340	6	ABU07846	Abu07846 Mouse eph
	9	637.5	34.5	334	2	AAW00287	Aaw00287 Mouse Eph

10	637.5	34.5	336	2	AAR92742	Aar92742 Murine he
11	635.5	34.4	336	6	ABU07844	Abu07844 Mouse eph
12	632	34.2	346	2	AAR55059	Aar55059 Elk tyros
13	632	34.2	346	2	AAR91930	Aar91930 Human cyt
14	632	34.2	346	2	AAW19249	Aaw19249 Human elk
15	632	34.2	346	2	AAW36055	Aaw36055 Human elk
16	632	34.2	346	2	AAW44323	Aaw44323 Human elk
17	632	34.2	346	6	ABU07841	Abu07841 Human eph
18	632	34.2	346	7	ABU62401	Abu62401 Human elk
19	631	34.1	346	2	AAR82606	Aar82606 Eph trans
20	630.5	34.1	331	2	AAW00288	Aaw00288 Chicken E
21	629.5	34.0	333	2	AAR94655	Aar94655 Ligand fo
22	629.5	34.0	333	2	AAR92743	Aar92743 Human hep
23	629.5	34.0	333	2	AAR89287	Aar89287 Human LER
24	629.5	34.0	333	2	AAW06337	Aaw06337 Full leng
25	629.5	34.0	333	2	AAW11308	Aaw11308 Receptor-
26	629.5	34.0	333	6	ABU07886	Abu07886 Novel hum
27	629.5	34.0	333	7	ADD89059	Add89059 TAT245. 1
28	619.5	33.5	308	2	AAR94656	Aar94656 Ligand fo
29	619.5	33.5	308	2	AAW06334	Aaw06334 Ligand #2
30	613.5	33.2	345	6	ABU07842	Abu07842 Mouse eph
31	492	26.6	89	3	AAY71438	Aay71438 Human eph
32	465	25.1	254	6	ABU07843	Abu07843 Human eph
33	453.5	24.5	658	3	AAY96782	Aay96782 Ephrin-B2
34	452.5	24.5	683	3	AAY96781	Aay96781 Ephrin-B1
35	447	24.2	229	5	AAE24019	Aae24019 Murine ep
36	443	23.9	229	5	AAE24020	Aae24020 Human eph
37	431.5	23.3	195	2	AAW06333	Aaw06333 Ligand #1
38	431.5	23.3	195	2	AAW11307	Aaw11307 Receptor-
39	284.5	15.4	92	4	AAM37671	Aam37671 Peptide #
40	284.5	15.4	92	5	ABG46524	Abg46524 Human pep
41	205.5	11.1	136	4	AAM37534	Aam37534 Peptide #
42	205.5	11.1	136	5	ABG46394	Abg46394 Human pep
43	204	11.0	82	3	AAY71437	Aay71437 Human eph
44	202.5	10.9	106	3	AAB54187	Aab54187 Human pan
45	201	10.9	82	3	AAY71436	Aay71436 Human eph

ALIGNMENTS

```
RESULT 1
AAW31544
    AAW31544 standard; protein; 340 AA.
ID
XX
AC
    AAW31544;
XX
\mathtt{DT}
     14-APR-1998 (first entry)
XX
     Human cytokine Lerk-8.
DE
XX
     Lerk-8; cytokine; human; hek; elk; receptor tyrosine kinase; ligand;
KW
KW
     neurodegenerative disease; wound healing; neovascularisation; diagnosis;
KW
     therapy.
XX
OS
     Homo sapiens.
XX
```

```
Location/Qualifiers
FΗ
     Key
FT
                     1. .27
     Peptide
                     /label= Sig peptide
FT
                     28. .340
FT
    Protein
FT
                     /label= Mat protein
                     28. .224
FT
    Domain
                     /note= "extracellular domain"
FΤ
                     210. .212
FΤ
    Modified-site
                     /note= "N-glycosylated"
FT
                     225. .251
FT
     Domain
                     /note= "transmembrane domain"
FT
FT
     Domain
                     252. .340
                     /note= "cytoplasmic domain"
FT
    Misc-difference 325
FT
                     /note= "residue 325 is Leu in Lerk-8 variant"
FT
XX
    W09736919-A2.
PN
XX
     09-OCT-1997.
PD
XX
                    97WO-US004533.
PF
     19-MAR-1997;
XX
                    96US-00621146.
PR
     21-MAR-1996;
XX
     (IMMV ) IMMUNEX CORP.
PΑ
XX
PΙ
    Cerretti DP;
XX
    WPI: 1997-503043/46.
DR
    N-PSDB; AAT89519.
DR
XX
     New isolated cytokine, Lerk-8 - binds to the hek and elk receptor
PT
     tyrosine kinases, used to develop products for diagnosis and therapy.
PT
XX
     Claim 3; Page 32-33; 37pp; English.
PS
XX
     This protein sequence comprises a novel human cytokine designated Lerk-8.
CC
     The amino acid sequence was deduced from a human foetal brain cDNA clone
CC
     (see AAT89519). Lerk-8 binds to the cell surface receptors hek and elk,
CC
     which are members of the eph/elk family of receptor tyrosine kinases.
CC
     Lerk-8 polypeptides, especially soluble polypeptides comprising amino
CC
     acid residues -27 to 142-197 of the full-length protein, can be expressed
CC
     in transformed host cells. These polypeptides can be used to purify hek
CC
     or elk proteins, and to purify or identify cells that express hek or elk
CC
     on the surface. Such cells can be used in various in vitro studies or in
CC
     vivo procedures, e.g. neural cells expressing elk can be administered to
CC
     a mammal afflicted with a neurodegenerative disorder. The Lerk-8
CC
     polypeptides can also be used to deliver diagnostic or therapeutic agents
CC
     to these cells (e.g. leukaemia cells). The Lerk-8 DNA and polypeptides
CC
     can also be used to: treat disorders mediated by defective or
CC
     insufficient amounts of Lerk-8; to treat disorders such as injury to
CC
     neural tissue or neurologic disease; to promote angiogenesis; and for
CC
     wound healing or stimulating neovascularisation of grafted tissues
CC
XX
     Sequence 340 AA;
SQ
```

100.0%; Score 1850; DB 2; Length 340;

Query Match

```
100.0%; Pred. No. 1.6e-142;
 Best Local Similarity
 Matches 340; Conservative 0; Mismatches 0; Indels
                                                                0:
                                                      0; Gaps
          1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Qу
            1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Db
         61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Qy
           61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Db
        121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
Qv
            121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
Db
        181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Οv
           181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Db
        241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGG 300
Qу
            241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGG 300
Db
        301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qу
            301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Db
RESULT 2
AAW33699
    AAW33699 standard; protein; 340 AA.
XX
AC
    AAW33699;
XX
DT
    30-APR-1998 (first entry)
XX
DΕ
    AL-2-short (AL-2s) protein.
XX
    AL-2s; AL-2; AL-2-short; human; treatment; neurological disorder; tumour;
KW
    rheumatoid arthritis; wound healing; paralysis; angiogenesis; leukaemia;
KW
    psoriasis; Alzheimer's disease; epilepsy.
KW
XX
OS
    Homo sapiens.
XX
                 Location/Qualifiers
FH
    Key
                 1. .26
FΤ
    Peptide
                 /note= "signal peptide"
FT
                 27. .340
FT
    Protein
                 /note= "mature protein"
FT
                 27. .219
FT
    Domain
                 /note= "extracellular domain"
FT
                 220. .245
FT
    Domain
                 /note= "hydrophobic transmembrane domain"
FT
XX
PN
    WO9740153-A1.
XX
PD
    30-OCT-1997.
```

```
XX
ΡF
    17-APR-1997;
                   97WO-US006345.
XX
                   96US-00635130.
    19-APR-1996;
PR
XX
     (GETH ) GENENTECH INC.
PA
XX
PΤ
    Caras IW:
XX
    WPI: 1997-535837/49.
DR
    N-PSDB; AAV06355.
DR
XX
    Human AL-2 neurotrophic factor and related DNA - used to develop products
PT
     for, e.g. treating neurologic disorders, angiogenesis disorders, tumours
PT
    or rheumatoid arthritis or for wound healing.
PT
XX
    Claim 20; Fig 2A-B; 86pp; English.
PS
XX
    This is a AL-2-short (AL-2s) protein. The AL-2 is a novel Eph-related
CC
     tyrosine kinase receptor ligand. AL-2 can be administered to patients in
CC
     whom the nervous system has been damaged by trauma, surgery, stroke,
CC
     ischaemia, infection, metabolic disease, nutritional deficiency,
CC
    malignancy, or toxic agents, to promote the survival or growth of
CC
     neurons. They can be used to treat motoneuron disorders such as
CC
     amyotrophic lateral sclerosis (Lou Gehrig's disease), Bell's palsy, and
CC
     various conditions involving spinal muscular atrophy, or paralysis. AL-2
CC
     can be used to treat human neurodegenerative disorders, such as
CC
     Alzheimer's disease, Parkinson's disease, epilepsy, demyelinating
CC
     diseases such as multiple sclerosis, Huntingtons chorea, Down's syndrome,
CC
     nerve deafness, Menier's disease, and other disorders of the cerebellum.
CC
     AL-2 can be used as cognitive enhancer, to enhance learning particularly
CC
     in dementias or trauma, since they can promote axonal outgrowth and
CC
     synaptic plasticity, particularly of hippocampal neurons that express AL-
CC
     2 binding Eph-family receptors and cortical neurons that express AL-2. AL
CC
     -2 can also be used for wound healing, i.e. accelerating
CC
     neovascularisation of, e.g. burns and ulcers. The encoding nucleic acids
CC
     are useful in preparing antibodies that specifically bind to the AL-2
CC
     protein. The antibodies and the AL-2 antagonists are useful in diagnosing
CC
     and treating various neuronal disorders. AL-2 antagonists can be used for
CC
     modulating angiogenesis. They can also be used for the treatment of
CC
     tumours, acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML),
CC
     myelodysplastic syndrome (MDS), diabetic retinopathy, neovascular
CC
     glaucoma, psoriasis and rheumatoid arthritis
CC
XX
SO
     Sequence 340 AA;
                         100.0%; Score 1850; DB 2; Length 340;
  Query Match
                         100.0%; Pred. No. 1.6e-142;
  Best Local Similarity
                                                               0; Gaps
                                                                           0;
  Matches 340; Conservative 0; Mismatches
                                                0; Indels
            1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Qу
              1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Db
           61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Qу
              61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Db
```

```
121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
Qу
            121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
Db
        181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
QУ
            181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Db
        241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGG 300
Qу
            241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGG 300
Db
        301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qу
            301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Db
RESULT 3
AAW10637
    AAW10637 standard; protein; 340 AA.
ID
XX
    AAW10637;
AC
XX
    23-JUN-1997 (first entry)
DT
XX
    NLERK2 ligand for eph-related kinase.
DΕ
XX
    LERK; ligand for eph-related kinase; ERK; NLERK2;
KW
    receptor protein tyrosine kinase; cell proliferation;
KW
    cell differentiation; cell survival; nerve cell.
KW
XX
    Homo sapiens.
OS
XX
                  Location/Qualifiers
FΗ
    Key
                  1. .29
FT
    Peptide
                  /label= Sig_peptide
FT
                  30. .340
FT
    Protein
FT
                  /label= Mat protein
                  210
FT
    Modified-site
                  /label= N-glycosylation site
FT
                  227. .251
FT
    Domain
                  /label= Transmembrane domain
FT
XX
    W09704091-A1.
PN
XX
    06-FEB-1997.
PD
XX
                 96WO-AU000460.
ΡF
    19-JUL-1996;
XX
                 95AU-00004263.
PR
    20-JUL-1995;
    27-NOV-1995;
                 95AU-00006847.
PR
    22-DEC-1995;
                 95AU-00007299.
PR
    05-FEB-1996;
                 96AU-00007890.
PR
XX
     (AMRA-) AMRAD OPERATIONS PTY LTD.
PΑ
XX
```

```
PΙ
    Nicola NA;
XX
    WPI; 1997-132632/12.
DR
DR
    N-PSDB; AAT60966.
XX
    Nucleic acid mol. encoding ligand for eph-related kinase - useful for
PT
    treatment of, pref. neuronal, cells to increase survival, proliferation
PT
    and differentiation.
PT
XX
    Claim 16; Page 37-39; 71pp; English.
PS
XX
    A novel human ligand for eph-related kinase (LERK) is designated NLERK2
CC
    (AAW10637). It is encoded by a cDNA clone (AAT60966) obtd. from a human
CC
    foetal brain cDNA library. The novel receptor ligand can be expressed in
CC
    transformed host cells and used in methods for regulating the
CC
    development, maintenance or regeneration of different cells (e.g.
CC
    neurons) and tissues in vivo and in vitro. Soluble NLERK2 peptides can be
CC
    used to treat injury, disease or abnormality in the nervous system, and
CC
    membrane-bound NLERK2 to modulate proliferation, different or survival
CC
    e.g. in grafting procedures or transplantation. NLERK2 can also be used
CC
    to raise antibodies for use in immunotherapy, and to detect anti-NLERK2
CC
    antibodies that may occur in some autoimmune diseases
CC
XX
    Sequence 340 AA;
SQ
                      100.0%; Score 1850; DB 2; Length 340;
 Ouerv Match
                      100.0%; Pred. No. 1.6e-142;
 Best Local Similarity
                                                                   0;
                                                        0; Gaps
                           0; Mismatches
                                           0; Indels
 Matches 340; Conservative
          1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Qу
            1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Db
          61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Qу
            61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Db
         121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
Qу
            121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
Db
         181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
QУ
            181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Db
         241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGMGPREAEPGELGIALRGG 300
Qу
            241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGMGPREAEPGELGIALRGG 300
Db
         301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qy
            301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Dh
```

RESULT 4 ABU07845

ID ABU07845 standard; protein; 340 AA.

XX AC ABU07845; XX 10-MAY-2003 (first entry) DTXX Human ephrin-B3 ligand. DE XX Cytostatic; vasodilator; antiinflammatory; cardiant; gene therapy; KW ligand-receptor binding modulator; ephrin ligand; angiogenesis; KW lymphangiogenesis; aberrant Ephrin-Tie biology; cell growth disorder; KW cell migration disorder; cell proliferation disorder; neovascularisation; KW ischaemia; infarction; tissue graft; transplant; human; ephrin-B3; KW tie receptor tyrosine kinase; Eph receptor ligand. KW XX Homo sapiens. OS XX PN WO2003004529-A2. XX 16-JAN-2003. PD XX 02-JUL-2002; 2002WO-IB002524. PFXX 02-JUL-2001; 2001US-0302960P. PR XX (LICN) LICENTIA LTD. PAXX PΙ Alitalo K, Kubo H; XX WPI; 2003-210341/20. DR N-PSDB; ABX12546. DR XX Identifying modulators of binding between a Tie receptor tyrosine kinase PTand an Ephrin ligand, useful for promoting neovascularization, comprises PTcontacting a Tie receptor with an Ephrin in the presence of a putative PTPTmodulator. XX Disclosure; Page 117-119; 199pp; English. PS XX The invention describes a method of identifying a modulator of binding CC between a Tie receptor tyrosine kinase and an Ephrin ligand. The method CC comprises contacting a Tie receptor composition with an Ephrin CC composition in the presence and in the absence of a putative modulator CC compound, and detecting the binding between Tie receptor and the Ephrin CCin the presence and in the absence of the putative modulator. The method CC is useful for identifying a modulator of binding between a Tie receptor CC tyrosine kinase and an Ephrin ligand. Modulators identified from the CC method are useful in modulating angiogenic processes, including CC lymphangiogenesis, for treating diseases associated with aberrant Ephrin-CC Tie biology, aberrant growth, migration or proliferation of cells that CC express a Tie receptor, or for promoting growth of vessel or CC neovascularisation (e.g. ischaemic tissue, an infarction, a new or CC chronic compound, or a tissue graft or transplant). This is the amino CC acid sequence of human Ephrin-B3, a member of the Ephrin-B subclass of

ligands that are bound to the membrane via a transmembrane domain and

short cytoplasmic tail and function as Eph receptor ligands

Sequence 340 AA;

CC

CC

CC XX SQ

```
100.0%; Score 1850; DB 6; Length 340;
 Query Match
                     100.0%; Pred. No. 1.6e-142;
 Best Local Similarity
                                            Indels
                                                               0;
                          0; Mismatches
                                          0;
                                                     0; Gaps
 Matches 340; Conservative
          1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Qv
           1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Db
         61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Qу
           61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Db
        121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
Qу
           121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
Db
        181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Qу
           181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Db
        241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGMGPREAEPGELGIALRGG 300
Qу
           241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGGGPREAEPGELGIALRGG 300
Db
        301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qу
           301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Db
RESULT 5
AAW17081
    AAW17081 standard; protein; 340 AA.
TD
XX
    AAW17081;
AC
XX
    09-AUG-1997 (first entry)
ΤС
XX
    EPH family ligand Ef1-6.
DΕ
XX
    Ef1-6; Eph; Elk; receptor tyrosine kinase; signal transduction; ligand;
KW
    neurological disease.
KW
XX
OS
    Homo sapiens.
XX
                 Location/Qualifiers
FH
    Key
FT
    Peptide
                 1. .24
                 /label= Sig peptide
FT
FT
    Protein
                 25. .340
FT
                 /label= Mat protein
FT
    Misc-difference 166
                 /label= Gln, Arg
FT
FT
    Domain
                 225. .249
FT
                 /label= Transmembrane domain
XX
    W09715667-A1.
PΝ
XX
```

```
PD
    01-MAY-1997.
XX
                 96WO-US017201.
    25-OCT-1996;
PF
XX
    25-OCT-1995;
                 95US-0007015P.
PR
XX
    (REGE-) REGENERON PHARM INC.
PΑ
XX
    Davis S, Gale NW, Yancopoulos GD;
PΙ
XX
    WPI; 1997-259021/23.
DR
    N-PSDB; AAT69808.
DR
XX
    New nucleic acid encoding Efl-6 ligand protein - used for promoting
РT
    growth and proliferation of neuronal cells and in drug screening.
PΤ
XX
    Claim 2; Fig 1; 36pp; English.
PS
XX
    A novel ligand (AAW17081), designated Efl-6 (or Eph transmembrane
CC
    tyrosine kinase family ligand 6), binds to the Elk, Nuk/Cek5, Hek2/Sek4,
CC
    Htk and Sekl receptors on cells. Its amino acid sequence was deduced from
CC
    a human frontal cortex cDNA clone (AAT69808). Recombinant Elf-6,
CC
    truncated soluble polypeptides comprising the extracellular domain of Elf
CC
    -6, and Efl-6 ligandbodies comprising soluble Efl-6 and the Fc portion of
CC
    IgG can be expressed in host cells. These can be used to support neuronal
CC
    and other Eph receptor-bearing cell populations for treatment of
CC
    neurological disorders, in drug screening and to raise diagnostic
CC
    antibodies
CC
XX
    Sequence 340 AA;
SQ
                      99.7%; Score 1844; DB 2; Length 340;
  Query Match
                      99.7%; Pred. No. 4.8e-142;
  Best Local Similarity
                                            1; Indels
                                                        0; Gaps
                                                                   0;
                           0; Mismatches
  Matches 339; Conservative
          1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Qу
            1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Db
          61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
QУ
            61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Db
         121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
Qу
            121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLXVGQSPRGGAVPRKP 180
Db
         181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
QУ
            181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Db
         241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGMGPREAEPGELGIALRGG 300
QУ
             241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGMGPREAEPGELGIALRGG 300
Dh
         301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
QУ
```

```
RESULT 6
AAW33698
    AAW33698 standard; protein; 455 AA.
ID
XX
    AAW33698;
AC
XX
     30-APR-1998 (first entry)
DT
XX
    AL-2-long (AL-21) protein.
DE
XX
     AL-21; AL-2; AL-2-long; human; treatment; neurological disorder; tumour;
KW
     rheumatoid arthritis; wound healing; paralysis; angiogenesis; leukaemia;
KW
     psoriasis; Alzheimer's disease; epilepsy.
KW
XX
OS
     Homo sapiens.
XX
                     Location/Qualifiers
FH
     Key
                     1. .26
FT
     Peptide
                     /note= "signal peptide"
FT
                     27. .455
FT
     Protein
                     /note= "mature protein"
FT
                     27. .219
FT
     Domain
                     /note= "extracellular domain"
FΤ
                     220. .245
FT
     Domain
                     /note= "hydrophobic transmembrane domain"
FT
XX
PN
     WO9740153-A1.
XX
PD
     30-OCT-1997.
XX
PF
     17-APR-1997;
                    97WO-US006345.
XX
                    96US-00635130.
PR
     19-APR-1996;
XX
     (GETH ) GENENTECH INC.
PΑ
XX
PΙ
     Caras IW;
XX
     WPI; 1997-535837/49.
DR
     N-PSDB; AAV06354.
DR
XX
     Human AL-2 neurotrophic factor and related DNA - used to develop products
PT
     for, e.g. treating neurologic disorders, angiogenesis disorders, tumours
PT
     or rheumatoid arthritis or for wound healing.
РΨ
XX
     Claim 20; Fig 1A-C; 86pp; English.
PS
XX
     This is a AL-2-long (AL-21) protein. The AL-2 is a novel Eph-related
CC
     tyrosine kinase receptor ligand. AL-2 can be administered to patients in
CC
     whom the nervous system has been damaged by trauma, surgery, stroke,
CC
     ischaemia, infection, metabolic disease, nutritional deficiency,
CC
     malignancy, or toxic agents, to promote the survival or growth of
CC
     neurons. They can be used to treat motoneuron disorders such as
CC
     amyotrophic lateral sclerosis (Lou Gehrig's disease), Bell's palsy, and
CC
```

```
various conditions involving spinal muscular atrophy, or paralysis. AL-2
CC
    can be used to treat human neurodegenerative disorders, such as
CC
    Alzheimer's disease, Parkinson's disease, epilepsy, demyelinating
CC
    diseases such as multiple sclerosis, Huntingtons chorea, Down's syndrome,
CC
    nerve deafness, Menier's disease, and other disorders of the cerebellum.
CC
    AL-2 can be used as cognitive enhancer, to enhance learning particularly
CC
    in dementias or trauma, since they can promote axonal outgrowth and
CC
    synaptic plasticity, particularly of hippocampal neurons that express AL-
CC
    2 binding Eph-family receptors and cortical neurons that express AL-2. AL
CC
    -2 can also be used for wound healing, i.e. accelerating
CC
    neovascularisation of, e.g. burns and ulcers. The encoding nucleic acids
CC
    are useful in preparing antibodies that specifically bind to the AL-2
CC
    protein. The antibodies and the AL-2 antagonists are useful in diagnosing
CC
    and treating various neuronal disorders. AL-2 antagonists can be used for
CC
    modulating angiogenesis. They can also be used for the treatment of
CC
    tumours, acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML),
CC
    myelodysplastic syndrome (MDS), diabetic retinopathy, neovascular
CC
    glaucoma, psoriasis and rheumatoid arthritis
CC
XX
    Sequence 455 AA;
SQ
                              Score 1841; DB 2; Length 455;
                       99.5%;
 Query Match
                       100.0%; Pred. No. 1.2e-141;
 Best Local Similarity
                                             0; Indels
                                                         0;
                                                             Gaps
                                                                    0;
                            0; Mismatches
 Matches 338; Conservative
          1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Qу
            1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Db
          61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
QУ
            61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Db
         121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
Qy
            121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
Db
         181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Qу
             181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Db
         241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGMGPREAEPGELGIALRGG 300
QУ
            241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGMGPREAEPGELGIALRGG 300
Db
         301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYY 338
Qу
             301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYY 338
Dh
RESULT 7
AAW46615
    AAW46615 standard; protein; 340 AA.
ΙD
XX
AC
    AAW46615;
XX
    06-JUL-1998 (first entry)
DТ
```

XX DEHuman transmembrane ligand Elk-L3. XX Elk-L3; Elk-related receptor tyrosine kinase; transmembrane ligand; KW human; signal transduction; axonogenesis; nerve cell; neurone; KW Alzheimer's disease; Parkinson's disease; Huntingdon's disease; KW demyelination; multiple sclerosis; amyotrophic lateral sclerosis; KW nervous system infection; Wernicke's disease; trauma; ischaemia; stroke; ΚW nutritional polyneuropathy; progressive supranuclear palsy; KW Shy Drager's syndrome; multistem degeneration; KW olivo ponto cerebellar atrophy, peripheral nerve damage. KW XX OS Homo sapiens. XX Location/Qualifiers FΗ Kev FTMisc-difference 166 /label= Gln, Arg FT225. .249 FTDomain /note= "transmembrane domain" FTXX W09801548-A1. PN XX 15-JAN-1998. PDXX 97WO-CA000473. 04-JUL-1997; PFXX 05-JUL-1996; 96US-0021272P. PR XX (MOUN) MOUNT SINAI HOSPITAL CORP. PΑ XX Holland S, Mbamalu G, Pawson T; PΙ XX WPI; 1998-101047/09. DR DR N-PSDB; AAV16097. XX Modulating transmembrane ligand for an Elk-related receptor tyrosine PTkinase - by formation of a complex between an oligomerised Elk-related PTreceptor tyrosine kinase and a transmembrane ligand. PTXX Disclosure; Fig 5A; 40pp; English. PS XX This polypeptide comprises human Elk-L3, a transmembrane ligand of Elk-CC related receptor tyrosine kinase (ERRTK). A novel method of modulating CC the biological activity of, or for affecting a pathway regulated by, a CC transmembrane ligand for an ERRTK in a cell expressing the transmembrane CC ligand comprises forming a complex between a purified and isolated CC oligomerised ERRTK, or an isoform or an extracellular domain of the CC ERRTK, and the transmembrane ligand expressed on the cell. The complex CC can also be used for evaluating a substance for its ability to modulate CC the biological activity of a transmembrane ligand for an ERRTK, and to CC identify substances that affect or modulate a pathway regulated by a CC

ERRTK. A purified and isolated oligomerised ERRTK can be used in the

regeneration, to treat diseases and conditions involving trauma and

regeneration in a subject, or in a medicament for modulating axonogenesis

in a subject (all claimed). The substances identified by the methods can

preparation of a medicament for modulating neuronal development or

be used to modulate axonogenesis, nerve cell interactions and

CC

CC

CC

CC

CC

```
disease, Huntingdon's disease, demyelinating diseases, such as multiple
CC
    sclerosis, amyotrophic lateral sclerosis, bacterial and viral infections
CC
    of the nervous system, deficiency diseases, such as Wernicke's disease
CC
    and nutritional polyneuropathy, progressive supranuclear palsy, Shy
CC
    Drager's syndrome, multistem degeneration and olivo ponto cerebellar
CC
    atrophy, peripheral nerve damage, trauma, and ischaemia resulting from
CC
CC
    stroke
XX
SO
    Sequence 340 AA;
                      99.2%; Score 1836; DB 2; Length 340;
 Query Match
                      99.4%; Pred. No. 2.2e-141;
 Best Local Similarity
                            0; Mismatches
                                            2:
                                               Indels
                                                        0; Gaps
                                                                   0;
 Matches 338; Conservative
          1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Qу
            1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Db
         61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Οv
            61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Db
        121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
Οv
            121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLXVGQSPRGGAVPRKP 180
Db
        181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Qу
            181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Db
        241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGMGPREAEPGELGIALRGG 300
Qy
            241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGMGPREAEPGELGIALRGG 300
Db
         301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qу
            +----
         301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPQNIYYKV 340
Db
RESULT 8
ABU07846
    ABU07846 standard; protein; 340 AA.
XX
    ABU07846;
AC
XX
DT
    10-MAY-2003 (first entry)
XX
    Mouse ephrin-B3 ligand.
DE
XX
    Cytostatic; vasodilator; antiinflammatory; cardiant; gene therapy;
ĸw
    ligand-receptor binding modulator; ephrin ligand; angiogenesis;
KW
    lymphangiogenesis; aberrant Ephrin-Tie biology; cell growth disorder;
KW
    cell migration disorder; cell proliferation disorder; neovascularisation;
KW
    ischaemia; infarction; tissue graft; transplant; mouse; ephrin-B3;
KW
    tie receptor tyrosine kinase; Eph receptor ligand.
KW
XX
```

injury to the nervous system, such as Alzheimer's disease, Parkinson's

```
OS
    Mus musculus.
XX
    WO2003004529-A2.
PN
XX
    16-JAN-2003.
PD
XX
    02-JUL-2002; 2002WO-IB002524.
ΡF
XX
    02-JUL-2001; 2001US-0302960P.
PR
XX
     (LICN ) LICENTIA LTD.
PΑ
XX
    Alitalo K, Kubo H;
PΙ
XX
    WPI; 2003-210341/20.
DR
    N-PSDB; ABX12547.
DR
XX
    Identifying modulators of binding between a Tie receptor tyrosine kinase
PT
    and an Ephrin ligand, useful for promoting neovascularization, comprises
PT
    contacting a Tie receptor with an Ephrin in the presence of a putative
PT
PΤ
     modulator.
XX
     Disclosure; Page 121-122; 199pp; English.
PS
XX
     The invention describes a method of identifying a modulator of binding
CC
    between a Tie receptor tyrosine kinase and an Ephrin ligand. The method
CC
     comprises contacting a Tie receptor composition with an Ephrin
CC
     composition in the presence and in the absence of a putative modulator
CC
     compound, and detecting the binding between Tie receptor and the Ephrin
CC
     in the presence and in the absence of the putative modulator. The method
CC
     is useful for identifying a modulator of binding between a Tie receptor
CC
     tyrosine kinase and an Ephrin ligand. Modulators identified from the
CC
     method are useful in modulating angiogenic processes, including
CC
     lymphangiogenesis, for treating diseases associated with aberrant Ephrin-
CC
     Tie biology, aberrant growth, migration or proliferation of cells that
CC
     express a Tie receptor, or for promoting growth of vessel or
CC
     neovascularisation (e.g. ischaemic tissue, an infarction, a new or
CC
     chronic compound, or a tissue graft or transplant). This is the amino
CC
     acid sequence of mouse Ephrin-B3, a member of the Ephrin-B subclass of
CC
     ligands that are bound to the membrane via a transmembrane domain and
CC
     short cytoplasmic tail and function as Eph receptor ligands
CC
XX
     Sequence 340 AA;
SO
                         96.2%; Score 1780; DB 6; Length 340;
  Query Match
                         95.6%; Pred. No. 8e-137;
  Best Local Similarity
                                                                          0;
                                                    Indels
                                                              0; Gaps
                               7; Mismatches
                                                 8;
  Matches 325; Conservative
            1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Qу
              1 MGAPHFGPGGVQVGALLLLGFAGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Dh
           61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Qу
              61 LCPRARPPGPHSSPSYEFYKLYLVEGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Db
          121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
Qу
```

```
121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
Db
        181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Qу
            181 VSEMPMERDRGAAHSAEPGRDTIPGDPSSNATSRGAEGPLPPPSMPAVAGAAGGMALLLL 240
Db
        241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGMGPREAEPGELGIALRGG 300
Qy
            241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGMGPREAEPGELGIALRGG 300
Db
        301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qу
            301 GTADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Db
RESULT 9
AAW00287
    AAW00287 standard; protein; 334 AA.
ID
XX
    AAW00287;
AC
XX
    19-JAN-1997 (first entry)
DT
XX
    Mouse Eph receptor ligand ELF-2.
DE
XX
    Eph receptor; ligand; ELF-2; tyrosine kinase; signal transduction;
KW
    organogenesis; oncogenesis; tumour; neurological disorder; diagnosis;
KW
    gene therapy.
KW
XX
OS
    Mus sp.
XX
                  Location/Qualifiers
FΗ
    Key
тч
    Domain
                   1. .224
                   /label= Extracellular domain
FT
                  31. .155
FT
    Binding-site
                   /label= Receptor binding site
FT
                   226. .251
FТ
    Domain
                   /label= Transmembrane_domain
FT
XX
    WO9626958-A2.
PN
XX
    06-SEP-1996.
PD
XX
                  96WO-US002673.
PF
    23-FEB-1996;
XX
                  95US-00395415.
    27-FEB-1995;
PR
XX
     (HARD ) HARVARD COLLEGE.
PΑ
XX
PΙ
    Flanagan JG, Bergemann AD;
XX
    WPI; 1996-433391/43.
DR
DR
    N-PSDB; AAT40230.
XX
     Eph receptor ligand, ELF-2, and DNA encoding it - used to treat or
PT
     prevent neurological diseases, and to modulate binding of ELF-2 to Eph
PT
```

```
receptor, e.g. to prevent or treat tumour formation.
PT
XX
PS
    Claim 6; Fig 1A-B; 50pp; English.
XX
    Mouse Eph receptor ligand ELF-2 (AAW00287) is strongly expressed in the
CC
    anterior hindbrain and newly-forming somites of embryos at the early
CC
    organogenesis stage of development. It is important in cellular
CC
    communication during pattern formation. Its amino acid sequence was
CC
    deduced from a cDNA clone (AAT40230) isolated from a newborn mouse brain
CC
    cDNA library. The ELF-2 ligand can be used to alter neurological
CC
    development, oncogenesis and growth regulation, to modulate binding of
CC
    ELF-2 to the Eph receptor, and in diagnostic assays
CC
XX
    Sequence 334 AA;
SQ
                        34.5%; Score 637.5; DB 2; Length 334;
  Query Match
                        42.1%; Pred. No. 1.2e-43;
  Best Local Similarity
 Matches 139; Conservative 49; Mismatches 129; Indels
                                                                        5;
                                                           13; Gaps
          14 GALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSS 73
QУ
                     : : |||:|||:| :|
                                           15 GLLMVLCRTAISRSIVLEPIYWNSSNSKFLPGQGLVLYPQIGDKLDIICPKV---DSKTV 71
Db
          74 PNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHH 133
Qy
                                      ||:||:|:|
          72 GQYEYYKVYMVDKDQADRCTIKKENTPLLNCARPDQDVKFTIKFQEFSPNLWGLEFQKNK 131
Db
         134 DYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQ--SPRGGAVPRKPVSEMPMER-DR 190
QУ
             132 DYYIISTSNGSLEGLDNQEGGVCQTRAMKILMKVGQDASSAGSARNHGPTRRPELEAGTN 191
Db
         191 GAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLLGVAGAGGAMC 250
Qу
             1::1:11::::
                                           : || | | : :: :
         192 GRSSTTSPFVKPNPGSSTDGNSAGHSGNNLLGSEVALFAGIASGCIIFIVIIITLVVLLL 251
Dh
         251 WRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGGGAADPPFCPH 310
Qy
                                               : | | :: | | |
                                                            : ||
                           252 KYRRRHRKHSPQHTTTLSLSTLATPKRGGNN----NGSEPSDVIIPLR---TADSVFCPH 304
Db
         311 YEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qу
             111111111111111111
         305 YEKVSGDYGHPVYIVQEMPPQSPANIYYKV 334
Db
RESULT 10
AAR92742
     AAR92742 standard; protein; 336 AA.
ΤD
XX
AC
     AAR92742;
XX
DT
     21-MAY-1996 (first entry)
XX
     Murine hepatoma transmembrane kinase receptor ligand.
DE
XX
     Hepatoma transmembrane kinase; Htk; receptor; ligand; tyrosine kinase;
KW
     neurodegenerative disease.
KW
XX
```

```
OS
    Mus musculus.
XX
    W09602645-A2.
PN
XX
    01-FEB-1996.
PD
XX
                   95WO-US008812.
    14-JUL-1995;
PF
XX
                   94US-00277722.
     20-JUL-1994;
PR
XX
     (GETH ) GENENTECH INC.
PA
XX
     Bennett BD, Matthews W;
PΙ
XX
    WPI: 1996-105907/11.
DR
    N-PSDB; AAT16470.
DR
XX
     Ligand for the hepatoma trans-membrane kinase receptor - useful for
PT
     stimulating and inhibiting cells carrying the receptor, e.g. for treating
PΤ
     neuro-degenerative disease.
PT
XX
     Claim 5; Fig 1(A-D); 88pp; English.
PS
XX
     Mouse (AAT16470) and human (AAT16471) Htk ligand which bind to, and
CC
     activate, the Htk receptor, have been identified in a variety of tissues
CC
     using a soluble Htk-Fc fusion protein. The predicted mol.wt. of the
CC
     murine Htk ligand protein following a signal peptide cleavage is 34 kD
CC
     with an estimated pI of 8.9. The murine and human ligands show 96%
CC
     homology at the amino acid level. The DNA is used to produce recombinant
CC
     ligands; for tissue- specific typing (partic. as a marker for breast
CC
     cancer) and as a marker for human chromosome 13. The ligands (partic. in
CC
     soluble form) are used to activate the tyrosine kinase domain of the Htk
CC
     receptor, i.e. to stimulate or inhibit growth, differentiation, and/or
CC
     activation of cells contg. the receptor, e.g. treatment of
CC
     neurodegenerative diseases, since they are strongly expressed in the
CC
     cerebral cortex, hippocampus, striatum and cerebellum. The ligands are
CC
     also useful as a control or standard in assays, for generation of
CC
     antibodies, as a mol. wt. marker, for growth in vitro of Htk-receptor
CC
     positive cells, as research agent, in screening, etc
CC
XX
     Sequence 336 AA;
SQ
                         34.5%; Score 637.5; DB 2; Length 336;
                         42.1%; Pred. No. 1.2e-43;
  Best Local Similarity
  Matches 139; Conservative 49; Mismatches 129; Indels 13; Gaps
                                                                          5;
           14 GALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSS 73
QУ
                      17 GLLMVLCRTAISRSIVLEPIYWNSSNSKFLPGQGLVLYPQIGDKLDIICPKV---DSKTV 73
Db
           74 PNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHH 133
Qу
                                       11:11:1:1
                          74 GQYEYYKVYMVDKDQADRCTIKKENTPLLNCARPDQDVKFTIKFQEFSPNLWGLEFQKNK 133
Db
          134 DYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQ--SPRGGAVPRKPVSEMPMER-DR 190
Qу
              134 DYYIISTSNGSLEGLDNQEGGVCQTRAMKILMKVGQDASSAGSARNHGPTRRPELEAGTN 193
Db
```

```
191 GAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLLGVAGAGGAMC 250
Qу
             11 1 : :: :
         194 GRSSTTSPFVKPNPGSSTDGNSAGHSGNNLLGSEVALFAGIASGCIIFIVIIITLVVLLL 253
Db
         251 WRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGGGAADPPFCPH 310
Qу
                     :| | : ||
                                                :|| :: | || || || || ||
         254 KYRRRHRKHSPQHTTTLSLSTLATPKRGGNN----NGSEPSDVIIPLR---TADSVFCPH 306
Db
         311 YEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
QУ
             307 YEKVSGDYGHPVYIVQEMPPQSPANIYYKV 336
Db
RESULT 11
ABU07844
    ABU07844 standard; protein; 336 AA.
ID
XX
    ABU07844;
AC
XX
    10-MAY-2003 (first entry)
DT
XX
    Mouse ephrin-B2 ligand.
DE
XX
     Cytostatic; vasodilator; antiinflammatory; cardiant; gene therapy;
KW
     ligand-receptor binding modulator; ephrin ligand; angiogenesis;
KW
     lymphangiogenesis; aberrant Ephrin-Tie biology; cell growth disorder;
KW
     cell migration disorder; cell proliferation disorder; neovascularisation;
KW
     ischaemia; infarction; tissue graft; transplant; mouse; ephrin-B2;
KW
     tie receptor tyrosine kinase; Eph receptor ligand.
KW
XX
     Mus musculus.
OS
XX
     WO2003004529-A2.
PN
XX
     16-JAN-2003.
PD
XX
     02-JUL-2002; 2002WO-IB002524.
ΡF
XX
     02-JUL-2001; 2001US-0302960P.
PR
XX
     (LICN ) LICENTIA LTD.
PA
XX
     Alitalo K, Kubo H;
PΙ
XX
     WPI; 2003-210341/20.
DR
     N-PSDB; ABX12545.
DR
XX
     Identifying modulators of binding between a Tie receptor tyrosine kinase
PT
     and an Ephrin ligand, useful for promoting neovascularization, comprises
PT
     contacting a Tie receptor with an Ephrin in the presence of a putative
PT
PT
     modulator.
XX
     Example 1; Page 113-114; 199pp; English.
PS
XX
     The invention describes a method of identifying a modulator of binding
CC
     between a Tie receptor tyrosine kinase and an Ephrin ligand. The method
```

```
comprises contacting a Tie receptor composition with an Ephrin
    composition in the presence and in the absence of a putative modulator
CC
    compound, and detecting the binding between Tie receptor and the Ephrin
CC
    in the presence and in the absence of the putative modulator. The method
CC
    is useful for identifying a modulator of binding between a Tie receptor
CC
    tyrosine kinase and an Ephrin ligand. Modulators identified from the
CC
    method are useful in modulating angiogenic processes, including
CC
    lymphangiogenesis, for treating diseases associated with aberrant Ephrin-
CC
    Tie biology, aberrant growth, migration or proliferation of cells that
CC
    express a Tie receptor, or for promoting growth of vessel or
CC
    neovascularisation (e.g. ischaemic tissue, an infarction, a new or
CC
    chronic compound, or a tissue graft or transplant). This is the amino
CC
    acid sequence of mouse Ephrin-B2, a member of the Ephrin-B subclass of
CC
    ligands that are bound to the membrane via a transmembrane domain and
CC
    short cytoplasmic tail and function as Eph receptor ligands
CC
XX
    Sequence 336 AA;
SQ
                        34.4%; Score 635.5; DB 6;
                                                   Length 336;
  Query Match
                        41.7%; Pred. No. 1.7e-43;
 Best Local Similarity
                                                                        5;
 Matches 139; Conservative 49; Mismatches 126;
                                                            19; Gaps
                                                   Indels
          14 GALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSS 73
Qу
                                           : : |||:|||:|:|:|
          17 GLLMVLCRTAISRSIVLEPIYWNSSNSKFLPGQGLVLYPQIGDKLDIICPKV---DSKTV 73
Db
          74 PNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHH 133
QУ
                                      ||:||:|:|
          74 GQYEYYKVYMVDKDQADRCTIKKENTPLLNCARPDQDVKFTIKFQEFSPNLWGLEFQKNK 133
Db
         134 DYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQ-----SPRGGAVPRKPVSEMPME 187
Qу
             134 DYYIISTSNGSLEGLDNQEGGVCQTRAMKILMKVGQDASSAGSTRNHGPTRRPELE---A 190
Db
         188 RDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLLGVAGAGG 247
Qy
                1:: | : | | : : : | : | | : :: :
         191 GTNGRSSTTSPFVKPNPGSSTDGNSAGHSGNNLLGSEVALFAGIASGCIIFIVIIITLVV 250
Db
         248 AMCWRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGGGAADPPF 307
QУ
                 111: :1
                              1
                                    : ||
                                                  :11 :: 1 11
         251 LLLKYRRRHRKHSPQHTTTLSLSTLATPKRGGNN----NGSEPSDVIIPLR---TADSVF 303
Db
         308 CPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
QУ
             304 CPHYEKVSGDYGHPVYIVQEMPPQSPANIYYKV 336
Db
RESULT 12
AAR55059
     AAR55059 standard; protein; 346 AA.
ID
XX
AC
     AAR55059;
XX
     25-MAR-2003 (revised)
DT
     28-JAN-1995 (first entry)
DT
XX
     Elk tyrosine kinase receptor ligand.
DE
```

```
XX
          Vectors; elk-L protein; elk; ligands; cell growth; differentiation.
KW
XX
OS
          Homo sapiens.
XX
                                           Location/Qualifiers
FH
          Key
                                           1. .24
FT
          Peptide
                                           /note= "signal peptide"
FT
                                           25. .346
FΨ
          Protein
                                           /note= "mature elk-L protein"
FT
XX
          WO9411384-A1.
ΡN
XX
PD
          26-MAY-1994.
XX
ΡF
          15-NOV-1993;
                                         93WO-US010955.
XX
                                         92US-00977693.
PR
          13-NOV-1992;
XX
           (IMMV ) IMMUNEX CORP.
PΑ
XX
                                                           Baum PR;
          Lyman S, Beckmann MP,
PΙ
XX
           WPI; 1994-183415/22.
DR
          N-PSDB; AAQ65486.
DR
XX
           New DNA encoding ligand for elk tyrosine kinase receptor - also related
 РΤ
           polypeptides, vectors, antibodies and probes, useful e.g. in studying
 PT
           cell differentiation or growth.
 PT
XX
           Claim 7; Page 30; 35pp; English.
PS
XX
           The sequence is that of the elk-L protein able to bind elk, a tyrosine
 CC
           kinase receptor. The DNA may be incorporated into vectors which can used
 CC
           to study the role of elk and its ligands in cell growth and
 CC
           differentiation. (Updated on 25-MAR-2003 to correct PN field.)
 CC
 XX
           Sequence 346 AA;
 SO
                                                      34.2%; Score 632; DB 2; Length 346;
     Query Match
     Best Local Similarity 39.5%; Pred. No. 3.4e-43;
    Matches 145; Conservative 48; Mismatches 116; Indels
                                                                                                                                                               9;
                                                                                                                                    58; Gaps
                          8 PGGVRVGALLLLGVLGLVSGL-----SLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLL 61
 Qy
                                                                                     : | | | | | : | | : | | : | | : | | : | | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | :
                                        :| |: |: : |
                          4 PGQRWLGKWLVAMVVWALCRLATPLAKNLEPVSWSSLNPKFLSGKGLVIYPKIGDKLDII 63
 Db
                        62 CPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYS 121
 QУ
                                                         - 1
                        64 CPRAEAGRP----YEYYKLYLVRPEQAAACSTVLDPNVLVTCNRPEQEIRFTIKFQEFS 118
 Db
                      122 PNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPV 181
 QУ
                              119 PNYMGLEFKKHHDYYITSTSNGSLEGLENREGGVCRTRTMKIIMKVGQDPNAVTPEQLTT 178
 Db
                      182 SEMPMERDRGAAHSLE-PGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLA---- 236
  Qy
                                  ||:|| :
```

```
179 SRPSKEADNTVKMATQAPGSRGSLGDSDGKHETVNQEEKSGP-----GASGGSSGDPD 231
Db
         237 -----LLLLGVAGAGGA------MCWRRRRAKPSESRHPGPGSFGRGGSLGL 277
Qу
                                          : |:| | ::
                   : | | | | |
         232 GFFNSKVALFAAVGAGCVIFLLIIIFLTVLLLKLRKRHRKHTQQ-----RAAALSL 282
Db
         278 ----GGGGGMGPREAEPGELGIALRGGGAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSP 333
Qv
                                       || :: | ||
         283 STLASPKGGSGTAGTEPSDIIIPLR---TTENNYCPHYEKVSGDYGHPVYIVQEMPPQSP 339
Db
         334 PNIYYKV 340
Qy
              340 ANIYYKV 346
Db
RESULT 13
AAR91930
    AAR91930 standard; protein; 346 AA.
XX
    AAR91930;
AC
XX
    25-MAR-2003 (revised)
DT
    11-DEC-1996 (first entry)
DT
XX
    Human cytokine elk-ligand (elk-L).
DE
XX
    Human; cytokine; elk-ligand; elk-L; tyrosine kinase receptor;
KW
    neurotrophic; neuroprotective; placenta; radiolabelled probe; treatment;
KW
    neural tissue; excito-toxicity; injury; disorder; neural culture reagent;
KW
    immunogenic fragment; antibody.
KW
XX
OS
    Homo sapiens.
XX
                    Location/Qualifiers
FΗ
    Key
                    1. .24
FT
     Peptide
                    /label= sig peptide
FT
                    25. .346
FT
     Peptide
                    /label= mat peptide
FT
XX
     US5512457-A.
PN
XX
     30-APR-1996.
PD
XX
     15-MAR-1994; 94US-00213403.
PF
XX
     13-NOV-1992; 92US-00977693.
PR
XX
     (IMMV ) IMMUNEX CORP.
PA
XX
     Carpenter MK, Lyman S, Beckmann MP, Baum PR;
PΙ
XX
     WPI; 1996-229866/23.
DR
     N-PSDB; AAT28770.
DR
XX
     DNA coding for neurotrophic human elk ligand cytokine - useful as probe
PT
     to isolate other elk ligand sequences.
PT
XX
```

```
Claim 1; Col 27-30; 18pp; English.
PS
XX
    The present sequence is the human cytokine elk-ligand (elk-L), which
CC
    binds a member of the tyrosine kinase receptor family. Elk-L exhibits
CC
    neurotrophic and neuroprotective properties, and has a calculated mol.
CC
    wt. 35180 daltons and a pI of 9.006. The elk-L cDNA, isolated from a
CC
    human placental cDNA library, can be radiolabelled and used as a probe
CC
    for isolating other mammalian elk-L cDNA. Elk-L can be used to treat
CC
    neural tissue disorders, partic. excito-toxicity associated injuries or
CC
    disorders, and as a neural culture reagent, while immunogenic fragments
CC
    of elk-L can be used to generate specific anti-elk-L antibodies. (Updated
CC
    on 25-MAR-2003 to correct PF field.)
CC
XX
    Sequence 346 AA;
SQ
                     34.2%; Score 632; DB 2; Length 346;
 Query Match
 Best Local Similarity 39.5%; Pred. No. 3.4e-43;
 Matches 145; Conservative 48; Mismatches 116; Indels 58; Gaps 9;
          8 PGGVRVGALLLLGVLGLVSGL-----SLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLL 61
Qу
           4 PGQRWLGKWLVAMVVWALCRLATPLAKNLEPVSWSSLNPKFLSGKGLVIYPKIGDKLDII 63
Db
         62 CPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYS 121
Qy
            64 CPRAEAGRP----YEYYKLYLVRPEQAAACSTVLDPNVLVTCNRPEQEIRFTIKFQEFS 118
Db
        122 PNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPV 181
QУ
            119 PNYMGLEFKKHHDYYITSTSNGSLEGLENREGGVCRTRTMKIIMKVGQDPNAVTPEQLTT 178
Db
        182 SEMPMERDRGAAHSLE-PGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLA---- 236
Qу
           179 SRPSKEADNTVKMATQAPGSRGSLGDSDGKHETVNQEEKSGP-----GASGGSSGDPD 231
Db
        237 -----LLLLGVAGAGGA-------MCWRRRRAKPSESRHPGPGSFGRGGSLGL 277
Qу
                                 : |:| | :: | :| |
                : 1 | 111
        232 GFFNSKVALFAAVGAGCVIFLLIIIFLTVLLLKLRKRHRKHTQQ-----RAAALSL 282
Db
        278 ----GGGGGMGPREAEPGELGIALRGGGAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSP 333
Qy
                  283 STLASPKGGSGTAGTEPSDIIIPLR---TTENNYCPHYEKVSGDYGHPVYIVQEMPPQSP 339
Db
        334 PNIYYKV 340
QУ
            340 ANIYYKV 346
Db
RESULT 14
AAW19249
    AAW19249 standard; protein; 346 AA.
XX
AC
    AAW19249;
XX
DΤ
    25-MAR-2003 (revised)
    18-AUG-1997 (first entry)
DT
XX
```

```
Human elk ligand protien.
DΕ
XX
     Human; elk; ligand; elk-L; cytokine; testing; measuring; purification;
KW
     neuroprotection; treatment; diabetic; hereditary; nutritional;
KW
     neuropathy; neurodegenerative disease; tissue culture.
KW
XX
OS
     Homo sapiens.
XX
                     Location/Qualifiers
FH
     Key
                     1. .24
FT
     Peptide
                     /label= sig peptide
FT
                     25. .346
FT
     Peptide
                     /label= mat peptide
FT
XX
     US5627267-A.
PΝ
XX
     06-MAY-1997.
ΡD
XX
                    95US-00458077.
PF
     01-JUN-1995;
XX
                    92US-00977693.
     13-NOV-1992;
PR
                    94US-00213403.
     15-MAR-1994;
PR
XX
     (IMMV ) IMMUNEX CORP.
PΑ
XX
     Beckmann MP, Lyman S, Baum PR;
PΙ
XX
     WPI: 1997-271366/24.
DR
     N-PSDB; AAT69766.
DR
XX
     Human elk ligand protein - for diagnostic or therapeutic use, e.g. as
PT
     neuro-protective agent.
PT
XX
PS
     Claim 1; Col 29-32; 18pp; English.
XX
     The present sequence is a human elk ligand (elk-L) protein, which binds
CC
     elk, has a calculated molecular weight of 35180 and an isoelectric point
CC
     of 9.006. Elk-L is a cytokine that can be used to test cells for elk
CC
     expression, measure the biological activity of elk, purify elk by
CC
     affinity chromatography and as a neuroprotective agent to treat diabetic,
CC
     hereditary and nutritional neuropathies and neurodegenerative diseases.
CC
     It may also be added to tissue cultures to prolong the life of neurons.
CC
     The elk-L cDNA was isolated from a human placental cDNA library, and is
CC
     present as a cDNA insert in the recombinant vector deposited in strain
CC
     ATCC 69085. (Updated on 25-MAR-2003 to correct PF field.)
CC
XX
SO
     Sequence 346 AA;
                           34.2%; Score 632; DB 2; Length 346;
  Query Match
                          39.5%; Pred. No. 3.4e-43;
  Best Local Similarity
  Matches 145; Conservative 48; Mismatches 116; Indels
                                                                 58; Gaps
                                                                              9;
             8 PGGVRVGALLLLGVLGLVSGL-----SLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLL 61
Qу
                                         :|||| |:| |:| : | |:||:||:||:||::|
                   :| |: |: : |
             4 PGQRWLGKWLVAMVVWALCRLATPLAKNLEPVSWSSLNPKFLSGKGLVIYPKIGDKLDII 63
 Db
            62 CPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYS 121
 Qy
```

```
||:|||||
                                             _ ||:|:||:||: |: |:||||||||
          64 CPRAEAGRP----YEYYKLYLVRPEQAAACSTVLDPNVLVTCNRPEQEIRFTIKFQEFS 118
Db
         122 PNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPV 181
Qy
             119 PNYMGLEFKKHHDYYITSTSNGSLEGLENREGGVCRTRTMKIIMKVGQDPNAVTPEQLTT 178
Db
         182 SEMPMERDRGAAHSLE-PGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLA---- 236
Qу
                                 : 1 1
                                                           :: 11
         179 SRPSKEADNTVKMATQAPGSRGSLGDSDGKHETVNQEEKSGP-----GASGGSSGDPD 231
Db
         237 -----LLLLGVAGAGGA------MCWRRRRAKPSESRHPGPGSFGRGGSLGL 277
Qу
                                          : |:| | ::
                        111
         232 GFFNSKVALFAAVGAGCVIFLLIIIFLTVLLLKLRKRHRKHTQQ-----RAAALSL 282
Db
         278 ----GGGGGMGPREAEPGELGIALRGGGAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSP 333
Qу
                                        11::11
         283 STLASPKGGSGTAGTEPSDIIIPLR---TTENNYCPHYEKVSGDYGHPVYIVQEMPPQSP 339
Db
         334 PNIYYKV 340
Qy
              11111
         340 ANIYYKV 346
Db
RESULT 15
AAW36055
    AAW36055 standard; protein; 346 AA.
TD
XX
    AAW36055;
AC
XX
     06-MAR-1998 (first entry)
DT
XX
    Human elk-L protein.
DE
XX
     Human; elk-L; cytokine; ligand; tyrosine kinase receptor; fusion protein;
KW
     extracellular domain; immunoglobulin; neurological disease.
KW
XX
     Homo sapiens.
OS
XX
                    Location/Qualifiers
FΗ
     Key
                    1. .24
FT
     Peptide
                    /note= "signal peptide"
FT
                    25. .346
FT
     Protein
                    /note= "mature protein"
FT
FT
     Domain
                    /note= "extracellular domain; this region is used to
FT
                    generate a fusion protein with the Fc portion of the
FT
                    human immunoglobulin G1"
FΨ
                    139. .141
     Modified-site
FT
                    /note= "Asn is N-glycosylated"
FT
FT
     Domain
                    238. .265
                    /note= "transmembrane domain"
FT
                    266. .346
FT
     Domain
                    /note= "intracellular domain"
FT
                    266. .267
     Cleavage-site
FT
                    /note= "KEX2 protease cleavage site"
FΤ
     Cleavage-site
                    267. .268
FT
```

```
/note= "KEX2 protease cleavage site"
FT
                   270. .271
FT
    Cleavage-site
                   /note= "KEX2 protease cleavage site"
FT
XX
    US5670625-A.
PN
XX
    23-SEP-1997.
PD
XX
                  95US-00460741.
PF
    02-JUN-1995;
XX
                   92US-00977693.
    13-NOV-1992;
PR
    15-MAR-1994;
                   94US-00213403.
PR
XX
     (IMMV ) IMMUNEX CORP.
PΑ
XX
     Beckmann MP, Lyman S, Baum PR;
PΙ
XX
     WPI; 1997-479524/44.
DR
     N-PSDB; AAT97976.
DR
XX
     Soluble fusion proteins of human elk-ligand and Fc immunoglobulin
РΤ
     fragment - and their dimers and oligomers, useful as neuro-protectants
PT
     and neurotrophic agents.
PT
XX
     Claim 1; Col 27-30; 18pp; English.
PS
XX
     This is the amino acid sequence of the human elk-L protein, a new
CC
     cytokine that is the ligand for the elk tyrosine kinase receptor. The
CC
     extracellular domain of the protein (amino acids 1-213) is used to
CC
     generate a fusion protein comprising the Fc polypeptide of the human
CC
     immunoglobulin G1 (extending from the hinge region to the C-terminus).
CC
     The fusion protein (which has the same activities as the natural elk-L
CC
     protein) has neuroprotective and neurotrophic activity so is potentially
CC
     useful for treating a wide range of neurological diseases
CC
XX
     Sequence 346 AA;
SO
                         34.2%; Score 632; DB 2; Length 346;
  Query Match
                         39.5%; Pred. No. 3.4e-43;
  Best Local Similarity
                                                                         9;
  Matches 145; Conservative 48; Mismatches 116; Indels
                                                             58; Gaps
            8 PGGVRVGALLLLGVLGLVSGL-----SLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLL 61
 Qy
                                       :|||| |:| |:| : | |:||:||:||:|
                  :| |: |: : |
            4 PGQRWLGKWLVAMVVWALCRLATPLAKNLEPVSWSSLNPKFLSGKGLVIYPKIGDKLDII 63
 Db
           62 CPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYS 121
 QУ
                                               1
           64 CPRAEAGRP----YEYYKLYLVRPEQAAACSTVLDPNVLVTCNRPEQEIRFTIKFQEFS 118
 Db
          122 PNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPV 181
 Qу
              119 PNYMGLEFKKHHDYYITSTSNGSLEGLENREGGVCRTRTMKIIMKVGQDPNAVTPEQLTT 178
 Db
          182 SEMPMERDRGAAHSLE-PGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLA---- 236
 Qу
                                  : | |
                        :: ||
                  179 SRPSKEADNTVKMATQAPGSRGSLGDSDGKHETVNQEEKSGP-----GASGGSSGDPD 231
 Db
```

QУ	237	LLLLGVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGL 277
Db	232	GFFNSKVALFAAVGAGCVIFLLIIIFLTVLLLKLRKRHRKHTQQRAAALSL 282
Qу	278	GGGGGMGPREAEPGELGIALRGGGAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSP 333
Db	283	STLASPKGGSGTAGTEPSDIIIPLRTTENNYCPHYEKVSGDYGHPVYIVQEMPPQSP 339
Qy	334	PNIYYKV 340
Db	340	ANIYYKV 346

Search completed: April 13, 2004, 09:24:16 Job time: 44.6226 secs

GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: April 13, 2004, 09:22:18; Search time 24.3774 Seconds

(without alignments)

720.046 Million cell updates/sec

Title: US-10-021-121-4

Perfect score: 1850

Sequence: 1 MGPPHSGPGGVRVGALLLLG.....PVYIVQDGPPQSPPNIYYKV 340

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents_AA:*

1: /cgn2_6/ptodata/2/iaa/5A_COMB.pep:*

2: /cgn2 6/ptodata/2/iaa/5B_COMB.pep:*

3: /cgn2_6/ptodata/2/iaa/6A_COMB.pep:*

4: /cgn2_6/ptodata/2/iaa/6B_COMB.pep:*

5: /cgn2_6/ptodata/2/iaa/PCTUS_COMB.pep:*

6: /cgn2 6/ptodata/2/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

		용				
Result		Query				
No.	Score	Match	Length	DB	ID	Description
1	1846	99.8	- 340	4	US-09-214-631-3	Sequence 3, Appli
2	1844	99.7	340	4	US-09-051-994-2	Sequence 2, Appli
3	637.5	34.5	336	1	US-08-436-044-2	Sequence 2, Appli
4	637.5	34.5	336	2	US-08-436-054-2	Sequence 2, Appli
5	637.5	34.5	336	5	PCT-US95-08812-2	Sequence 2, Appli
6	632	34.2	346	1	US-08-213-403-2	Sequence 2, Appli
7	632	34.2	346	1	US-08-458-077-2	Sequence 2, Appli
8	632	34.2	346	1	US-08-460-741-2	Sequence 2, Appli
9	632	34.2	346	1	US-08-747-240-2	Sequence 2, Appli
10	632	34.2	346	1	US-08-299-567-6	Sequence 6, Appli
11	632	34.2	346	4	US-09-039-642B-2	Sequence 2, Appli

```
Sequence 4, Appli
    629.5
            34.0
                    333 1
                            US-08-436-044-4
12
                                                       Sequence 4, Appli
                            US-08-436-054-4
    629.5
            34.0
                    333 2
13
                                                       Sequence 2, Appli
                            US-08-271-948-2
            34.0
                    333 4
    629.5
14
                    333 4
                            US-08-739-333-2
                                                       Sequence 2, Appli
     629.5
            34.0
15
                                                       Sequence 2, Appli
                    333 4
                            US-09-754-105-2
     629.5
            34.0
16
                                                       Sequence 2, Appli
            34.0
                    333 4
                            US-09-978-339-2
     629.5
17
                                                       Sequence 2, Appli
                    333 5
                            PCT-US95-08534-2
            34.0
     629.5
18
                                                       Sequence 4, Appli
                    333 5 PCT-US95-08812-4
            34.0
     629.5
19
                                                       Sequence 4, Appli
                    333 4 US-09-214-631-4
            33.6
     622.5
20
                                                       Sequence 5, Appli
                    345 4 US-09-214-631-5
     608.5
            32.9
21
                                                       Sequence 13, Appl
                    89 4
                            US-09-214-631-13
       498
             26.9
22
                                                       Sequence 11, Appl
                     82 4
                            US-09-214-631-11
23
       201
            10.9
                                                       Sequence 12, Appl
                     82 4 US-09-214-631-12
     200.5
            10.8
24
                                                       Sequence 5, Appli
                     234 1 US-08-299-567-5
       179
             9.7
25
                                                       Sequence 2, Appli
                     238 1 US-08-240-124-2
              9.7
       179
26
                                                       Sequence 2, Appli
              9.7
                     238 1
                            US-08-453-943-2
       179
27
                     238 2
                                                       Sequence 2, Appli
              9.7
                            US-09-057-121-2
28
       179
                     238 3 US-09-358-734-2
                                                        Sequence 2, Appli
       179
              9.7
29
                     135 1
                                                       Sequence 7, Appli
                            US-08-299-567-7
     176.5
              9.5
30
                                                       Sequence 2, Appli
                            US-09-609-324A-2
                     184 1
              9.5
       176
31
                     184 2
                            US-08-920-440B-2
                                                        Sequence 2, Appli
              9.5
       176
32
                     184 3 US-09-173-492-2
                                                        Sequence 2, Appli
              9.5
33
       176
                                                        Sequence 2, Appli
                     184 3 US-09-173-133-2
       176
              9.5
34
                                                        Sequence 2, Appli
                     184 3
                            US-09-165-533-2
              9.5
       176
35
                     184 4
                            US-09-580-236A-2
                                                        Sequence 2, Appli
       176
              9.5
36
                     184 5
                                                        Sequence 2, Appli
                            PCT-US95-12779-2
              9.5
37
       176
                                                        Sequence 2, Appli
                     184
                          5
                             PCT-US95-15781-2
              9.5
       176
38
                                                        Sequence 2, Appli
                     209 1
                            US-08-455-001-2
              9.5
       176
39
                                                        Sequence 2, Appli
                     209 3
                            US-08-308-814-2
       176
              9.5
40
                                                        Sequence 2, Appli
                     209 5 PCT-US95-11869-2
       176
              9.5
41
                                                        Sequence 10, Appl
                            US-09-609-324A-10
                     213 1
     175.5
              9.5
42
                     213 2
                                                        Sequence 10, Appl
                            US-08-920-440B-10
43
     175.5
              9.5
                     213 3
                                                        Sequence 10, Appl
                            US-09-173-492-10
44
     175.5
              9.5
                                                        Sequence 10, Appl
                     213 3 US-09-173-133-10
     175.5
              9.5
45
```

ALIGNMENTS

```
RESULT 1
US-09-214-631-3
; Sequence 3, Application US/09214631
: Patent No. 6413730
; GENERAL INFORMATION:
  APPLICANT: Holland, Sacha
  APPLICANT: Mbamalu, Geraldine
  APPLICANT: Pawson, Tony
  TITLE OF INVENTION: OLIGOMERIZED RECEPTORS WHICH AFFECT PATHWAYS REGULATED
  TITLE OF INVENTION: BY TRANSMEMBRANE LIGANDS FOR ELK-RELATED RECEPTOR
  TITLE OF INVENTION: TYROSINE KINASES
  FILE REFERENCE: 11757.23USWO
  CURRENT APPLICATION NUMBER: US/09/214,631
  CURRENT FILING DATE: 1999-03-12
  EARLIER APPLICATION NUMBER: PCT/CA97/00473
  EARLIER FILING DATE: 1997-07-04
  EARLIER APPLICATION NUMBER: 60/021,272
   EARLIER FILING DATE: 1996-07-05
```

```
; NUMBER OF SEQ ID NOS: 13
  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
   LENGTH: 340
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-214-631-3
                     99.8%; Score 1846; DB 4; Length 340;
 Query Match
                     99.7%; Pred. No. 2.2e-146;
 Best Local Similarity
                                                                 0;
                                          0; Indels
                                                      0; Gaps
 Matches 339; Conservative
                           1; Mismatches
          1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Qу
            1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Db
         61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
QУ
            61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Db
        121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
Qy
            121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLQVGQSPRGGAVPRKP 180
Db
        181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Qу
            181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Db
        241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGG 300
Qу
            241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGG 300
Db
        301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qу
            301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Db
RESULT 2
US-09-051-994-2
; Sequence 2, Application US/09051994A
; Patent No. 6602683
; GENERAL INFORMATION:
  APPLICANT: REGENERON PHARMACEUTICALS, INC.
   TITLE OF INVENTION: BIOLOGICALLY ACTIVE EPH FAMILY LIGANDS
   FILE REFERENCE: REG-341-PCT-US
   CURRENT APPLICATION NUMBER: US/09/051,994A
   CURRENT FILING DATE: 1998-04-24
   EARLIER APPLICATION NUMBER: PCT/US96/17201
   EARLIER FILING DATE: 1996-10-25
   EARLIER APPLICATION NUMBER: 60/007,015
   EARLIER FILING DATE: 1995-10-25
   NUMBER OF SEQ ID NOS: 3
   SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
    LENGTH: 340
    TYPE: PRT
    ORGANISM: Homo sapiens
```

```
FEATURE:
   NAME/KEY: site
   LOCATION: (166)
   OTHER INFORMATION: Xaa=Arg or Gln
US-09-051-994-2
                     99.7%; Score 1844; DB 4; Length 340;
 Query Match
                     99.7%; Pred. No. 3.3e-146;
 Best Local Similarity
                                                                0;
                           0; Mismatches
                                         1;
                                             Indels
                                                      0; Gaps
 Matches 339; Conservative
         1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Qу
           1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Db
         61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Qу
           61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Db
        121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
Qv
           121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLXVGQSPRGGAVPRKP 180
Db
        181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Qy
           181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Db
        241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGMGPREAEPGELGIALRGG 300
Qу
           241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGGGPREAEPGELGIALRGG 300
Db
        301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qу
            301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Db
RESULT 3
US-08-436-044-2
; Sequence 2, Application US/08436044
; Patent No. 5624899
  GENERAL INFORMATION:
    APPLICANT: Bennett, Brian D.
    APPLICANT: Matthews, William
    TITLE OF INVENTION: HTK LIGAND
    NUMBER OF SEQUENCES: 7
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Genentech, Inc.
      STREET: 460 Point San Bruno Blvd
      CITY: South San Francisco
      STATE: California
      COUNTRY: USA
      ZIP: 94080
    COMPUTER READABLE FORM:
      MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: patin (Genentech)
    CURRENT APPLICATION DATA:
```

```
APPLICATION NUMBER: US/08/436,044
     FILING DATE: 05-MAY-1995
     CLASSIFICATION: 435
    PRIOR APPLICATION DATA:
     APPLICATION NUMBER: 08/277722
     FILING DATE: 20-JUL-1994
    ATTORNEY/AGENT INFORMATION:
     NAME: Lee, Wendy M.
     REGISTRATION NUMBER: 00,000
     REFERENCE/DOCKET NUMBER: 902D3
    TELECOMMUNICATION INFORMATION:
     TELEPHONE: 415/225-1994
     TELEFAX: 415/952-9881
     TELEX: 910/371-7168
  INFORMATION FOR SEQ ID NO: 2:
    SEQUENCE CHARACTERISTICS:
     LENGTH: 336 amino acids
     TYPE: amino acid
     TOPOLOGY: linear
US-08-436-044-2
                      34.5%; Score 637.5; DB 1; Length 336;
 Query Match
 Best Local Similarity 42.1%; Pred. No. 1.7e-45;
 Matches 139; Conservative 49; Mismatches 129; Indels
                                                      13; Gaps
                                                                  5;
         14 GALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSS 73
Qу
            17 GLLMVLCRTAISRSIVLEPIYWNSSNSKFLPGQGLVLYPQIGDKLDIICPKV---DSKTV 73
Db
         74 PNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHH 133
QУ
              74 GQYEYYKVYMVDKDQADRCTIKKENTPLLNCARPDQDVKFTIKFQEFSPNLWGLEFQKNK 133
Db
        134 DYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQ--SPRGGAVPRKPVSEMPMER-DR 190
Qy
            134 DYYIISTSNGSLEGLDNQEGGVCQTRAMKILMKVGQDASSAGSARNHGPTRRPELEAGTN 193
Db
        191 GAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLLGVAGAGGAMC 250
QУ
            194 GRSSTTSPFVKPNPGSSTDGNSAGHSGNNLLGSEVALFAGIASGCIIFIVIIITLVVLLL 253
Db
        251 WRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGGGAADPPFCPH 310
Qy
              ]||: :| | : | !
                                           :|| :: | ||
                                                       254 KYRRRHRKHSPQHTTTLSLSTLATPKRGGNN----NGSEPSDVIIPLR---TADSVFCPH 306
Db
        311 YEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qу
            307 YEKVSGDYGHPVYIVQEMPPQSPANIYYKV 336
Dh
RESULT 4
US-08-436-054-2
; Sequence 2, Application US/08436054
; Patent No. 5864020
; GENERAL INFORMATION:
    APPLICANT: Bennett, Brian D.
    APPLICANT: Matthews, William
```

```
TITLE OF INVENTION: HTK LIGAND
    NUMBER OF SEQUENCES: 7
    CORRESPONDENCE ADDRESS:
     ADDRESSEE: Genentech, Inc.
     STREET: 460 Point San Bruno Blvd
     CITY: South San Francisco
     STATE: California
     COUNTRY: USA
     ZIP: 94080
    COMPUTER READABLE FORM:
     MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
     COMPUTER: IBM PC compatible
     OPERATING SYSTEM: PC-DOS/MS-DOS
     SOFTWARE: patin (Genentech)
    CURRENT APPLICATION DATA:
     APPLICATION NUMBER: US/08/436,054
     FILING DATE: 05-MAY-1995
     CLASSIFICATION: 435
    PRIOR APPLICATION DATA:
     APPLICATION NUMBER: 08/277722
     FILING DATE: 20-JUL-1994
    ATTORNEY/AGENT INFORMATION:
     NAME: Lee, Wendy M.
      REGISTRATION NUMBER: 00,000
     REFERENCE/DOCKET NUMBER: 902D1
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 415/225-1994
      TELEFAX: 415/952-9881
      TELEX: 910/371-7168
  INFORMATION FOR SEQ ID NO: 2:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 336 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
US-08-436-054-2
                       34.5%; Score 637.5; DB 2; Length 336;
 Query Match
 Best Local Similarity 42.1%; Pred. No. 1.7e-45;
 Matches 139; Conservative 49; Mismatches 129; Indels
                                                                    5;
                                                        13; Gaps
         14 GALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSS 73
QУ
            17 GLLMVLCRTAISRSIVLEPIYWNSSNSKFLPGQGLVLYPQIGDKLDIICPKV---DSKTV 73
Db
          74 PNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHH 133
QУ
                                   ||:||:|:|
          74 GQYEYYKVYMVDKDQADRCTIKKENTPLLNCARPDQDVKFTIKFQEFSPNLWGLEFQKNK 133
Db
         134 DYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQ--SPRGGAVPRKPVSEMPMER-DR 190
QУ
            1
         134 DYYIISTSNGSLEGLDNQEGGVCQTRAMKILMKVGQDASSAGSARNHGPTRRPELEAGTN 193
Db
         191 GAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLLGVAGAGGAMC 250
Qy
            194 GRSSTTSPFVKPNPGSSTDGNSAGHSGNNLLGSEVALFAGIASGCIIFIVIIITLVVLLL 253
Db
         251 WRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGGGAADPPFCPH 310
QУ
```

```
254 KYRRRHRKHSPQHTTTLSLSTLATPKRGGNN----NGSEPSDVIIPLR---TADSVFCPH 306
Db
        311 YEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qу
            307 YEKVSGDYGHPVYIVQEMPPQSPANIYYKV 336
Db
RESULT 5
PCT-US95-08812-2
; Sequence 2, Application PC/TUS9508812
  GENERAL INFORMATION:
    APPLICANT: Genentech, Inc.
    TITLE OF INVENTION: HTK LIGAND
    NUMBER OF SEQUENCES: 7
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Genentech, Inc.
;
      STREET: 460 Point San Bruno Blvd
      CITY: South San Francisco
      STATE: California
      COUNTRY: USA
      ZIP: 94080
    COMPUTER READABLE FORM:
;
      MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
      COMPUTER: IBM PC compatible
     OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: patin (Genentech)
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: PCT/US95/08812
;
      FILING DATE:
      CLASSIFICATION:
;
   PRIOR APPLICATION DATA:
     APPLICATION NUMBER:
      FILING DATE:
   ATTORNEY/AGENT INFORMATION:
      NAME: Lee, Wendy M.
      REGISTRATION NUMBER: 00,000
      REFERENCE/DOCKET NUMBER: 902PCT
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 415/225-1994
      TELEFAX: 415/952-9881
      TELEX: 910/371-7168
   INFORMATION FOR SEQ ID NO: 2:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 336 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
PCT-US95-08812-2
                       34.5%; Score 637.5; DB 5; Length 336;
  Query Match
  Best Local Similarity 42.1%; Pred. No. 1.7e-45;
  Matches 139; Conservative 49; Mismatches 129; Indels 13; Gaps
          14 GALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSS 73
Qу
            17 GLLMVLCRTAISRSIVLEPIYWNSSNSKFLPGQGLVLYPQIGDKLDIICPKV---DSKTV 73
Db
```

```
74 PNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHH 133
Qy
              ||:||:|:|
                                    74 GQYEYYKVYMVDKDQADRCTIKKENTPLLNCARPDQDVKFTIKFQEFSPNLWGLEFQKNK 133
Db
        134 DYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQ--SPRGGAVPRKPVSEMPMER-DR 190
Qv
            134 DYYIISTSNGSLEGLDNQEGGVCQTRAMKILMKVGQDASSAGSARNHGPTRRPELEAGTN 193
Db
         191 GAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLLGVAGAGGAMC 250
Qу
            194 GRSSTTSPFVKPNPGSSTDGNSAGHSGNNLLGSEVALFAGIASGCIIFIVIIITLVVLLL 253
Db
         251 WRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGGGAADPPFCPH 310
Qу
                                             :|| :: | || || || || ||
              111: :1 : !!
         254 KYRRRHRKHSPQHTTTLSLSTLATPKRGGNN----NGSEPSDVIIPLR---TADSVFCPH 306
Db
         311 YEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qу
            307 YEKVSGDYGHPVYIVQEMPPQSPANIYYKV 336
Db
RESULT 6
US-08-213-403-2
; Sequence 2, Application US/08213403
; Patent No. 5512457
  GENERAL INFORMATION:
    APPLICANT: Lyman, Stewart D.
    APPLICANT: Beckmann, M. Patricia
    APPLICANT: Baum, Peter R
;
    APPLICANT: Carpenter, Melissa
;
    TITLE OF INVENTION: No. 5512457el Cytokine Designated elk Ligand
    NUMBER OF SEQUENCES: 2
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Immunex Corporation
      STREET: 51 University Street
      CITY: Seattle
      STATE: Washington
      COUNTRY: USA
;
      ZIP: 98101
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: Apple Macintosh
      OPERATING SYSTEM: Apple System 7.1
      SOFTWARE: Microsoft Word for Apple, Version 5.1a
;
    CURRENT APPLICATION DATA:
;
      APPLICATION NUMBER: US/08/213,403
      FILING DATE: 15-MAR-1994
      CLASSIFICATION: 435
     PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US 07/977,693
      FILING DATE: 13-NOV-1992
     ATTORNEY/AGENT INFORMATION:
      NAME: Seese, Kathryn A.
      REGISTRATION NUMBER: 32,172
      REFERENCE/DOCKET NUMBER: 2807-A
     TELECOMMUNICATION INFORMATION:
      TELEPHONE: (206) 587-0430
```

```
TELEFAX: (206) 233-0644
 INFORMATION FOR SEQ ID NO: 2:
   SEQUENCE CHARACTERISTICS:
     LENGTH: 346 amino acids
     TYPE: amino acid
     TOPOLOGY: linear
   MOLECULE TYPE: protein
US-08-213-403-2
 Query Match 34.2%; Score 632; DB 1; Length 346; Best Local Similarity 39.5%; Pred. No. 5e-45;
 Matches 145; Conservative 48; Mismatches 116; Indels 58; Gaps 9;
         8 PGGVRVGALLLLGVLGLVSGL-----SLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLL 61
Qy
           4 PGQRWLGKWLVAMVVWALCRLATPLAKNLEPVSWSSLNPKFLSGKGLVIYPKIGDKLDII 63
Db
         62 CPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYS 121
Qy
           64 CPRAEAGRP----YEYYKLYLVRPEQAAACSTVLDPNVLVTCNRPEQEIRFTIKFQEFS 118
Db
        122 PNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPV 181
Qy
           119 PNYMGLEFKKHHDYYITSTSNGSLEGLENREGGVCRTRTMKIIMKVGQDPNAVTPEQLTT 178
Db
        182 SEMPMERDRGAAHSLE-PGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLA---- 236
QУ
         179 SRPSKEADNTVKMATQAPGSRGSLGDSDGKHETVNQEEKSGP------GASGGSSGDPD 231
Db
        237 -----LLLLGVAGAGGA-------MCWRRRRAKPSESRHPGPGSFGRGGSLGL 277
QУ
                232 GFFNSKVALFAAVGAGCVIFLLIIIFLTVLLLKLRKRHRKHTQQ-----RAAALSL 282
Db
        278 ----GGGGGMGPREAEPGELGIALRGGGAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSP 333
QУ
                283 STLASPKGGSGTAGTEPSDIIIPLR---TTENNYCPHYEKVSGDYGHPVYIVQEMPPQSP 339
Db
        334 PNIYYKV 340
QУ
            340 ANIYYKV 346
Db
RESULT 7
US-08-458-077-2
; Sequence 2, Application US/08458077
; Patent No. 5627267
; GENERAL INFORMATION:
    APPLICANT: Lyman, Stewart D.
    APPLICANT: Beckmann, M. Patricia
    APPLICANT: Baum, Peter R
    APPLICANT: Carpenter, Melissa
    TITLE OF INVENTION: No. 5627267el Cytokine Designated elk Ligand
    NUMBER OF SEQUENCES: 2
   CORRESPONDENCE ADDRESS:
     ADDRESSEE: Immunex Corporation
     STREET: 51 University Street
     CITY: Seattle
```

```
STATE: Washington
;
     COUNTRY: USA
     ZIP: 98101
    COMPUTER READABLE FORM:
     MEDIUM TYPE: Floppy disk
     COMPUTER: Apple Macintosh
     OPERATING SYSTEM: Apple System 7.1
     SOFTWARE: Microsoft Word for Apple, Version 5.1a
;
    CURRENT APPLICATION DATA:
     APPLICATION NUMBER: US/08/458,077
     FILING DATE: 01-JUN-1995
     CLASSIFICATION: 514
;
    PRIOR APPLICATION DATA:
;
     APPLICATION NUMBER: US 08/213,403
     FILING DATE: 15-MAR-1994
     APPLICATION NUMBER: US 07/977,693
     FILING DATE: 13-NOV-1992
     CLASSIFICATION: 514
    ATTORNEY/AGENT INFORMATION:
     NAME: Seese, Kathryn A.
     REGISTRATION NUMBER: 32,172
;
     REFERENCE/DOCKET NUMBER: 2807-A
;
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (206) 587-0430
     TELEFAX: (206) 233-0644
  INFORMATION FOR SEQ ID NO: 2:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 346 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-458-077-2
                     34.2%; Score 632; DB 1; Length 346;
  Query Match
  Best Local Similarity 39.5%; Pred. No. 5e-45;
 Matches 145; Conservative 48; Mismatches 116; Indels 58; Gaps
          8 PGGVRVGALLLLGVLGLVSGL-----SLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLL 61
Qу
           4 PGQRWLGKWLVAMVVWALCRLATPLAKNLEPVSWSSLNPKFLSGKGLVIYPKIGDKLDII 63
Db
         62 CPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYS 121
Qу
            64 CPRAEAGRP----YEYYKLYLVRPEQAAACSTVLDPNVLVTCNRPEQEIRFTIKFQEFS 118
Db
         122 PNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPV 181
Qу
            119 PNYMGLEFKKHHDYYITSTSNGSLEGLENREGGVCRTRTMKIIMKVGQDPNAVTPEQLTT 178
Db
         182 SEMPMERDRGAAHSLE-PGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLA---- 236
Qу
           179 SRPSKEADNTVKMATQAPGSRGSLGDSDGKHETVNQEEKSGP-----GASGGSSGDPD 231
Db
         QУ
         232 GFFNSKVALFAAVGAGCVIFLLIIIFLTVLLLKLRKRHRKHTQQ-----RAAALSL 282
 Db
```

```
278 ----GGGGGMGPREAEPGELGIALRGGGAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSP 333
QУ
                    283 STLASPKGGSGTAGTEPSDIIIPLR---TTENNYCPHYEKVSGDYGHPVYIVQEMPPQSP 339
Db
         334 PNIYYKV 340
Qу
              11111
          340 ANIYYKV 346
RESULT 8
US-08-460-741-2
; Sequence 2, Application US/08460741
; Patent No. 5670625
  GENERAL INFORMATION:
     APPLICANT: Lyman, Stewart D.
     APPLICANT: Beckmann, M. Patricia
    APPLICANT: Baum, Peter R
APPLICANT: Carpenter, Melissa
    TITLE OF INVENTION: No. 5670625el Cytokine Designated elk Ligand
     NUMBER OF SEQUENCES: 2
     CORRESPONDENCE ADDRESS:
       ADDRESSEE: Immunex Corporation
       STREET: 51 University Street
;
       CITY: Seattle
       STATE: Washington
       COUNTRY: USA
       ZIP: 98101
     COMPUTER READABLE FORM:
       MEDIUM TYPE: Floppy disk
       COMPUTER: Apple Macintosh
       OPERATING SYSTEM: Apple System 7.1
       SOFTWARE: Microsoft Word for Apple, Version 5.1a
     CURRENT APPLICATION DATA:
       APPLICATION NUMBER: US/08/460,741
       FILING DATE: 02-JUN-1995
       CLASSIFICATION: 530
     PRIOR APPLICATION DATA:
       APPLICATION NUMBER: US 08/213,403
       FILING DATE: 15-MAR-1994
       APPLICATION NUMBER: US 07/977,693
       FILING DATE: 13-NOV-1992
       CLASSIFICATION: 530
     ATTORNEY/AGENT INFORMATION:
       NAME: Seese, Kathryn A.
       REGISTRATION NUMBER: 32,172
       REFERENCE/DOCKET NUMBER: 2807-A
     TELECOMMUNICATION INFORMATION:
       TELEPHONE: (206) 587-0430
       TELEFAX: (206) 233-0644
   INFORMATION FOR SEQ ID NO: 2:
     SEQUENCE CHARACTERISTICS:
       LENGTH: 346 amino acids
       TYPE: amino acid
       TOPOLOGY: linear
     MOLECULE TYPE: protein
 US-08-460-741-2
```

```
34.2%; Score 632; DB 1; Length 346;
 Query Match
 Best Local Similarity 39.5%; Pred. No. 5e-45;
 Matches 145; Conservative 48; Mismatches 116; Indels 58; Gaps 9;
         8 PGGVRVGALLLLGVLGLVSGL-----SLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLL 61
Qу
           4 PGQRWLGKWLVAMVVWALCRLATPLAKNLEPVSWSSLNPKFLSGKGLVIYPKIGDKLDII 63
Db
         62 CPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYS 121
Qу
           64 CPRAEAGRP----YEYYKLYLVRPEQAAACSTVLDPNVLVTCNRPEQEIRFTIKFQEFS 118
Db
        122 PNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPV 181
Qу
           119 PNYMGLEFKKHHDYYITSTSNGSLEGLENREGGVCRTRTMKIIMKVGQDPNAVTPEQLTT 178
Db
        182 SEMPMERDRGAAHSLE-PGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLA---- 236
QУ
          179 SRPSKEADNTVKMATQAPGSRGSLGDSDGKHETVNQEEKSGP-----GASGGSSGDPD 231
Db
        237 -----LLLLGVAGAGGA-------MCWRRRRAKPSESRHPGPGSFGRGGSLGL 277
Qy
                                  : |:| | :: | :| |
                : | 111
        232 GFFNSKVALFAAVGAGCVIFLLIIIFLTVLLLKLRKRHRKHTQQ-----RAAALSL 282
Db
        278 ----GGGGGMGPREAEPGELGIALRGGGAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSP 333
QУ
                 283 STLASPKGGSGTAGTEPSDIIIPLR---TTENNYCPHYEKVSGDYGHPVYIVQEMPPQSP 339
Db
        334 PNIYYKV 340
Qу
            11111
        340 ANIYYKV 346
Db
RESULT 9
US-08-747-240-2
; Sequence 2, Application US/08747240
; Patent No. 5728813
; GENERAL INFORMATION:
    APPLICANT: Lyman, Stewart D.
    APPLICANT: Beckmann, M. Patricia
    APPLICANT: Baum, Peter R
    APPLICANT: Carpenter, Melissa
    TITLE OF INVENTION: No. 5728813el Cytokine Designated elk Ligand
    NUMBER OF SEQUENCES: 2
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Immunex Corporation
      STREET: 51 University Street
      CITY: Seattle
      STATE: Washington
      COUNTRY: USA
      ZIP: 98101
     COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: Apple Macintosh
      OPERATING SYSTEM: Apple System 7.1
      SOFTWARE: Microsoft Word for Apple, Version 5.1a
     CURRENT APPLICATION DATA:
```

```
APPLICATION NUMBER: US/08/747,240
     FILING DATE: 12-NOV-1996
;
     CLASSIFICATION: 435
    PRIOR APPLICATION DATA:
     APPLICATION NUMBER: US 08/213,403
     FILING DATE: 15-MAR-1994
     APPLICATION NUMBER: US 07/977,693
     FILING DATE: 13-NOV-1992
     CLASSIFICATION: 435
   ATTORNEY/AGENT INFORMATION:
     NAME: Seese, Kathryn A.
     REGISTRATION NUMBER: 32,172
     REFERENCE/DOCKET NUMBER: 2807-A
    TELECOMMUNICATION INFORMATION:
     TELEPHONE: (206) 587-0430
     TELEFAX: (206) 233-0644
  INFORMATION FOR SEQ ID NO: 2:
    SEQUENCE CHARACTERISTICS:
     LENGTH: 346 amino acids
     TYPE: amino acid
     TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-747-240-2
 Query Match 34.2%; Score 632; DB 1; Length 346; Best Local Similarity 39.5%; Pred. No. 5e-45;
 Matches 145; Conservative 48; Mismatches 116; Indels 58; Gaps 9;
          8 PGGVRVGALLLLGVLGLVSGL-----SLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLL 61
Qу
           4 PGQRWLGKWLVAMVVWALCRLATPLAKNLEPVSWSSLNPKFLSGKGLVIYPKIGDKLDII 63
Db
         62 CPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYS 121
QУ
           64 CPRAEAGRP----YEYYKLYLVRPEQAAACSTVLDPNVLVTCNRPEQEIRFTIKFQEFS 118
Db
        122 PNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPV 181
ΟV
            119 PNYMGLEFKKHHDYYITSTSNGSLEGLENREGGVCRTRTMKIIMKVGQDPNAVTPEQLTT 178
Db
        182 SEMPMERDRGAAHSLE-PGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLA---- 236
Qу
          179 SRPSKEADNTVKMATQAPGSRGSLGDSDGKHETVNQEEKSGP-----GASGGSSGDPD 231
Db
        237 -----LLLLGVAGAGGA-------MCWRRRRAKPSESRHPGPGSFGRGGSLGL 277
Qу
                232 GFFNSKVALFAAVGAGCVIFLLIIIFLTVLLLKLRKRHRKHTQQ-----RAAALSL 282
Db
        278 ----GGGGGMGPREAEPGELGIALRGGGAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSP 333
Qу
                 283 STLASPKGGSGTAGTEPSDIIIPLR---TTENNYCPHYEKVSGDYGHPVYIVQEMPPQSP 339
Db
        334 PNIYYKV 340
Qу
            1111
        340 ANIYYKV 346
Db
```

```
RESULT 10
US-08-299-567-6
; Sequence 6, Application US/08299567
; Patent No. 5747033
  GENERAL INFORMATION:
    APPLICANT: Davis, et al.
    TITLE OF INVENTION: METHOD OF ENHANCING THE BIOLOGICAL
    TITLE OF INVENTION: ACTIVITY OF EPH FAMILY LIGANDS
    NUMBER OF SEQUENCES: 8
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Regeneron Pharmaceuticals, Inc.
      STREET: 777 Old Saw Mill River Road
;
      CITY: Tarrytown
;
      STATE: New York
      COUNTRY: U.S.A.
;
      ZIP: 10591-6707
;
    COMPUTER READABLE FORM:
     MEDIUM TYPE: Floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: PatentIn Release #1.0, Version #1.30
    CURRENT APPLICATION DATA:
     APPLICATION NUMBER: US/08/299,567
      FILING DATE: 01-SEP-1994
      CLASSIFICATION: 435
    ATTORNEY/AGENT INFORMATION:
     NAME: Kempler, Gail M.
      REGISTRATION NUMBER: 32,143
      REFERENCE/DOCKET NUMBER: REG 290
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: 914-345-7400
      TELEFAX: 914-345-7721
   INFORMATION FOR SEQ ID NO: 6:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 346 amino acids
      TYPE: amino acid
      STRANDEDNESS:
      TOPOLOGY: unknown
    MOLECULE TYPE: protein
US-08-299-567-6
                       34.2%; Score 632; DB 1; Length 346;
  Ouery Match
  Best Local Similarity 39.5%; Pred. No. 5e-45;
  Matches 145; Conservative 48; Mismatches 116; Indels 58; Gaps 9;
           8 PGGVRVGALLLLGVLGLVSGL-----SLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLL 61
Qу
             4 PGQRWLGKWLVAMVVWALCRLATPLAKNLEPVSWSSLNPKFLSGKGLVIYPKIGDKLDII 63
Db
          62 CPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYS 121
Qу
             64 CPRAEAGRP----YEYYKLYLVRPEQAAACSTVLDPNVLVTCNRPEQEIRFTIKFQEFS 118
Db
         122 PNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPV 181
QУ
             119 PNYMGLEFKKHHDYYITSTSNGSLEGLENREGGVCRTRTMKIIMKVGQDPNAVTPEQLTT 178
 Db
```

```
182 SEMPMERDRGAAHSLE-PGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLA---- 236
Qy
           179 SRPSKEADNTVKMATQAPGSRGSLGDSDGKHETVNQEEKSGP-----GASGGSSGDPD 231
Db
        237 -----LLLLGVAGAGGA------MCWRRRRAKPSESRHPGPGSFGRGGSLGL 277
Qv
                232 GFFNSKVALFAAVGAGCVIFLLIIIFLTVLLLKLRKRHRKHTQQ-----RAAALSL 282
Db
        278 ----GGGGGMGPREAEPGELGIALRGGGAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSP 333
Qу
                 283 STLASPKGGSGTAGTEPSDIIIPLR---TTENNYCPHYEKVSGDYGHPVYIVQEMPPQSP 339
Db
        334 PNIYYKV 340
Qу
            340 ANIYYKV 346
Db
RESULT 11
US-09-039-642B-2
; Sequence 2, Application US/09039642B
; Patent No. 6540992
; GENERAL INFORMATION:
; APPLICANT: Lyman, Stewart D.
 APPLICANT: Beckmann, M. Patricia
; APPLICANT: Baum, Peter R.
; APPLICANT: Carpenter, Melissa K.
  TITLE OF INVENTION: NOVEL CYTOKINE DESIGNATED ELK LIGAND
; FILE REFERENCE: GENENT.67CPDV3
  CURRENT APPLICATION NUMBER: US/09/039,642B
  CURRENT FILING DATE: 1998-03-16
; PRIOR APPLICATION NUMBER: 08/213,403
; PRIOR FILING DATE: 1994-03-15
; PRIOR APPLICATION NUMBER: 07/977,693
; PRIOR FILING DATE: 1992-11-13
; PRIOR APPLICATION NUMBER: 08/747,240
; PRIOR FILING DATE: 1996-10-12
  PRIOR APPLICATION NUMBER: 08/460,741
  PRIOR FILING DATE: 1995-06-02
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEO ID NO 2
   LENGTH: 346
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-039-642B-2
  Query Match 34.2%; Score 632; DB 4; Length 346; Best Local Similarity 39.5%; Pred. No. 5e-45;
  Matches 145; Conservative 48; Mismatches 116; Indels 58; Gaps 9;
           8 PGGVRVGALLLLGVLGLVSGL-----SLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLL 61
Qу
            4 PGQRWLGKWLVAMVVWALCRLATPLAKNLEPVSWSSLNPKFLSGKGLVIYPKIGDKLDII 63
Db
          62 CPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYS 121
QУ
            64 CPRAEAGRP----YEYYKLYLVRPEQAAACSTVLDPNVLVTCNRPEQEIRFTIKFQEFS 118
Db
```

```
122 PNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPV 181
QУ
            119 PNYMGLEFKKHHDYYITSTSNGSLEGLENREGGVCRTRTMKIIMKVGQDPNAVTPEQLTT 178
Db
        182 SEMPMERDRGAAHSLE-PGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLA---- 236
QУ
            179 SRPSKEADNTVKMATQAPGSRGSLGDSDGKHETVNQEEKSGP-----GASGGSSGDPD 231
        237 -----LLLLGVAGAGGA------MCWRRRRAKPSESRHPGPGSFGRGGSLGL 277
QУ
                                    : |:| | :: | :| |
                 : 1 111
        232 GFFNSKVALFAAVGAGCVIFLLIIIFLTVLLLKLRKRHRKHTQQ-----RAAALSL 282
Db
        278 ----GGGGGMGPREAEPGELGIALRGGGAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSP 333
Qy
                  283 STLASPKGGSGTAGTEPSDIIIPLR---TTENNYCPHYEKVSGDYGHPVYIVQEMPPQSP 339
Db
        334 PNIYYKV 340
Qy
             340 ANIYYKV 346
Db
RESULT 12
US-08-436-044-4
; Sequence 4, Application US/08436044
; Patent No. 5624899
  GENERAL INFORMATION:
    APPLICANT: Bennett, Brian D.
    APPLICANT: Matthews, William
    TITLE OF INVENTION: HTK LIGAND
    NUMBER OF SEQUENCES: 7
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Genentech, Inc.
      STREET: 460 Point San Bruno Blvd
      CITY: South San Francisco
      STATE: California
;
      COUNTRY: USA
      ZIP: 94080
     COMPUTER READABLE FORM:
      MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
      SOFTWARE: patin (Genentech)
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/436,044
      FILING DATE: 05-MAY-1995
      CLASSIFICATION: 435
     PRIOR APPLICATION DATA:
      APPLICATION NUMBER: 08/277722
       FILING DATE: 20-JUL-1994
     ATTORNEY/AGENT INFORMATION:
       NAME: Lee, Wendy M.
       REGISTRATION NUMBER: 00,000
       REFERENCE/DOCKET NUMBER: 902D3
     TELECOMMUNICATION INFORMATION:
       TELEPHONE: 415/225-1994
       TELEFAX: 415/952-9881
```

```
TELEX: 910/371-7168
 INFORMATION FOR SEQ ID NO: 4:
    SEQUENCE CHARACTERISTICS:
     LENGTH: 333 amino acids
     TYPE: amino acid
     TOPOLOGY: linear
US-08-436-044-4
                      34.0%; Score 629.5; DB 1; Length 333;
 Query Match
 Best Local Similarity 40.9%; Pred. No. 7.8e-45;
 Matches 135; Conservative 52; Mismatches 130; Indels 13; Gaps
         14 GALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSS 73
Qу
            14 GVLMVLCRTAISKSIVLEPIYWNSSNSKFLPGQGLVLYPQIGDKLDIICPKV---DSKTV 70
Db
         74 PNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHH 133
QУ
             71 GQYEYYKVYMVDKDQADRCTIKKENTPLLNCAKPDQDIKFTIKFQEFSPNLWGLEFQKNK 130
Db
        134 DYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQ--SPRGGAVPRKPVSEMPMER-DR 190
Qy
            131 DYYIISTSNGSLEGLDNQEGGVCQTRAMKILMKVGQDASSAGSTRNKDPTRRPELEAGTN 190
Db
        191 GAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLLGVAGAGGAMC 250
Qу
            191 GRSSTTSPFVKPNPGSSTDGNSAGHSGNNILGSEVALFAGIASGCIIFIVIIITLVVLLL 250
Db
        251 WRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGGGAADPPFCPH 310
QУ
                             |||: :| |
        251 KYRRRHRKHSPQHTTTLSLSTLATPKRSGNN----NGSEPSDIIIPLR---TADSVFCPH 303
Db
         311 YEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qy
            111111111111111111111111111111111111
         304 YEKVSGDYGHPVYIVQEMPPQSPANIYYKV 333
Db
RESULT 13
US-08-436-054-4
; Sequence 4, Application US/08436054
; Patent No. 5864020
  GENERAL INFORMATION:
    APPLICANT: Bennett, Brian D.
    APPLICANT: Matthews, William
    TITLE OF INVENTION: HTK LIGAND
    NUMBER OF SEQUENCES: 7
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Genentech, Inc.
      STREET: 460 Point San Bruno Blvd
      CITY: South San Francisco
      STATE: California
      COUNTRY: USA
      ZIP: 94080
    COMPUTER READABLE FORM:
      MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
      COMPUTER: IBM PC compatible
      OPERATING SYSTEM: PC-DOS/MS-DOS
```

```
SOFTWARE: patin (Genentech)
;
    CURRENT APPLICATION DATA:
     APPLICATION NUMBER: US/08/436,054
     FILING DATE: 05-MAY-1995
     CLASSIFICATION: 435
    PRIOR APPLICATION DATA:
     APPLICATION NUMBER: 08/277722
     FILING DATE: 20-JUL-1994
    ATTORNEY/AGENT INFORMATION:
;
     NAME: Lee, Wendy M.
     REGISTRATION NUMBER: 00,000
     REFERENCE/DOCKET NUMBER: 902D1
    TELECOMMUNICATION INFORMATION:
     TELEPHONE: 415/225-1994
      TELEFAX: 415/952-9881
     TELEX: 910/371-7168
  INFORMATION FOR SEQ ID NO: 4:
    SEQUENCE CHARACTERISTICS:
     LENGTH: 333 amino acids
     TYPE: amino acid
     TOPOLOGY: linear
US-08-436-054-4
                      34.0%; Score 629.5; DB 2; Length 333;
 Query Match
 Best Local Similarity 40.9%; Pred. No. 7.8e-45;
 Matches 135; Conservative 52; Mismatches 130; Indels 13; Gaps
         14 GALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSS 73
Qу
                   14 GVLMVLCRTAISKSIVLEPIYWNSSNSKFLPGQGLVLYPQIGDKLDIICPKV---DSKTV 70
Db
         74 PNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHH 133
Qу
              71 GQYEYYKVYMVDKDQADRCTIKKENTPLLNCAKPDQDIKFTIKFQEFSPNLWGLEFQKNK 130
Db
        134 DYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQ--SPRGGAVPRKPVSEMPMER-DR 190
Qy
            131 DYYIISTSNGSLEGLDNQEGGVCQTRAMKILMKVGQDASSAGSTRNKDPTRRPELEAGTN 190
Db
        191 GAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLLGVAGAGGAMC 250
Qy
            1:: | : | | : : : : : | | | | ::::
        191 GRSSTTSPFVKPNPGSSTDGNSAGHSGNNILGSEVALFAGIASGCIIFIVIIITLVVLLL 250
Db
        251 WRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGMGPREAEPGELGIALRGGGAADPPFCPH 310
QУ
              251 KYRRRHRKHSPQHTTTLSLSTLATPKRSGNN----NGSEPSDIIIPLR---TADSVFCPH 303
Db
        311 YEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qγ
            304 YEKVSGDYGHPVYIVQEMPPQSPANIYYKV 333
Db
RESULT 14
US-08-271-948-2
; Sequence 2, Application US/08271948
; Patent No. 6303769
; GENERAL INFORMATION:
```

```
APPLICANT: Cerretti, Douglas P.
    APPLICANT: Reddy, Pranhitha
    TITLE OF INVENTION: No. 6303769el Cytokine Designated Lerk-5
;
    NUMBER OF SEQUENCES: 3
    CORRESPONDENCE ADDRESS:
     ADDRESSEE: Immunex Corporation
      STREET: 51 University Street
     CITY: Seattle
      STATE: Washington
      COUNTRY: US
      ZIP: 98101
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: Apple Macintosh
      OPERATING SYSTEM: Apple 7.1
      SOFTWARE: Microsoft Word, Version 5.1a
   CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/271,948
      FILING DATE:
      CLASSIFICATION: 435
    ATTORNEY/AGENT INFORMATION:
      NAME: Seese, Kathryn A.
      REGISTRATION NUMBER: 32,172
      REFERENCE/DOCKET NUMBER: 2823
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (206) 587-0430
      TELEFAX: (206) 233-0644
      TELEX: 756822
  INFORMATION FOR SEQ ID NO: 2:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 333 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
    MOLECULE TYPE: protein
US-08-271-948-2
                       34.0%; Score 629.5; DB 4; Length 333;
 Query Match
 Best Local Similarity 40.9%; Pred. No. 7.8e-45;
 Matches 135; Conservative 52; Mismatches 130; Indels
                                                       13; Gaps
                                                                    5;
          14 GALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSS 73
Qу
            14 GVLMVLCRTAISKSIVLEPIYWNSSNSKFLPGQGLVLYPQIGDKLDIICPKV---DSKTV 70
Db
          74 PNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHH 133
QУ
                                   71 GQYEYYKVYMVDKDQADRCTIKKENTPLLNCAKPDQDIKFTIKFQEFSPNLWGLEFQKNK 130
Db
         134 DYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQ--SPRGGAVPRKPVSEMPMER-DR 190
QУ
            131 DYYIISTSNGSLEGLDNQEGGVCQTRAMKILMKVGQDASSAGSTRNKDPTRRPELEAGTN 190
Db
         191 GAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLLGVAGAGGAMC 250
Qy
             191 GRSSTTSPFVKPNPGSSTDGNSAGHSGNNILGSEVALFAGIASGCIIFIVIIITLVVLLL 250
Db
         251 WRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGGGAADPPFCPH 310
Qу
```

```
1
                      : |
         251 KYRRRHRKHSPQHTTTLSLSTLATPKRSGNN----NGSEPSDIIIPLR---TADSVFCPH 303
Db
         311 YEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Q·γ
             304 YEKVSGDYGHPVYIVQEMPPQSPANIYYKV 333
Db
RESULT 15
US-08-739-333-2
; Sequence 2, Application US/08739333
; Patent No. 6479459
  GENERAL INFORMATION:
    APPLICANT: Cerretti, Douglas P.
    APPLICANT: Reddy, Pranhitha
    TITLE OF INVENTION: No. 6479459el Cytokine Designated Lerk-5
;
    NUMBER OF SEQUENCES: 3
    CORRESPONDENCE ADDRESS:
      ADDRESSEE: Immunex Corporation
      STREET: 51 University Street
      CITY: Seattle
      STATE: Washington
      COUNTRY: US
      ZIP: 98101
    COMPUTER READABLE FORM:
      MEDIUM TYPE: Floppy disk
      COMPUTER: Apple Macintosh
      OPERATING SYSTEM: Apple 7.1
      SOFTWARE: Microsoft Word, Version 5.1a
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/739,333
       FILING DATE: 29-OCT-1996
      CLASSIFICATION: 536
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US 08/271,948
      FILING DATE: 08-JUL-1994
    ATTORNEY/AGENT INFORMATION:
      NAME: Seese, Kathryn A.
       REGISTRATION NUMBER: 32,172
      REFERENCE/DOCKET NUMBER: 2823
     TELECOMMUNICATION INFORMATION:
       TELEPHONE: (206) 587-0430
       TELEFAX: (206) 233-0644
       TELEX: 756822
   INFORMATION FOR SEQ ID NO: 2:
     SEQUENCE CHARACTERISTICS:
       LENGTH: 333 amino acids
       TYPE: amino acid
       TOPOLOGY: linear
     MOLECULE TYPE: protein
US-08-739-333-2
                         34.0%; Score 629.5; DB 4; Length 333;
  Query Match
  Best Local Similarity 40.9%; Pred. No. 7.8e-45;
  Matches 135; Conservative 52; Mismatches 130; Indels 13; Gaps
                                                                         5;
```

		:: : : :	7.0
Db	14	GVLMVLCRTAISKSIVLEPIYWNSSNSKFLPGQGLVLYPQIGDKLDIICPKVDSKTV	70
QУ	74	PNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHH	133
Db		GQYEYYKVYMVDKDQADRCTIKKENTPLLNCAKPDQDIKFTIKFQEFSPNLWGLEFQKNK	
QУ		DYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPVSEMPMER-DR	
Db		DYYIISTSNGSLEGLDNQEGGVCQTRAMKILMKVGQDASSAGSTRNKDPTRRPELEAGTN	
QУ		GAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLLGVAGAGGAMC : : : : : : : : : : : : : : : : :	
Db		GRSSTTSPFVKPNPGSSTDGNSAGHSGNNILGSEVALFAGIASGCIIFIVIIITLVVLLL	
QΆ	_	WRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGGGAADPPFCPH	
Db		KYRRRHRKHSPQHTTTLSLSTLATPKRSGNNNGSEPSDIIIPLRTADSVFCPH	303
QУ		YEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340	
Db	304	YEKVSGDYGHPVYIVQEMPPQSPANIYYKV 333	

Search completed: April 13, 2004, 09:29:18 Job time: 25.3774 secs

GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: April 13, 2004, 09:22:17; Search time 14.5409 Seconds

(without alignments)

2249.184 Million cell updates/sec

Title: US-10-021-121-4

Perfect score: 1850

Sequence: 1 MGPPHSGPGGVRVGALLLLG.....PVYIVQDGPPQSPPNIYYKV 340

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283366 seqs, 96191526 residues

Total number of hits satisfying chosen parameters: 283366

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: PIR_78:*

1: pir1:*

2: pir2:*

3: pir3:*

4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	guery Match	Length	DB	ID	Description
1 2 3 4 5 6 7 8 9 10 11 12 13	637.5 632 629.5 613.5 608.5 214.5 179 176 175.5 170.5 169.5 167.5	34.5 34.2 34.0 33.2 32.9 11.6 9.7 9.5 9.5 9.2 9.2 9.1	336 346 333 345 345 237 238 209 213 228 201 228 205	2 2 2 2 2 2 2 2 2 2 2	I49766 S46993 I84743 I48780 I58406 T19914 I38849 A54984 JE0322 A57084 I38850 I58170 A36377	hepatoma transmemb elk ligand - human hepatoma transmemb Stral/Eplg2 protei LERK-2 - rat hypothetical prote LERK-3 - human ELF-1 protein precephrin-A2 - human repulsive axon gui LERK-4 - human LERK-7 precursor - B61 protein precur

14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39	159 154.5 153.5 151.5 149 148.5 148.5 146.5 146.5 146.5 146.5 145.5 145 145.5 145 145 141 143 142.5 142 142 141.5	8.4 8.3 8.1 8.0 9.9 9.9 9.9 7.7 7.7 7.7 7.7 7.7 7.7 7.7	680 1049 1670 301 325 569 316 921 1315 1492 1774 675 305 674 931 438 1027 1747 743 1496 744 1029 1763 1466 319 744	2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	S31216 CGBO7S CGHU3B B31219 T32248 S42886 T20497 S42617 A56101 A40333 B56101 S20819 T20906 S13301 S13580 S53787 S28774 A54121 S23779 CGHU2V S15435 S21369 S16366 CGHU7L T32250 A34246 S23298	collagen alpha 1(X collagen alpha 1(I collagen alpha 3(I collagen 2 - Caeno hypothetical prote collagen - silkwor hypothetical prote collagen alpha 1(I collagen alpha 1(X collagen alpha 1(X collagen alpha 1(X collagen alpha 3(I hypothetical prote collagen alpha 1(X collagen alpha 1(X collagen alpha 1(X collagen alpha 1(X collagen alpha 1(I collagen alpha cha collagen alpha cha collagen alpha 1(V collagen alpha 2(V collagen alpha 2(V collagen alpha 2(I collagen alpha 1(I hypothetical prote collagen alpha 1(I hypothetical prote collagen alpha 1(V collagen alph
39 40	141 141	7.6	744	1	S23298	collagen alpha 1(V
41	140.5	7.6	305	2	T30165	hypothetical prote
42	140.5	7.6	304	2	T22482	hypothetical prote
	140	7.6	680	1	CGHU1D	collagen alpha 1(X
43		7.5	210	2	B44984	collagen - nematod
44	139.5		940	2	JE0291	FB19 protein - hum
45	139	7.5	940	2	050231	1213 P10 0011

ALIGNMENTS

```
RESULT 1
I49766
hepatoma transmembrane kinase ligand - mouse
C; Species: Mus musculus (house mouse)
C;Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 05-Nov-1999
C; Accession: I49766
R; Bennett, B.D.; Zeigler, F.C.; Gu, Q.; Fendly, B.; Goddard, A.D.; Gillett, N.;
Matthews, W.
Proc. Natl. Acad. Sci. U.S.A. 92, 1866-1870, 1995
A; Title: Molecular cloning of a ligand for the EPH-related receptor protein-
tyrosine kinase Htk.
A; Reference number: I49766; MUID:95199254; PMID:7534404
A; Accession: I49766
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-336 < RES>
A; Cross-references: GB:L38847; NID:g769677; PIDN:AAC42052.1; PID:g769678
C; Genetics:
A; Gene: HTK
```

```
34.5%; Score 637.5; DB 2; Length 336;
 Query Match
 Best Local Similarity 42.1%; Pred. No. 1.8e-37;
                                                                     5;
 Matches 139; Conservative 49; Mismatches 129; Indels
                                                         13; Gaps
         14 GALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSS 73
QУ
                    17 GLLMVLCRTAISRSIVLEPIYWNSSNSKFLPGQGLVLYPQIGDKLDIICPKV---DSKTV 73
Db
         74 PNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHH 133
Qу
                                    11:11:1:1
         74 GQYEYYKVYMVDKDQADRCTIKKENTPLLNCARPDQDVKFTIKFQEFSPNLWGLEFQKNK 133
Db
         134 DYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQ--SPRGGAVPRKPVSEMPMER-DR 190
Qу
            134 DYYIISTSNGSLEGLDNQEGGVCQTRAMKILMKVGQDASSAGSARNHGPTRRPELEAGTN 193
Db
         191 GAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLLGVAGAGGAMC 250
Qy
            194 GRSSTTSPFVKPNPGSSTDGNSAGHSGNNLLGSEVALFAGIASGCIIFIVIIITLVVLLL 253
Db
         251 WRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGGGAADPPFCPH 310
Qу
                                             :11::111
                                                          : ||
                          1
                     : |
         254 KYRRRHRKHSPQHTTTLSLSTLATPKRGGNN----NGSEPSDVIIPLR---TADSVFCPH 306
Db
         311 YEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qу
            307 YEKVSGDYGHPVYIVQEMPPQSPANIYYKV 336
Db
RESULT 2
S46993
elk ligand - human
C; Species: Homo sapiens (man)
C;Date: 15-Jul-1995 #sequence revision 10-Nov-1995 #text_change 28-May-1999
C; Accession: S46993
R; Beckmann, M.P.; Cerretti, D.P.; Baum, P.; vanden Bos, T.; James, L.; Farrah,
T.; Kozlosky, C.; Hollingsworth, T.; Shilling, H.; Maraskovsky, E.; Fletcher,
F.A.; Lhotak, V.; Pawson, T.; Lyman, S.D.
EMBO J. 13, 3757-3762, 1994
A; Title: Molecular characterization of a family of ligands for eph-related
tyrosine kinase receptors.
A; Reference number: S46993; MUID: 94349923; PMID: 8070404
A; Accession: S46993
A; Status: preliminary
A; Molecule type: mRNA
A: Residues: 1-346 <BEC>
A; Cross-references: GB: U09304; NID: g538366; PIDN: AAA53093.1; PID: g538367
                       34.2%; Score 632; DB 2; Length 346;
  Query Match
                       39.5%; Pred. No. 4.4e-37;
  Best Local Similarity
  Matches 145; Conservative 48; Mismatches 116; Indels 58; Gaps
                                                                     9;
           8 PGGVRVGALLLLGVLGLVSGL-----SLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLL 61
QУ
                                     :|||| |:| |:| : | |:||:||:||:||:||:
                 :| |: |: : |
           4 PGQRWLGKWLVAMVVWALCRLATPLAKNLEPVSWSSLNPKFLSGKGLVIYPKIGDKLDII 63
Db
          62 CPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYS 121
Qу
```

```
64 CPRAEAGRP----YEYYKLYLVRPEQAAACSTVLDPNVLVTCNRPEQEIRFTIKFQEFS 118
Db
        122 PNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPV 181
Qy
            119 PNYMGLEFKKHHDYYITSTSNGSLEGLENREGGVCRTRTMKIIMKVGQDPNAVTPEQLTT 178
Db
        182 SEMPMERDRGAAHSLE-PGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLA---- 236
Qy
                                        : | |
                       :: ||
                                11
            1 1
         179 SRPSKEADNTVKMATQAPGSRGSLGDSDGKHETVNQEEKSGP-----GASGGSSGDPD 231
Db
         237 -----LLLLGVAGAGGA------MCWRRRRAKPSESRHPGPGSFGRGGSLGL 277
Qу
                                        : 1:1 1 ::
                       : |
         232 GFFNSKVALFAAVGAGCVIFLLIIIFLTVLLLKLRKRHRKHTQQ-----RAAALSL 282
Db
         278 ----GGGGGMGPREAEPGELGIALRGGGAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSP 333
Qу
                                     11:: | ||
         283 STLASPKGGSGTAGTEPSDIIIPLR---TTENNYCPHYEKVSGDYGHPVYIVQEMPPQSP 339
Db
         334 PNIYYKV 340
Qу
             +
         340 ANIYYKV 346
Db
RESULT 3
I84743
hepatoma transmembrane kinase ligand - human
C; Species: Homo sapiens (man)
C; Date: 24-May-1996 #sequence_revision 24-May-1996 #text_change 05-Nov-1999
C; Accession: I84743
R; Bennett, B.D.; Zeigler, F.C.; Gu, Q.; Fendly, B.; Goddard, A.D.; Gillett, N.;
Matthews, W.
Proc. Natl. Acad. Sci. U.S.A. 92, 1866-1870, 1995
A; Title: Molecular cloning of a ligand for the EPH-related receptor protein-
tyrosine kinase Htk.
A; Reference number: 149766; MUID: 95199254; PMID: 7534404
A; Accession: 184743
A; Status: preliminary; translated from GB/EMBL/DDBJ
A: Molecule type: mRNA
A; Residues: 1-333 < RES>
A; Cross-references: GB:L38734; NID:g769675; PIDN:AAC41752.1; PID:g769676
C:Genetics:
A; Gene: GDB: EPLG5; LERK5
A; Cross-references: GDB: 438338; OMIM: 600527
A; Map position: 13q33-13q33
                       34.0%; Score 629.5; DB 2; Length 333;
  Query Match
  Best Local Similarity 40.9%; Pred. No. 6.4e-37;
  Matches 135; Conservative 52; Mismatches 130; Indels 13; Gaps
                                                                     5;
          14 GALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSS 73
Qу
                                         : : |||:|||:| :|
          14 GVLMVLCRTAISKSIVLEPIYWNSSNSKFLPGQGLVLYPQIGDKLDIICPKV---DSKTV 70
Db
          74 PNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHH 133
Qy
                                     11:11:1:1
          71 GQYEYYKVYMVDKDQADRCTIKKENTPLLNCAKPDQDIKFTIKFQEFSPNLWGLEFQKNK 130
Db
```

```
134 DYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQ--SPRGGAVPRKPVSEMPMER-DR 190
Qу
              : |
         131 DYYIISTSNGSLEGLDNQEGGVCQTRAMKILMKVGQDASSAGSTRNKDPTRRPELEAGTN 190
Db
         191 GAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLLGVAGAGGAMC 250
QУ
              1:: 1: 11 | :: : : : : 11 | | ::::
         191 GRSSTTSPFVKPNPGSSTDGNSAGHSGNNILGSEVALFAGIASGCIIFIVIIITLVVLLL 250
Db
         251 WRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGGGAADPPFCPH 310
Qу
                                                  :|| :: | ||
                       :|
                                  :
                             1
          251 KYRRRHRKHSPQHTTTLSLSTLATPKRSGNN----NGSEPSDIIIPLR---TADSVFCPH 303
Db
          311 YEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
QУ
              304 YEKVSGDYGHPVYIVQEMPPQSPANIYYKV 333
Db
RESULT 4
T48780
Stra1/Eplg2 protein - mouse
C; Species: Mus musculus (house mouse)
C;Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 05-Nov-1999
C; Accession: I48780; A55507; A55062; S52670
R; Bouillet, P.; Oulad-Abdelghani, M.; Vicaire, S.; Garnier, J.M.; Schuhbaur, B.;
Dolle, P.; Chambon, P.
Dev. Biol. 170, 420-433, 1995
A; Title: Efficient cloning of cDNAs of retinoic acid-responsive genes in P19
embryonal carcinoma cells and characterization of a novel mouse gene, Stral
(mouse LERK-2/Eplg2).
A; Reference number: I48780; MUID: 95377533; PMID: 7649373
A; Accession: I48780
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-345 < RES>
A; Cross-references: EMBL: Z48781; NID: g747858; PIDN: CAA88695.1; PID: g747859
R; Fletcher, F.A.; Renshaw, B.; Hollingsworth, T.; Baum, P.; Lyman, S.D.;
Jenkins, N.A.; Gilbert, D.J.; Copeland, N.G.; Davison, B.L.
Genomics 24, 127-132, 1994
A; Title: Genomic organization and chromosomal localization of mouse Eplg2, a
gene encoding a binding protein for the receptor tyrosine kinase Elk.
A; Reference number: A55507; MUID: 95203867; PMID: 7896266
A; Accession: A55507
A; Status: preliminary
A; Molecule type: DNA
A; Residues: 1-345 <FLE>
A; Cross-references: GB: U07598
R; Shao, H.; Lou, L.; Pandey, A.; Pasquale, E.B.; Dixit, V.M.
 J. Biol. Chem. 269, 26606-26609, 1994
 A; Title: cDNA cloning and characterization of a ligand for the Cek5 receptor
 protein-tyrosine kinase.
 A; Reference number: A55062; MUID: 95014510; PMID: 7929389
 A; Accession: A55062
 A; Status: preliminary; not compared with conceptual translation
 A; Molecule type: mRNA
 A; Residues: 1-89, 'T', 91-345 <SHA>
 A; Cross-references: GB:U12983; NID:g575928; PIDN:AAA53231.1; PID:g575929
```

```
C; Genetics:
A; Gene: EPLG2
```

```
33.2%; Score 613.5; DB 2; Length 345;
 Query Match
 Best Local Similarity 38.2%; Pred. No. 8.7e-36;
 Matches 138; Conservative 51; Mismatches 107; Indels
                                                      65; Gaps 10;
         15 ALLLLGVLGLVSGL--SLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHS 72
Qу
           15 AMVVLTLCRLATPLAKNLEPVSWSSLNPKFLSGKGLVIYPKIGDKLDIICPRAEAGRP-- 72
Db
         73 SPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSH 132
QУ
              73 ---YEYYKLYLVRPEQAAACSTVLDPNVLVTCNKPHQEIRFTIKFQEFSPNYMGLEFKKY 129
Db
        133 HDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPVSEMPMERDRGA 192
QУ
            130 HDYYITSTSNGSLEGLENREGGVCRTRTMKIVMKVGQDP-NAVTPEQLTTSRPSKESDNT 188
Db
        193 AHSLEPGKENLPGDPTSNATSRGAEGP-----LPPPSMPAVAGAAGG-----LA 236
Qy
                                             : | ||::|
        189 VKT-----ATQAPGRGSQGDSDGKHETVNQEEKSGPGAGGGGSGDSDSFFNSK 236
Db
        237 LLLLGVAGAGGA-----GG 279
Qу
                                : |:| | :: | :| |
            : 1 111
        237 VALFAAVGAGCVIFLLIIIFLTVLLLKLRKRHRKHTQQ-----RAAALSLSTLASP 287
Db
        280 GGGMGPREAEPGELGIALRGGGAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYK 339
QУ
             288 KGGSGTAGTEPSDIIIPLR---TTENNYCPHYEKVSGDYGHPVYIVQEMPPQSPANIYYK 344
Db
         340 V 340
Qу
         345 V 345
Dh
RESULT 5
I58406
LERK-2 - rat
C; Species: Rattus norvegicus (Norway rat)
C; Date: 26-Jul-1996 #sequence_revision 26-Jul-1996 #text_change 05-Nov-1999
C; Accession: I58406
R; Fletcher, F.A.; Carpenter, M.; Shilling, H.; Baum, P.; Ziegler, S.; Gimpel,
S.; Hollingsworth, T.; VandenBos, T.; Davison, B.L.; Lyman, S.D.; Beckmann, M.P.
Oncogene 9, 3241-3248, 1994
A; Title: LERK-2, a ligand for the receptor tyrosine kinase ELK, is
evolutionarily conserved and expressed in a developmentally regulated pattern.
A; Reference number: I58406; MUID: 95022634; PMID: 7936648
A; Accession: I58406
A;Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-345 < RES>
A; Cross-references: EMBL: U07560; NID: g563118; PIDN: AAA53092.1; PID: g563119
C; Genetics:
A; Gene: Eplg2
                      32.9%; Score 608.5; DB 2; Length 345;
  Ouery Match
```

```
Best Local Similarity 38.0%; Pred. No. 1.9e-35;
 Matches 137; Conservative 52; Mismatches 107; Indels 65; Gaps 10;
         15 ALLLLGVLGLVSGL--SLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHS 72
Qv
           15 AMVVLTLCRLATPLAKNLEPVSWSSLNPKFLSGKGLVIYPKIGDKLDIICPRAEAGRP-- 72
Dh
         73 SPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSH 132
Qу
              73 ---YEYYKLYLVRPEQAAACSTVLDPNVLVTCNKPQQEIRFTIKFQEFSPNYMGLEFKKY 129
Db
        133 HDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPVSEMPMERDRGA 192
QУ
            130 HDYYITSTSNGSLEGLENREGGVCRTRTMKIVMKVGQDP-NAVTPEQLTTSRPSKESDNT 188
Db
        193 AHSLEPGKENLPGDPTSNATSRGAEGP-----LPPPSMPAVAGAAGG-----LA 236
Qу
                                             1 1 1: 1
                         : | ||::|
             :
        189 VKT-----ATQAPGRGSQGDSDGKHETVNQQEKSGPGAGGSGSGDTDSFFNSK 236
Db
        237 LLLLGVAGAGGA-----GG 279
QУ
                                : |:| | ::
                                                   1 :1 1
            : 1 111
        237 VALFAAVGAGCVIFLLIIIFLTVLLLKLRKRHRKHTQQ-----RAAALSLSTLASP 287
Db
        280 GGGMGPREAEPGELGIALRGGGAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYK 339
QУ
             288 KGDSGTAGTEPSDIIIPLR---TTENNYCPHYEKVSGDYGHPVYIVQEMPPQSPANIYYK 344
Db
        340 V 340
Qу
        345 V 345
Db
RESULT 6
T19914
hypothetical protein C43F9.8 - Caenorhabditis elegans
C; Species: Caenorhabditis elegans
C; Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 15-Oct-1999
C; Accession: T19914
R: Mortimore, B.
submitted to the EMBL Data Library, November 1996
A; Reference number: Z19195
A; Accession: T19914
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A: Residues: 1-237 <WIL>
A; Cross-references: EMBL: Z82262; PIDN: CAB54195.1; GSPDB: GN00022; CESP: C43F9.8
A; Experimental source: clone C43F9
C; Genetics:
A; Gene: CESP:C43F9.8
A; Map position: 4
A; Introns: 32/2; 96/3; 214/1
                       11.6%; Score 214.5; DB 2; Length 237;
  Query Match
  Best Local Similarity 25.7%; Pred. No. 4.6e-08;
  Matches 53; Conservative 41; Mismatches 83; Indels 29; Gaps
                                                                   6;
QУ
```

```
1 MQIATFILLSLFPFIGWARKIPDINWISSNPIFDVSNTDHVISVHIGDRVSIRCPKSDET 60
Db
         69 GPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHE 128
Qу
          61 G----KYEYSYIYMVSDEEYDHCFL-SKPRLVGACDNQTINASINIVFRSFTPTPGGFE 114
Db
        129 FRSHHDYYIIA-----TSDGTREGLESLQGGVCLTRGMKVLLRVGQ 169
Qу
                                    1: :::::
        115 FQPGKNYFLISKSEVDALIIYETANQIFPGTSDGTLEGIDRKKDGLCTAKQMKIKFEVGQ 174
Db
        170 SPRGGAVPRKPVSEMPMERDRGAAHS 195
Qу
                 -|: : :::|| | ||
        175 DRRGIENPK--FAARTLKKDRDAEHS 198
Db
RESULT 7
I38849
LERK-3 - human
C; Species: Homo sapiens (man)
C;Date: 29-May-1998 #sequence_revision 29-May-1998 #text_change 29-Sep-1999
C; Accession: I38849
R; Kozlosky, C.J.; Maraskovsky, E.; McGrew, J.T.; VandenBos, T.; Teepe, M.;
Lyman, S.D.; Srinivasan, S.; Fletcher, F.A.; Gayle, R.B.
Oncogene 10, 299-306, 1995
A; Title: Ligands for the receptor tyrosine kinases hek and elk: isolation of
cDNAs encoding a family of proteins.
A; Reference number: I38849; MUID: 95140419; PMID: 7838529
A; Accession: I38849
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-238 < RES>
A; Cross-references: EMBL: U14187; NID: g642832; PIDN: AAC50078.1; PID: g642833
C; Genetics:
A; Gene: GDB: EPLG3
A; Cross-references: GDB: 438336; OMIM: 601381
A; Map position: 1q21-1q22
C; Superfamily: axon guidance signal protein
                       9.7%; Score 179; DB 2; Length 238;
  Ouery Match
  Best Local Similarity 28.4%; Pred. No. 1.4e-05;
          65; Conservative 24; Mismatches 80; Indels 60; Gaps 12;
          7 GPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCP--R 64
Qу
            24 GPG-----GALG----NRHAVYWNSSNQHLRRE-GYTVQVNVNDYLDIYCPHYN 67
Db
          65 ARPPGPHSSP----NYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDL---DLRFTIKF 117
 QУ
            68 SSGVGPGAGPGPGGGAEQYVLYMVSRNGYRTCNASQGFK-RWECNRPHAPHSPIKFSEKF 126
 Db
         118 QEYSPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVP 177
 QУ
            127 QRYSAFSLGYEFHAGHEYYYISTPTHNLH------WKCLR--MKVFVCCASTSHSG--- 174
 Db
         178 RKPVSEMP------MERDRGAAHSLE-----PGKENLP 204
 QУ
                               |: ||
             111 :1
```

```
RESULT 8
A54984
ELF-1 protein precursor - mouse
N; Alternate names: Cek7 ligand
C; Species: Mus musculus (house mouse)
C; Date: 11-Nov-1994 #sequence_revision 11-Nov-1994 #text_change 29-Sep-1999
C; Accession: A54984; A55873
R; Cheng, H.J.; Flanagan, J.G.
Cell 79, 157-168, 1994
A; Title: Identification and cloning of ELF-1, a developmentally expressed ligand
for the Mek4 and Sek receptor tyrosine kinases.
A; Reference number: A54984; MUID: 95007776; PMID: 7522971
A; Accession: A54984
A; Status: preliminary
A; Molecule type: mRNA
A; Residues: 1-209 <CHE>
A;Cross-references: GB:U14941; NID:g558836; PIDN:AAA53636.1; PID:g558837
R; Shao, H.; Lou, L.; Pandey, A.; Verderame, M.F.; Siever, D.A.; Dixit, V.M.
J. Biol. Chem. 270, 3467-3470, 1995
A; Title: cDNA cloning and characterization of a Cek7 receptor protein-tyrosine
kinase ligand that is identical to the ligand (ELF-1) for the Mek-4 and Sek
receptor protein-tyrosine kinases.
A; Reference number: A55873; MUID: 95181289; PMID: 7876076
A; Accession: A55873
A; Status: preliminary
A; Molecule type: mRNA
A; Residues: 1-209 <SHA>
A; Cross-references: GB:U14752; NID:g681886; PIDN:AAA68520.1; PID:g681887
C; Superfamily: axon guidance signal protein
C; Keywords: lipoprotein; membrane protein
                          9.5%; Score 176; DB 2; Length 209;
  Query Match
  Best Local Similarity 29.3%; Pred. No. 2e-05;
          58; Conservative 19; Mismatches 69; Indels 52; Gaps
                                                                         7;
           33 VYWNSANKRFQAE----GGYVLYPQIGDRLDLLCPRARPPGPHSSPNYEFYKLYLVGGA 87
Qу
              35 VYWNRSNPRFQVSAVGDGGGYTVEVSINDYLDIYCPHYGAPLP-PAERMERYILYMVNGE 93
 Db
           88 QGRRCEAPPAPNLLLTCDRPDL---DLRFTIKFQEYSPNLWGHEFRSHHDYYIIATSDGT 144
 Qу
                                      1:11
           94 GHASCDHRQRGFKRWECNRPAAPGGPLKFSEKFQLFTPFSLGFEFRPGHEYYYISATP-- 151
 Db
          145 REGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPVSEMPMERDRGAAHSLEPGKENLP 204
 QУ
                        11 :11 :1
          152 ----PNLVDRPCLR--LKVYVR-------PTNETLY 174
 Db
          205 GDP----TSNATSRGAEG 218
 Qy
                     111:: 1 1
                - 1
          175 EAPEPIFTSNSSCSGLGG 192
 Db
```

RESULT 9 JE0322

```
ephrin-A2 - human
C; Species: Homo sapiens (man)
C; Date: 05-Feb-1999 #sequence_revision 05-Feb-1999 #text_change 21-Jul-2000
C; Accession: JE0322
R; Aasheim, H.; Pedeutour, F.; Grosgeorge, J.; Logtenberg, T.
Biochem. Biophys. Res. Commun. 252, 378-382, 1998
A; Title: Cloning, chromosal mapping, and tissue expression of the gene encoding
the human Eph-family kinase ligand ephrin-A2.
A; Reference number: JE0322; MUID: 99045414; PMID: 9826538
A; Accession: JE0322
A; Status: preliminary
A; Molecule type: mRNA
A; Residues: 1-213 <AAS>
A; Cross-references: GB:AJ007292; NID:g3688367; PIDN:CAA07435.1; PID:g3688368
C; Superfamily: axon guidance signal protein
                          9.5%; Score 175.5; DB 2; Length 213;
  Query Match
                         36.8%; Pred. No. 2.2e-05;
  Best Local Similarity
                                                                           3;
                                               51; Indels
                                                               9; Gaps
                              14; Mismatches
           43; Conservative
  Matches
           33 VYWNSANKRFQA----EGGYVLYPQIGDRLDLLCPRARPPGPHSSPNYEFYKLYLVGGA 87
QУ
                               1111:111
           39 VYWNRSNPRFHAGAGDDGGGYTVEVSINDYLDIYCPHYGAPLP-PAERMEHYVLYMVNGE 97
Db
           88 QGRRCEAPPAPNLLLTCDRPDL---DLRFTIKFQEYSPNLWGHEFRSHHDYYIIATS 141
QУ
                                       1:1: 111 ::1
                                                     1:11
           98 GHASCDHRQRGFKRWECNRPAAPGGPLKFSEKFQLFTPFSLGFEFRPGHEYYYISAT 154
Dh
RESULT 10
A57084
repulsive axon guidance signal protein RAGS precursor - chicken
C; Species: Gallus gallus (chicken)
C;Date: 03-Nov-1995 #sequence_revision 03-Nov-1995 #text_change 20-Jun-2000
C; Accession: A57084
R; Drescher, U.; Kremoser, C.; Handweker, C.; Loeschinger, J.; Noda, M.;
Bonhoeffer, F.
Cell 82, 359-370, 1995
A; Title: In vitro guidance of retinal ganglion cell axons by RAGS, a 25 kDa
tectal protein related to ligands for Eph receptor tyrosine kinases.
A; Reference number: A57084; MUID: 95360980; PMID: 7634326
 A; Accession: A57084
A; Status: preliminary; not compared with conceptual translation
 A; Molecule type: mRNA
 A; Residues: 1-228 < DRE>
A; Cross-references: GB: X90377; NID: g1061113; PIDN: CAA62027.1; PID: g984118
 C; Superfamily: axon guidance signal protein
 C; Keywords: glycoprotein; membrane protein; phosphatidylinositol linkage
 F;1-20/Domain: signal sequence #status predicted <SIG>
                           9.2%; Score 170.5; DB 2; Length 228;
   Query Match
   Best Local Similarity 28.9%; Pred. No. 5.3e-05;
           73; Conservative 30; Mismatches 91; Indels
                                                               59; Gaps
                                                                           13;
            16 LLLLGVLGL-VSGLSLEP------VYWNSANKRFQAEGGYVLYPQIGDRLDLLCPR 64
 QУ
                                         6 MLLLAVAALWVCVRGQEPGRKAVADRYAVYWNSTNPRFQ-QGDYHIDVCINDYLDVFCPH 64
 Db
```

```
65 ARPPGPHSSPNYEFYKLYLVG------GAQGRRCEAPPAPNLLLTCDRPDLDLR 112
               QУ
         65 YEDSVPEDKT--ERYVLYMVNFDGYSSCDHISKGFKRWECNRPHSPN------GPLK 113
Db
        113 FTIKFQEYSPNLWGHEFRSHHDYYIIATS---DGTREGLESLQGGVCLTRGMKVLLRVGQ 169
Qу
            114 FSEKFQLFTPFSLGFEFRPGREYFYISSAIPDNGRRS-----CLK--LKVFVR--- 159
        170 SPRGGAVPRKPVSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMP--A 227
QУ
                : |: :: :|||| :: | | ||| |||
                                                         | : |
        160 -PANSCMKTIGVHDRVFDVNDKVENSLEPADDTV---RESAEPSRG-ENAAQTPRIPIRL 214
Db
        228 VAGAAGGLALLLL 240
QΨ
                  11:11:
        215 LATLLFLLAMLLI 227
Db
RESULT 11
T38850
LERK-4 - human
C; Species: Homo sapiens (man)
C; Date: 29-May-1998 #sequence_revision 29-May-1998 #text_change 29-Sep-1999
C; Accession: I38850
R; Kozlosky, C.J.; Maraskovsky, E.; McGrew, J.T.; VandenBos, T.; Teepe, M.;
Lyman, S.D.; Srinivasan, S.; Fletcher, F.A.; Gayle, R.B.
Oncogene 10, 299-306, 1995
A; Title: Ligands for the receptor tyrosine kinases hek and elk: isolation of
cDNAs encoding a family of proteins.
A; Reference number: I38849; MUID:95140419; PMID:7838529
A; Accession: I38850
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-201 <RES>
A; Cross-references: EMBL: U14188; NID: g642834; PIDN: AAC50079.1; PID: g642835
C; Genetics:
A; Gene: GDB: EPLG4
A; Cross-references: GDB:438337; OMIM:601380
A; Map position: 1q21-1q22
C; Superfamily: axon guidance signal protein
                        9.2%; Score 169.5; DB 2; Length 201;
  Query Match
  Best Local Similarity 29.9%; Pred. No. 5.4e-05;
  Matches 66; Conservative 18; Mismatches 82; Indels 55; Gaps
          24 LVSGLSL-EPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSSPNYEFYKLY 82
 Qу
             20 LRGGSSLRHVVYWNSSNPRL-LRGDAVVELGLNDYLDIVCPHYEGPGPPEGP--ETFALY 76
 Db
          83 LVGGAQGRRCEAP-PAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHHDYYIIATS 141
 Qу
                    1:1 1 1 1:1:1 1 1::1 1 1::1
          77 MVDWPGYESCQAEGPRAYKRWVCSLPFGHVQFSEKIQRFTPFSLGFEFLPGETYYYISVP 136
 Db
         142 DGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPVSEMPMERDRGAAHSLEPGKE 201
 QУ
                                           1 1
         137 --TPE----SSGQCL----- 164
 Db
```

```
202 NLPGDPTSNATS--RGAEGPLPPPSMPAVAGAAGGLALLLL 240
Qу
               | | : | | | : | |
         165 ---GSPGESGTSGWRGGDTPSP-----LCLLLL 189
Db
RESULT 12
I58170
LERK-7 precursor - human
N; Alternate names: AL-1
C; Species: Homo sapiens (man)
C; Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 29-Sep-1999
C; Accession: I58170; G01812
R; Winslow, J.W.; Moran, P.; Valverde, J.; Shih, A.; Yuan, J.Q.; Wong, S.C.;
Tsai, S.P.; Goddard, A.; Henzel, W.J.; Hefti, F.
Neuron 14, 973-981, 1995
A; Title: Cloning of AL-1, a ligand for an Eph-related tyrosine kinase receptor
involved in axon bundle formation.
A; Reference number: I58170; MUID: 95267434; PMID: 7748564
A; Accession: I58170
A; Status: preliminary; translated from GB/EMBL/DDBJ
A: Molecule type: mRNA
A; Residues: 1-228 < RES>
A; Cross-references: GB: S77167; NID: g914184; PID: g914185
R; Kozlosky, C.J.; VandenBos, T.; Park, L.S.; Cerretti, D.P.; Carpenter, M.K.
submitted to the EMBL Data Library, May 1995
A; Reference number: G08477
A; Accession: G01812
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: mRNA
A; Residues: 1-228 < KOZ>
A; Cross-references: EMBL: U26403; NID: g1019430; PIDN: AAB60377.1; PID: g1019431
C; Genetics:
A; Gene: GDB: EPLG7; AF1; LERK7
A; Cross-references: GDB: 568757; OMIM: 601535
A; Map position: 13q33-13q33
C; Superfamily: axon guidance signal protein
                         9.1%; Score 167.5; DB 2; Length 228;
  Ouery Match
  Best Local Similarity 28.8%; Pred. No. 8.5e-05;
  Matches 65; Conservative 29; Mismatches 81; Indels 51; Gaps
                                                                     11:
          33 VYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSSPNYEFYKLYLVG----- 85
QУ
             34 VYWNSSNPRFQ-RGDYHIDVCINDYLDVFCPHYEDSVPEDKT--ERYVLYMVNFDGYSAC 90
Db
          86 ----GAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHHDYYIIAT 140
Qу
                  91 DHTSKGFKRWECNRPHSPN-----GPLKFSEKFQLFTPFSLGFEFRPGREYFYISS 141
 Db
         141 S---DGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPVSEMPMERDRGAAHSLE 197
 QУ
             142 AIPDNGRRS-----CLK--LKVFVR----PTNSCMKTIGVHDRVFDVNDKVENSLE 186
 Db
          198 PGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLLGVA 243
 QУ
             187 PADDTV---HESAEPSRG-ENAAQTPRIPSRL----LAILLFLLA 223
 Db
```

```
RESULT 13
A36377
B61 protein precursor - human
C; Species: Homo sapiens (man)
C;Date: 28-Mar-1991 #sequence_revision 28-Mar-1991 #text_change 29-Sep-1999
C; Accession: A36377
R; Holzman, L.B.; Marks, R.M.; Dixit, V.M.
Mol. Cell. Biol. 10, 5830-5838, 1990
A; Title: A novel immediate-early response gene of endothelium is induced by
cytokines and encodes a secreted protein.
A; Reference number: A36377; MUID: 91042512; PMID: 2233719
A; Accession: A36377
A; Status: preliminary
A; Molecule type: mRNA
A; Residues: 1-205 < HOL>
A; Cross-references: GB:M57730; GB:M37476; NID:g179320; PIDN:AAA58388.1;
PID:q179321
C; Superfamily: axon guidance signal protein
                            9.0%; Score 166; DB 2; Length 205;
  Query Match
                           27.5%; Pred. No. 9.7e-05;
  Best Local Similarity
                                                                  16; Gaps
                               31; Mismatches 74; Indels
           46; Conservative
           18 LLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSSPN-- 75
QУ
                              |:|||:| :|: | | :: |: | :|::||
            8 LLGLCCSLAAADRHTVFWNSSNPKFRNE-DYTIHVQLNDYVDIICPHYE---DHSVADAA 63
Db
           76 YEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDL---DLRFTIKFQEYSPNLWGHEFRSH 132
QУ
                                                      :: ||| ::| | ||:
                                       : |:||
                          :: |:
                | | | | | |
           64 MEQYILYLVEHEEYQLCQPQSKDQVRWQCNRPSAKHGPEKLSEKFQRFTPFTLGKEFKEG 123
Db
           133 HDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRK 179
Qy
                                          : | :: ||:
                                      11
                           - 1
           124 HSYYYISKPIHQHEDR-----CLRLKVTVSGKITHSPQAHVNPQE 163
Db
 RESULT 14
 S31216
 collagen alpha 1(X) chain precursor - mouse
 C; Species: Mus musculus (house mouse)
 C; Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 13-Aug-1999
 C; Accession: $31216; $28807; $\overline{5}22215; $30127; $148299; $26\overline{3}97; $31830
 R; Kong, R.Y.C.; Kwan, K.M.; Lau, E.T.; Thomas, J.T.; Boot-Handford, R.P.; Grant,
 M.E.; Cheah, K.S.E.
 Eur. J. Biochem. 213, 99-111, 1993
 A; Title: Intron-exon structure, alternative use of promoter and expression of
 the mouse collagen X gene, CollOa-1.
 A; Reference number: S31216; MUID: 93238750; PMID: 8477738
 A; Accession: S31216
 A; Molecule type: DNA
 A; Residues: 1-680 <KON>
 A; Cross-references: EMBL: Z21610; NID: g49793; PIDN: CAA79736.1; PID: g49794
 R; Elima, K.; Eerola, I.; Rosati, R.; Metsaeranta, M.; Garofalo, S.; Peraelae,
 M.; de Crombrugghe, B.; Vuorio, E.
 Biochem. J. 289, 247-253, 1993
```

```
A; Title: The mouse collagen X gene: complete nucleotide sequence, exon structure
and expression pattern.
A; Reference number: S28807; MUID: 93143676; PMID: 8424763
A; Accession: S28807
A; Molecule type: DNA
A; Residues: 1-285, 'A', 287-680 <ELI>
A; Cross-references: EMBL: X67348; NID: g50480; PIDN: CAA47763.1; PID: g50481
R; Elima, K.; Metsaeranta, M.; Kallio, J.; Peraelae, M.; Eerola, I.; Garofalo,
S.; de Crombrugghe, B.; Vuorio, E.
Biochim. Biophys. Acta 1130, 78-80, 1992
A; Title: Specific hybridization probes for mouse alpha-2(IX) and alpha-1(X)
collagen mRNAs.
A; Reference number: S22215; MUID: 92182017; PMID: 1543751
A; Accession: S22215
A; Status: preliminary
A; Molecule type: mRNA
A; Residues: 385-450, 'K', 452-627 < ELA>
A; Cross-references: EMBL: X63013; NID: g49795; PIDN: CAA44741.1; PID: g49796
R; Apte, S.S.; Olsen, B.R.
Matrix 13, 165-179, 1993
A; Title: Characterization of the mouse type X collagen gene.
A; Reference number: S30127; MUID: 93261348; PMID: 8492743
A; Accession: S30127
A; Status: preliminary
A; Molecule type: mRNA
A; Residues: 1-12, 'F', 14-26, 'S', 28-247, 'L', 249-285, 'A', 287-305, 'F', 307-
416,'S',418-499,'L',501-566,'C',568,'H',570,'IY',573-634,'T',636-680 <APT>
R; Apte, S.S.; Seldin, M.F.; Hayashi, M.; Olsen, B.R.
Eur. J. Biochem. 206, 217-224, 1992
A; Title: Cloning of the human and mouse type X collagen genes and mapping of the
mouse type X collagen gene to chromosome 10.
A; Reference number: 148299; MUID: 92267014; PMID: 1587271
A; Accession: I48299
A; Status: preliminary; translated from GB/EMBL/DDBJ
A; Molecule type: DNA
A; Residues: 52-247, 'L', 249-285, 'A', 287-305, 'F', 307-416, 'S', 418-499, 'L', 501-
 566,'C',568,'H',570,'IY',573-634,'T',636-680 <RES>
A; Cross-references: EMBL: X65121; NID: g50482; PIDN: CAA46237.1; PID: g667031
 R; Summers, T.A.; Irwin, M.H.; Mayne, R.; Balian, G.
 J. Biol. Chem. 263, 581-587, 1988
 A; Title: Monoclonal antibodies to type X collagen. Biosynthetic studies using an
 antibody to the amino-terminal domain.
 A; Reference number: S26397; MUID: 88087150; PMID: 2826450
 A; Accession: S26397
 A; Molecule type: protein
 A; Residues: 'SDGYFSQ',24-26,'KQ' <SUM>
 C; Genetics:
 A; Gene: CollOa-1
 A; Map position: 10
 A; Introns: 51/3
 C; Superfamily: collagen alpha 1(VIII) chain; complement Clq carboxyl-terminal
 homology
 C; Keywords: coiled coil; extracellular matrix; glycoprotein; homotrimer
 F;1-18/Domain: signal sequence #status predicted <SIG>
 F;19-680/Product: collagen alpha 1(X) chain #status predicted <MAT>
 F;553-679/Domain: complement Clq carboxyl-terminal homology <ClQ>
```

```
8.6%; Score 159; DB 2; Length 680;
   Query Match
   Best Local Similarity 25.5%; Pred. No. 0.0011;
   Matches 97; Conservative 30; Mismatches 108; Indels 146; Gaps
                                                                                                                                  24:
                    1 MGPPHSGPGGV-RVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLD 59
QУ
                                                                                         :: | | |
                                                   | |:
                       : | | | | | | | |
                211 IGPP--GPSGVGRRGENGFPGQPGI------KGDRGFPGEMG------ 244
Db
                  60 LLCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQE 119
Qу
                                245 ----PSGPPGPQGPP-------GKQGR--EGIGKPGAIGSPGQPGI----- 277
Db
                 120 YSPNLWGHEFRSHHDYYIIATSDGT----REGLESLQGGVCLTRGMKVLLRVGQSPRGGA 175
QУ
                          278 --PGEKGHPGSPG----IAGPPGAPGFGKQGLPGLRG----QRG-----PAG-- 314
Db
                 176 VPRKPVSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGL 235
QУ
                       :| |: ::|| | : || | | : || | | : || | | : || | | : || | | : || | | : || | | : || | | : || | | : || | | : || | | : || | | : || | | : || | | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : || | : ||
                 315 LPGAPGA----KGERGPAG--HPGEPGLPGSP----GNMGPQGPKGIPGNHGIPGAKGEI 364
Db
                 236 ALLLLGVAGAGGAMCWRRRRAKP---SESRHPG-----PGSFGRGGSLGLGGGGG 282
Qv
                             365 G--LVGPAGPPGA---RGARGPPGLDGKTGYPGEPGLNGPKGNPGLPGQKGDPGVGGTPG 419
Db
                 283 M-----GPREAEPGELGIALRGGGAADPPFCPHYEKVSGDYGHPVY 323
Qу
                                                          420 LRGPVGPVGAKGVPGHNGEAGPR-GEPGIPGTR----GPTGPPGVPGFPGSKGDPGNP-- 472
Db
                 324 IVQDGP-----PQSPP 334
QУ
                            473 -GAPGPAGIATKGLNGPTGPP 492
Db
RESULT 15
CGBO7S
collagen alpha 1(III) chain - bovine
C; Species: Bos primigenius taurus (cattle)
C; Date: 04-Dec-1986 #sequence revision 04-Dec-1986 #text change 07-May-1999
C; Accession: A02862; A38001; A38002; A38003; A38004; A38005; S71946
R; Fietzek, P.P.; Allmann, H.; Rauterberg, J.; Henkel, W.; Wachter, E.; Kuehn, K.
Hoppe-Seyler's Z. Physiol. Chem. 360, 809-820, 1979
A; Title: The covalent structure of calf skin type III collagen. I. The amino
acid sequence of the amino terminal region of the alphal(III) chain (position 1-
222).
A; Reference number: A02862; MUID: 80026026; PMID: 488906
A; Accession: A02862
A: Molecule type: protein
A; Residues: 1-242 <FIE>
R; Dewes, H.; Fietzek, P.P.; Kuehn, K.
 Hoppe-Seyler's Z. Physiol. Chem. 360, 821-832, 1979
A; Title: The covalent structure of calf skin type III collagen. II. The amino
 acid sequence of the cyanogen bromide peptide alpha1(III)CB1,8,10,2 (positions
 223-402).
 A; Reference number: A38001; MUID: 80026027; PMID: 488907
 A; Accession: A38001
 A; Molecule type: protein
 A; Residues: 243-422 < DEW1>
```

```
R; Bentz, H.; Fietzek, P.P.; Kuehn, K.
Hoppe-Seyler's Z. Physiol. Chem. 360, 833-840, 1979
A; Title: The covalent structure of calf skin type III collagen. III. The amino
acid sequence of the cyanogen bromide peptide alpha1(III)CB4 (positions 403-
551).
A; Reference number: A38002; MUID: 80026028; PMID: 488908
A; Accession: A38002
A; Molecule type: protein
A; Residues: 423-571 <BEN>
R; Lang, H.; Glanville, R.W.; Fietzek, P.P.; Kuehn, K.
Hoppe-Seyler's Z. Physiol. Chem. 360, 841-850, 1979
A; Title: The covalent structure of calf skin type III collagen. IV. The amino
acid sequence of the cyanogen bromide peptide alpha1(III)CB5 (positions 552-
788).
A; Reference number: A38003; MUID: 80026029; PMID: 488909
A:Accession: A38003
A; Molecule type: protein
A; Residues: 572-808 < LAN>
R; Dewes, H.; Fietzek, P.P.; Kuehn, K.
Hoppe-Seyler's Z. Physiol. Chem. 360, 851-860, 1979
A; Title: The covalent structure of calf skin type III collagen. V. The amino
acid sequence of the cyanogen bromide peptide alpha1(III)CB9A (position 789 to
927).
A; Reference number: A38004; MUID: 80026030; PMID: 488910
A; Accession: A38004
A; Molecule type: protein
A; Residues: 809-947 < DEW 2>
R; Allmann, H.; Fietzek, P.P.; Glanville, R.W.; Kuehn, K.
Hoppe-Seyler's Z. Physiol. Chem. 360, 861-868, 1979
A; Title: The covalent structure of calf skin type III collagen. VI. The amino
acid sequence of the carboxyterminal cyanogen bromide peptide alpha1(III)CB9B
(position 928-1028).
A; Reference number: A38005; MUID: 80026031; PMID: 488911
A; Accession: A38005
A; Molecule type: protein
A; Residues: 948-1049 < ALL>
A; Experimental source: skin
R;Henkel, W.
Biochem. J. 318, 497-503, 1996
A; Title: Cross-link analysis of the C-telopeptide domain from type III collagen.
A; Reference number: S71946; MUID: 96404897; PMID: 8809038
A; Accession: S71946
A; Molecule type: protein
A; Residues: 87-106;1017-1029;1037-1049 <HEN>
C; Comment: Prolines at the third position of the tripeptide repeating unit (G-X-
Y) are hydroxylated in some or all of the chains.
C; Comment: The type III collagen molecule is a trimer of identical chains,
linked to each other by interchain disulfide bonds. Trimers are also cross-
linked by allysines forming desmosine.
C; Superfamily: collagen alpha 1(I) chain; fibrillar collagen carboxyl-terminal
homology; von Willebrand factor type C repeat homology
C; Keywords: coiled coil; extracellular matrix; glycoprotein; hydroxylysine;
hydroxyproline; skin; trimer; triple helix
F;1-1049/Product: collagen alpha 1(III) chain #status experimental <CAB>
F;1-14/Region: amino-terminal nonhelical telopeptide
F;15-1040/Region: helical
F;587-589/Region: cell attachment (R-G-D) motif
```

```
F;752-754/Region: cell attachment (R-G-D) motif
F;875-877/Region: cell attachment (R-G-D) motif
F;878-880/Region: cell attachment (R-G-D) motif
F;935-937/Region: cell attachment (R-G-D) motif
F;1041-1049/Region: carboxyl-terminal nonhelical telopeptide
F;95,107,119,938,950/Modified site: 5-hydroxylysine (Lys) #status experimental
F;107,950/Modified site: allysine (Lys) #status predicted
F;107/Binding site: carbohydrate (Lys) (covalent) #status experimental
F;1040,1041/Disulfide bonds: interchain #status predicted
                      8.4%; Score 154.5; DB 1; Length 1049;
 Query Match
 Best Local Similarity 26.5%; Pred. No. 0.0036;
 Matches 60; Conservative 9; Mismatches 74; Indels 83; Gaps 8;
        171 PRGGAVPRKPVSEMPMERDRGA------AHSLEPGKEN 202
Qу
                                                      1 111:
           | | | | : : : | | : : : | | :
        688 PAGGSGPAGPPGPQGVKGERGSPGGPGAAGFPGGRGPPGPPGSNGNPGPPGSSGAPGKDG 747
Db
        203 LPGDPTSNAT-----SRGAEGPLPPPSMPAVAGAAGGLALLLLGVAGA 245
QУ
            748 PPGPPGSNGAPGSPGISGPKGDSGPPGERGAPGPQGPPGAPGPLGIAG----LTGARGL 802
Db
        246 GGAMCWRRRRAKP-----SESRHPGP-----GSFGRGGSLGLGGGGGMGPREAEPGE 292
Qу
            803 AGPPGMPGARGSPGPQGIKGENGKPGPSGQNGERGPPGPQGLPGLAGTAGEPGRDGNPGS 862
Db
        293 LGIALRGG-----GAADPPFCPHYEKVSGDYGHPVYIVQDGPP 330
QУ
            863 DGLPGRDGAPGAKGDRGENGSPGAP-----GAPGHP-----GPP 896
Db
```

Search completed: April 13, 2004, 09:25:01 Job time: 15.5409 secs

GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: April 13, 2004, 09:26:02; Search time 32.0755 Seconds

(without alignments)

2787.142 Million cell updates/sec

Title: US-10-021-121-4

Perfect score: 1850

Sequence: 1 MGPPHSGPGGVRVGALLLLG.....PVYIVQDGPPQSPPNIYYKV 340

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1073127 seqs, 262937947 residues

Total number of hits satisfying chosen parameters: 1073127

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: Published_Applications_AA:*

1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep:*

2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep:* 3: /cgn2_6/ptodata/2/pubpaa/US06_NEW PUB.pep:*

3: /cgn2_6/ptodata/2/pubpaa/USU6_NEW_PUB.pep:*
4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep:*

5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep:*

: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep:*

7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep:*

8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep:*
9: /cgn2_6/ptodata/2/pubpaa/US09A_PUBCOMB.pep:*

10: /cgn2_6/ptodata/2/pubpaa/US09B_PUBCOMB.pep:*

11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep:*

12: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep:*

13: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pep:*

14: /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pep:*

15: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep:*
16: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB_pop:*

16: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep:*
17: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep:*

17: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep:*
18: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

ક

Result Query

No. Score Match Length DB ID

Description

```
Sequence 4, Appli
Sequence 3, Appli
Sequence 2, Appli
Sequence 2, Appli
    1850 100.0 340 13 US-10-021-121-4
                   340 13 US-10-138-787-3
           99.8
2
     1846
            99.7 340 15 US-10-417-924A-2
3
     1844
                 455 13 US-10-021-121-2
            99.5
4
     1841
                                                  Sequence 2, Appli
Sequence 2, Appli
Sequence 2, Appli
                   346 13 US-10-021-121-9
     632
            34.2
5
                   346 16 US-10-356-289-2
      632 34.2
6
                   333 9 US-09-754-105-2
    629.5 34.0
7
                                                   Sequence 2, Appli
    629.5 34.0 333 9 US-09-978-339-2
8
                                                    Sequence 10, Appl
    629.5 34.0 333 13 US-10-021-121-10
9
                                                    Sequence 63, Appl
                 333 15 US-10-331-496A-63
            34.0
10
    629.5
                  333 13 US-10-138-787-4
                                                     Sequence 4, Appli
            33.6
11
    622.5
           32.9 345 13 US-10-138-787-5
                                                     Sequence 5, Appli
    608.5
12
                                                     Sequence 17, Appl
    498 26.9 89 9 US-09-862-179A-17
13
                                                     Sequence 13, Appl
                   89 13 US-10-138-787-13
      498 26.9
14
                                                     Sequence 48262, A
                   92 9 US-09-864-761-48262
15
   284.5 15.4
                                                     Sequence 48257, A
   205.5 11.1
                  136 9 US-09-864-761-48257
16
   202.5 10.9 106 9 US-09-925-297-639

201 10.9 82 9 US-09-862-179A-15

201 10.9 82 13 US-10-138-787-11

200.5 10.8 82 9 US-09-862-179A-16
                                                     Sequence 639, App
17
                                                     Sequence 15, Appl
18
                                                     Sequence 11, Appl
19
                                                     Sequence 16, Appl
20
                   82 13 US-10-138-787-12
                                                     Sequence 12, Appl
    200.5 10.8
21
                                                    Sequence 2, Appli
      179 9.7 238 9 US-09-904-954-2
22
                                                    Sequence 2, Appli
           9.7 238 10 US-09-733-756-2
      179
23
                                                     Sequence 72, Appl
                 238 14 US-10-241-220-72
           9.7
24
      179
                                                     Sequence 130, App
                    238 15 US-10-295-027-130
            9.7
25
      179
                                                    Sequence 2, Appli
          9.5
                    209 9 US-09-921-984-2
      176
26
                                                     Sequence 7, Appli
                   233 13 US-10-138-787-7
    174.5 9.4
27
                                                     Sequence 510, App
                   218 9 US-09-925-297-510
   172.5 9.3
28
                                                     Sequence 4, Appli
                   201 9 US-09-904-954-4
   169.5 9.2
29
                                                    Sequence 8, Appli
     169 9.1
                   201 13 US-10-138-787-8
30
                                                      Sequence 6, Appli
                   209 13 US-10-138-787-6
           9.1
31
    168.5
                   228 8 US-08-578-684-4
                                                     Sequence 4, Appli
            9.1
32
    167.5
                                                     Sequence 10, Appl
                    205 13 US-10-138-787-10
           9.0
33
     166
                                                     Sequence 50, Appl
                    205 14 US-10-171-311-50
34
      166 9.0
                                                     Sequence 34, Appl
     166 9.0 205 15 US-10-372-683-34
35
                                                    Sequence 288, App
    164.5 8.9 204 12 US-10-147-493-288
36
                                                    Sequence 288, App
                   204 12 US-10-145-127-288
    164.5 8.9
37
                                                   Sequence 288, App
Sequence 48, Appl
Sequence 288, App
Sequence 288, App
                   204 12 US-10-160-503-288
    164.5 8.9
38
                   204 12 US-10-143-118-288
           8.9
    164.5
39
                    204 12 US-10-144-993-288
    164.5
            8.9
40
                    204 12 US-10-158-787-288
           8.9
    164.5
41
                   204 12 US-10-140-024-288
            8.9
42
    164.5
                   204 13 US-10-001-054-48
            8.9
43
    164.5
                    204 14 US-10-028-072-288
            8.9
44
     164.5
                    204 14 US-10-121-049-288
            8.9
     164.5
45
```

ALIGNMENTS

```
RESULT 1
US-10-021-121-4
; Sequence 4, Application US/10021121
; Publication No. US20020142444A1
; GENERAL INFORMATION:
; APPLICANT: Caras, Ingrid W
```

```
TITLE OF INVENTION: A2-1 Neurotrophic Factor
       NUMBER OF SEQUENCES: 10
       CORRESPONDENCE ADDRESS:
            ADDRESSEE: Genentech, Inc.
            STREET: 1 DNA Way
            CITY: South San Francisco
            STATE: California
            COUNTRY: USA
            ZIP: 94080
       COMPUTER READABLE FORM:
            MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
            COMPUTER: IBM PC compatible
            OPERATING SYSTEM: PC-DOS/MS-DOS
            SOFTWARE: WinPatin (Genentech)
       CURRENT APPLICATION DATA:
            APPLICATION NUMBER: US/10/021,121
            FILING DATE: 06-Dec-2001
            CLASSIFICATION: <Unknown>
       PRIOR APPLICATION DATA:
            APPLICATION NUMBER: US/08/635,130
            FILING DATE: 19-Mar-1996
       ATTORNEY/AGENT INFORMATION:
            NAME: Torchia, PhD., Timothy E.
            REGISTRATION NUMBER: 36,700
            REFERENCE/DOCKET NUMBER: P1001
        TELECOMMUNICATION INFORMATION:
            TELEPHONE: 650/225-8674
            TELEFAX: 650/952-9881
   INFORMATION FOR SEQ ID NO: 4:
        SEQUENCE CHARACTERISTICS:
            LENGTH: 340 amino acids
            TYPE: Amino Acid
            TOPOLOGY: Linear
        SEQUENCE DESCRIPTION: SEQ ID NO: 4:
US-10-021-121-4
                       100.0%; Score 1850; DB 13; Length 340;
 Query Match
                               Pred. No. 7.3e-136;
                       100.0%;
 Best Local Similarity
                                                                    0;
                             0; Mismatches
                                                         0;
                                                             Gaps
                                             0; Indels
 Matches 340; Conservative
          1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Qу
            1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Db
          61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
QУ
            61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Db
         121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
Qу
            121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
Db
         181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Qу
             181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Db
         241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGMGPREAEPGELGIALRGG 300
Qу
```

```
241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGMGPREAEPGELGIALRGG 300
Db
        301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qу
           301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Db
RESULT 2
US-10-138-787-3
; Sequence 3, Application US/10138787
; Publication No. US20020172984A1
; GENERAL INFORMATION:
  APPLICANT: Holland, Sacha
  APPLICANT: Mbamalu, Geraldine
            Pawson, Tony
  APPLICANT:
  TITLE OF INVENTION: OLIGOMERIZED RECEPTORS WHICH AFFECT PATHWAYS REGULATED
  TITLE OF INVENTION: BY TRANSMEMBRANE LIGANDS FOR ELK-RELATED RECEPTOR
  TITLE OF INVENTION: TYROSINE KINASES
  FILE REFERENCE: 11757.23USWO
  CURRENT APPLICATION NUMBER: US/10/138,787
  CURRENT FILING DATE: 2002-05-03
  PRIOR APPLICATION NUMBER: US/09/214,631
  PRIOR FILING DATE: 1999-03-12
  PRIOR APPLICATION NUMBER: PCT/CA97/00473
  PRIOR FILING DATE: 1997-07-04
  PRIOR APPLICATION NUMBER: 60/021,272
  PRIOR FILING DATE: 1996-07-05
  NUMBER OF SEQ ID NOS: 13
  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
   LENGTH: 340
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-138-787-3
                                              Length 340;
                      99.8%; Score 1846; DB 13;
  Query Match
                      99.7%; Pred. No. 1.5e-135;
  Best Local Similarity
                                              Indels
                                                                 0;
                            1; Mismatches
                                                       0;
                                                          Gaps
  Matches 339; Conservative
          1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
QУ
            1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Db
         61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Qу
            61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Db
        121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
Qу
            121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLQVGQSPRGGAVPRKP 180
Db
        181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Qy
            181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Db
        241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGMGPREAEPGELGIALRGG 300
Qу
```

```
241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGMGPREAEPGELGIALRGG 300
Db
        301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qу
            301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Db
RESULT 3
US-10-417-924A-2
; Sequence 2, Application US/10417924A
; Publication No. US20030215918A1
; GENERAL INFORMATION:
  APPLICANT: Samuel Davis, et al.
  TITLE OF INVENTION: BIOLOGICALLY ACTIVE EPH FAMILY LIGANDS
  FILE REFERENCE: REG-341Z
  CURRENT APPLICATION NUMBER: US/10/417,924A
  CURRENT FILING DATE: 2003-04-17
  PRIOR APPLICATION NUMBER: 09/051,994
  PRIOR FILING DATE: 1998-04-24
  PRIOR APPLICATION NUMBER: PCT/US96/17201
  PRIOR FILING DATE: 1996-10-25
  PRIOR APPLICATION NUMBER: 60/007,015
  PRIOR FILING DATE: 1995-10-25
  NUMBER OF SEQ ID NOS: 3
  SOFTWARE: PatentIn Ver. 2.0
 SEQ ID NO 2
   LENGTH: 340
   TYPE: PRT
   ORGANISM: Homo sapiens
   FEATURE:
   NAME/KEY: Misc. feature
   LOCATION: (166)
   OTHER INFORMATION: Xaa = unknown or other
US-10-417-924A-2
                      99.7%; Score 1844; DB 15;
                                              Length 340;
  Query Match
                      99.7%; Pred. No. 2.1e-135;
  Best Local Similarity
                                                                 0;
                                                       0;
                                                          Gaps
                            0; Mismatches
                                           1;
                                              Indels
  Matches 339; Conservative
          1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
QУ
            1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Db
         61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
QУ
            61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Db
         121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
QУ
            121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLXVGQSPRGGAVPRKP 180
Db
         181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
QУ
            181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Db
         241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGG 300
QУ
```

```
241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGMGPREAEPGELGIALRGG 300
Db
         301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qу
            301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Db
RESULT 4
US-10-021-121-2
; Sequence 2, Application US/10021121
; Publication No. US20020142444A1
   GENERAL INFORMATION:
        APPLICANT: Caras, Ingrid W
        TITLE OF INVENTION: A2-1 Neurotrophic Factor
;
        NUMBER OF SEQUENCES: 10
;
        CORRESPONDENCE ADDRESS:
            ADDRESSEE: Genentech, Inc.
             STREET: 1 DNA Way
            CITY: South San Francisco
             STATE: California
             COUNTRY: USA
            ZIP: 94080
        COMPUTER READABLE FORM:
            MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
             COMPUTER: IBM PC compatible
             OPERATING SYSTEM: PC-DOS/MS-DOS
             SOFTWARE: WinPatin (Genentech)
        CURRENT APPLICATION DATA:
             APPLICATION NUMBER: US/10/021,121
             FILING DATE: 06-Dec-2001
             CLASSIFICATION: <Unknown>
        PRIOR APPLICATION DATA:
            APPLICATION NUMBER: US/08/635,130
             FILING DATE: 19-Mar-1996
        ATTORNEY/AGENT INFORMATION:
             NAME: Torchia, PhD., Timothy E.
             REGISTRATION NUMBER: 36,700
             REFERENCE/DOCKET NUMBER: P1001
        TELECOMMUNICATION INFORMATION:
             TELEPHONE: 650/225-8674
             TELEFAX: 650/952-9881
    INFORMATION FOR SEQ ID NO: 2:
;
        SEQUENCE CHARACTERISTICS:
             LENGTH: 455 amino acids
             TYPE: Amino Acid
             TOPOLOGY: Linear
        SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-10-021-121-2
                        99.5%; Score 1841; DB 13; Length 455;
  Query Match
  Best Local Similarity 100.0%; Pred. No. 5.2e-135;
                                                                       0;
                             0; Mismatches
                                                            0; Gaps
                                               0; Indels
  Matches 338; Conservative
           1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Qy
             1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Db
```

```
61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Qу
            61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Db
        121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
Qy
            121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
Db
        181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Qу
            181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Db
        241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGG 300
Qу
            241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGG 300
Db
        301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYY 338
Qу
            301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYY 338
Db
RESULT 5
US-10-021-121-9
; Sequence 9, Application US/10021121
; Publication No. US20020142444A1
   GENERAL INFORMATION:
       APPLICANT: Caras, Ingrid W
       TITLE OF INVENTION: A2-1 Neurotrophic Factor
       NUMBER OF SEQUENCES: 10
       CORRESPONDENCE ADDRESS:
            ADDRESSEE: Genentech, Inc.
            STREET: 1 DNA Way
            CITY: South San Francisco
            STATE: California
            COUNTRY: USA
            ZIP: 94080
       COMPUTER READABLE FORM:
            MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
            COMPUTER: IBM PC compatible
            OPERATING SYSTEM: PC-DOS/MS-DOS
            SOFTWARE: WinPatin (Genentech)
        CURRENT APPLICATION DATA:
            APPLICATION NUMBER: US/10/021,121
            FILING DATE: 06-Dec-2001
            CLASSIFICATION: <Unknown>
        PRIOR APPLICATION DATA:
            APPLICATION NUMBER: US/08/635,130
            FILING DATE: 19-Mar-1996
        ATTORNEY/AGENT INFORMATION:
            NAME: Torchia, PhD., Timothy E.
            REGISTRATION NUMBER: 36,700
            REFERENCE/DOCKET NUMBER: P1001
        TELECOMMUNICATION INFORMATION:
            TELEPHONE: 650/225-8674
            TELEFAX: 650/952-9881
   INFORMATION FOR SEQ ID NO: 9:
```

```
SEQUENCE CHARACTERISTICS:
           LENGTH: 346 amino acids
           TYPE: Amino Acid
           TOPOLOGY: Linear
       SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-10-021-121-9
                    34.2%; Score 632; DB 13; Length 346;
 Query Match
 Best Local Similarity 39.5%; Pred. No. 4.4e-41;
 Matches 145; Conservative 48; Mismatches 116; Indels 58; Gaps 9;
         8 PGGVRVGALLLLGVLGLVSGL-----SLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLL 61
QУ
          4 PGQRWLGKWLVAMVVWALCRLATPLAKNLEPVSWSSLNPKFLSGKGLVIYPKIGDKLDII 63
Db
        62 CPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYS 121
Qу
           64 CPRAEAGRP----YEYYKLYLVRPEQAAACSTVLDPNVLVTCNRPEQEIRFTIKFQEFS 118
Db
        122 PNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPV 181
Qy
           119 PNYMGLEFKKHHDYYITSTSNGSLEGLENREGGVCRTRTMKIIMKVGQDPNAVTPEQLTT 178
Db
        182 SEMPMERDRGAAHSLE-PGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLA---- 236
QУ
          179 SRPSKEADNTVKMATQAPGSRGSLGDSDGKHETVNQEEKSGP-----GASGGSSGDPD 231
Db
        237 -----LLLLGVAGAGGA------MCWRRRRAKPSESRHPGPGSFGRGGSLGL 277
Qу
               232 GFFNSKVALFAAVGAGCVIFLLIIIFLTVLLLKLRKRHRKHTQQ-----RAAALSL 282
Db
        278 ----GGGGGMGPREAEPGELGIALRGGGAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSP 333
Qу
                283 STLASPKGGSGTAGTEPSDIIIPLR---TTENNYCPHYEKVSGDYGHPVYIVQEMPPQSP 339
Db
       334 PNIYYKV 340
Qу
            340 ANIYYKV 346
Db
RESULT 6
US-10-356-289-2
; Sequence 2, Application US/10356289
; Publication No. US20040022767A1
; GENERAL INFORMATION:
; APPLICANT: Lyman, Stewart D.
; APPLICANT: Beckmann, M. Patricia
; APPLICANT: Baum, Peter R.
; APPLICANT: Carpenter, Melissa K.
 TITLE OF INVENTION: NOVEL CYTOKINE DESIGNATED ELK LIGAND
  FILE REFERENCE: GENENT.67CPDV3
  CURRENT APPLICATION NUMBER: US/10/356,289
  CURRENT FILING DATE: 2003-01-31
; PRIOR APPLICATION NUMBER: US/09/039,642B
; PRIOR FILING DATE: 1998-03-16
; PRIOR APPLICATION NUMBER: 08/213,403
; PRIOR FILING DATE: 1994-03-15
```

```
; PRIOR FILING DATE: 1992-11-13
  PRIOR APPLICATION NUMBER: 08/747,240
 PRIOR FILING DATE: 1996-10-12
 PRIOR APPLICATION NUMBER: 08/460,741
  PRIOR FILING DATE: 1995-06-02
; NUMBER OF SEQ ID NOS: 5
 SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
  LENGTH: 346
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-356-289-2
                     34.2%; Score 632; DB 16; Length 346;
 Query Match
 Best Local Similarity 39.5%; Pred. No. 4.4e-41;
 Matches 145; Conservative 48; Mismatches 116; Indels 58; Gaps
         8 PGGVRVGALLLLGVLGLVSGL-----SLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLL 61
Qу
           4 PGQRWLGKWLVAMVVWALCRLATPLAKNLEPVSWSSLNPKFLSGKGLVIYPKIGDKLDII 63
Db
         62 CPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYS 121
Qy
           64 CPRAEAGRP----YEYYKLYLVRPEQAAACSTVLDPNVLVTCNRPEQEIRFTIKFQEFS 118
Db
        122 PNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPV 181
Qу
           119 PNYMGLEFKKHHDYYITSTSNGSLEGLENREGGVCRTRTMKIIMKVGQDPNAVTPEQLTT 178
Db
        182 SEMPMERDRGAAHSLE-PGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLA---- 236
Qу
              179 SRPSKEADNTVKMATQAPGSRGSLGDSDGKHETVNQEEKSGP----GASGGSSGDPD 231
Db
        237 -----LLLLGVAGAGGA------MCWRRRRAKPSESRHPGPGSFGRGGSLGL 277
Qу
                232 GFFNSKVALFAAVGAGCVIFLLIIIFLTVLLLKLRKRHRKHTQQ-----RAAALSL 282
Db
        278 ----GGGGGMGPREAEPGELGIALRGGGAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSP 333
QУ
                 283 STLASPKGGSGTAGTEPSDIIIPLR---TTENNYCPHYEKVSGDYGHPVYIVQEMPPQSP 339
Db
        334 PNIYYKV 340
QУ
            340 ANIYYKV 346
Dh
RESULT 7
US-09-754-105-2
; Sequence 2, Application US/09754105
; Patent No. US20010009768A1
; GENERAL INFORMATION:
 APPLICANT: Cerretti, Douglas
; APPLICANT: Reddy, Pranhitha
 TITLE OF INVENTION: POLYNUCLEOTIDES ENCODING CYTOKINE DESIGNATED LERK-5
; FILE REFERENCE: 28232
; CURRENT APPLICATION NUMBER: US/09/754,105
```

; PRIOR APPLICATION NUMBER: 07/977,693

```
; CURRENT FILING DATE: 2001-01-03
; PRIOR APPLICATION NUMBER: 09/329,531
; PRIOR FILING DATE: 1999-06-10
  NUMBER OF SEQ ID NOS: 3
  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
   LENGTH: 333
   TYPE: PRT
   ORGANISM: homo sapiens
US-09-754-105-2
 Query Match 34.0%; Score 629.5; DB 9; Length 333; Best Local Similarity 40.9%; Pred. No. 6.6e-41;
 Matches 135; Conservative 52; Mismatches 130; Indels
                                                        13; Gaps
                                                                   5;
         14 GALLLIGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSS 73
Qу
                   14 GVLMVLCRTAISKSIVLEPIYWNSSNSKFLPGQGLVLYPQIGDKLDIICPKV---DSKTV 70
Db
         74 PNYEFYKLYLVGGAOGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHH 133
QУ
                                    ||:||:|:|
         71 GOYEYYKVYMVDKDQADRCTIKKENTPLLNCAKPDQDIKFTIKFQEFSPNLWGLEFQKNK 130
Db
         134 DYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQ--SPRGGAVPRKPVSEMPMER-DR 190
Qy
            131 DYYIISTSNGSLEGLDNQEGGVCQTRAMKILMKVGQDASSAGSTRNKDPTRRPELEAGTN 190
Db
         191 GAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLLGVAGAGGAMC 250
QУ
            191 GRSSTTSPFVKPNPGSSTDGNSAGHSGNNILGSEVALFAGIASGCIIFIVIIITLVVLLL 250
Db
         251 WRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGGGAADPPFCPH 310
Qу
              |||: :| | : | :| :| |
                                                         251 KYRRRHRKHSPOHTTTLSLSTLATPKRSGNN----NGSEPSDIIIPLR---TADSVFCPH 303
Db
         311 YEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
QУ
            304 YEKVSGDYGHPVYIVQEMPPQSPANIYYKV 333
Dh
RESULT 8
US-09-978-339-2
; Sequence 2, Application US/09978339
; Patent No. US20020103358A1
   GENERAL INFORMATION:
        APPLICANT: Cerretti, Douglas P.
                  Reddy, Pranhitha
;
        TITLE OF INVENTION: No. US20020103358Alel Cytokine Designated Lerk-5
        NUMBER OF SEQUENCES: 3
        CORRESPONDENCE ADDRESS:
            ADDRESSEE: Immunex Corporation
            STREET: 51 University Street
            CITY: Seattle
            STATE: Washington
            COUNTRY: US
            ZIP: 98101
        COMPUTER READABLE FORM:
```

```
MEDIUM TYPE: Floppy disk
            COMPUTER: Apple Macintosh
            OPERATING SYSTEM: Apple 7.1
            SOFTWARE: Microsoft Word, Version 5.1a
       CURRENT APPLICATION DATA:
           APPLICATION NUMBER: US/09/978,339
            FILING DATE: 15-Oct-2001
            CLASSIFICATION: <Unknown>
       PRIOR APPLICATION DATA:
           APPLICATION NUMBER: 08/271,948
            FILING DATE: <Unknown>
       ATTORNEY/AGENT INFORMATION:
           NAME: Seese, Kathryn A.
            REGISTRATION NUMBER: 32,172
            REFERENCE/DOCKET NUMBER: 2823
       TELECOMMUNICATION INFORMATION:
            TELEPHONE: (206) 587-0430
            TELEFAX: (206) 233-0644
           TELEX: 756822
   INFORMATION FOR SEQ ID NO: 2:
       SEQUENCE CHARACTERISTICS:
           LENGTH: 333 amino acids
            TYPE: amino acid
            TOPOLOGY: linear
       MOLECULE TYPE: protein
       SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-09-978-339-2
                      34.0%; Score 629.5; DB 9; Length 333;
 Query Match
 Best Local Similarity 40.9%; Pred. No. 6.6e-41;
 Matches 135; Conservative 52; Mismatches 130; Indels
                                                      13; Gaps
                                                                  5;
         14 GALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSS 73
Qу
            14 GVLMVLCRTAISKSIVLEPIYWNSSNSKFLPGOGLVLYPOIGDKLDIICPKV---DSKTV 70
Db
         74 PNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHH 133
Qy
             71 GOYEYYKVYMVDKDQADRCTIKKENTPLLNCAKPDQDIKFTIKFQEFSPNLWGLEFQKNK 130
Db
        134 DYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQ--SPRGGAVPRKPVSEMPMER-DR 190
Qy
            131 DYYIISTSNGSLEGLDNQEGGVCQTRAMKILMKVGQDASSAGSTRNKDPTRRPELEAGTN 190
Db
        191 GAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLLGVAGAGGAMC 250
Qу
            191 GRSSTTSPFVKPNPGSSTDGNSAGHSGNNILGSEVALFAGIASGCIIFIVIIITLVVLLL 250
Db
        251 WRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGGGAADPPFCPH 310
Qу
                                           :|| :: | ||
             251 KYRRRHRKHSPOHTTTLSLSTLATPKRSGNN----NGSEPSDIIIPLR---TADSVFCPH 303
Db
        311 YEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qу
            304 YEKVSGDYGHPVYIVQEMPPQSPANIYYKV 333
Db
```

```
RESULT 9
US-10-021-121-10
; Sequence 10, Application US/10021121
; Publication No. US20020142444A1
    GENERAL INFORMATION:
        APPLICANT: Caras, Ingrid W
        TITLE OF INVENTION: A2-1 Neurotrophic Factor
        NUMBER OF SEQUENCES: 10
        CORRESPONDENCE ADDRESS:
             ADDRESSEE: Genentech, Inc.
             STREET: 1 DNA Way
             CITY: South San Francisco
             STATE: California
             COUNTRY: USA
             ZIP: 94080
        COMPUTER READABLE FORM:
             MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
             COMPUTER: IBM PC compatible
             OPERATING SYSTEM: PC-DOS/MS-DOS
             SOFTWARE: WinPatin (Genentech)
        CURRENT APPLICATION DATA:
             APPLICATION NUMBER: US/10/021,121
             FILING DATE: 06-Dec-2001
             CLASSIFICATION: <Unknown>
        PRIOR APPLICATION DATA:
             APPLICATION NUMBER: US/08/635,130
             FILING DATE: 19-Mar-1996
        ATTORNEY/AGENT INFORMATION:
             NAME: Torchia, PhD., Timothy E.
             REGISTRATION NUMBER: 36,700
             REFERENCE/DOCKET NUMBER: P1001
        TELECOMMUNICATION INFORMATION:
             TELEPHONE: 650/225-8674
             TELEFAX: 650/952-9881
    INFORMATION FOR SEQ ID NO: 10:
        SEQUENCE CHARACTERISTICS:
             LENGTH: 333 amino acids
             TYPE: Amino Acid
             TOPOLOGY: Linear
        SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-10-021-121-10
                        34.0%; Score 629.5; DB 13; Length 333;
  Query Match
  Best Local Similarity 40.9%; Pred. No. 6.6e-41;
                                                                         5;
  Matches 135; Conservative 52; Mismatches 130; Indels
                                                            13; Gaps
          14 GALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSS 73
Qу
                     1 1::1
          14 GVLMVLCRTAISKSIVLEPIYWNSSNSKFLPGQGLVLYPQIGDKLDIICPKV---DSKTV 70
Db
          74 PNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHH 133
Qу
               ||:||:|:| | | ||
                                      71 GQYEYYKVYMVDKDQADRCTIKKENTPLLNCAKPDQDIKFTIKFQEFSPNLWGLEFQKNK 130
Db
         134 DYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQ--SPRGGAVPRKPVSEMPMER-DR 190
Qу
             : |
         131 DYYIISTSNGSLEGLDNQEGGVCQTRAMKILMKVGQDASSAGSTRNKDPTRRPELEAGTN 190
Db
```

```
Qу
         191 GAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLLGVAGAGGAMC 250
             191 GRSSTTSPFVKPNPGSSTDGNSAGHSGNNILGSEVALFAGIASGCIIFIVIIITLVVLLL 250
Db
         251 WRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGGGAADPPFCPH 310
Qу
              251 KYRRRHRKHSPQHTTTLSLSTLATPKRSGNN----NGSEPSDIIIPLR---TADSVFCPH 303
Db
         311 YEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qу
             Db
         304 YEKVSGDYGHPVYIVQEMPPQSPANIYYKV 333
RESULT 10
US-10-331-496A-63
; Sequence 63, Application US/10331496A
; Publication No. US20030228305A1
; GENERAL INFORMATION:
; APPLICANT: FRANTZ, GRETCHEN
  APPLICANT: HILLAN, KENNETH J.
  APPLICANT: PHILLIPS, HEIDI S.
  APPLICANT: POLAKIS, PAUL
  APPLICANT: SMITH, VICTORIA
  APPLICANT: SPENCER, SUSAN D.
  APPLICANT: WILLIAMS, P. MICKEY
  APPLICANT: WU, THOMAS D.
  APPLICANT: ZHANG, ZEMIN
  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND
  TITLE OF INVENTION: TREATMENT OF TUMOR
  FILE REFERENCE: P5014R1-PCT
  CURRENT APPLICATION NUMBER: US/10/331,496A
  CURRENT FILING DATE: 2002-12-30
  PRIOR APPLICATION NUMBER: US 60/345,444
  PRIOR FILING DATE: 2002-01-02
  PRIOR APPLICATION NUMBER: US 60/351,885
  PRIOR FILING DATE: 2002-01-25
  PRIOR APPLICATION NUMBER: US 60/360,066
  PRIOR FILING DATE: 2002-02-25
  PRIOR APPLICATION NUMBER: US 60/362,004
  PRIOR FILING DATE: 2002-03-05
  PRIOR APPLICATION NUMBER: US 60/366,869
  PRIOR FILING DATE: 2002-03-20
  PRIOR APPLICATION NUMBER: US 60/366,284
  PRIOR FILING DATE: 2002-03-21
  PRIOR APPLICATION NUMBER: US 60/368,679
  PRIOR FILING DATE: 2002-03-28
  PRIOR APPLICATION NUMBER: US 60/404,809
  PRIOR FILING DATE: 2002-08-19
  PRIOR APPLICATION NUMBER: US 60/405,645
  PRIOR FILING DATE: 2002-08-21
 NUMBER OF SEQ ID NOS: 95
; SEQ ID NO 63
   LENGTH: 333
   TYPE: PRT
   ORGANISM: Homo sapien
US-10-331-496A-63
```

```
34.0%; Score 629.5; DB 15; Length 333;
 Best Local Similarity 40.9%; Pred. No. 6.6e-41;
 Matches 135; Conservative 52; Mismatches 130; Indels 13; Gaps
         14 GALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSS 73
Qy
            14 GVLMVLCRTAISKSIVLEPIYWNSSNSKFLPGQGLVLYPQIGDKLDIICPKV---DSKTV 70
Db
         74 PNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHH 133
Qу
                                   11:11:1:1
         71 GOYEYYKVYMVDKDQADRCTIKKENTPLLNCAKPDQDIKFTIKFQEFSPNLWGLEFQKNK 130
Db
         134 DYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQ--SPRGGAVPRKPVSEMPMER-DR 190
Qу
            131 DYYIISTSNGSLEGLDNQEGGVCQTRAMKILMKVGQDASSAGSTRNKDPTRRPELEAGTN 190
Db
         191 GAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLLGVAGAGGAMC 250
Qy
            1:: | : | | : : : : : | | | | | | ::::
         191 GRSSTTSPFVKPNPGSSTDGNSAGHSGNNILGSEVALFAGIASGCIIFIVIIITLVVLLL 250
Db
         251 WRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGGGAADPPFCPH 310
Qу
              | | | : : | | : |
                                             :|| :: | ||
                                                          - | | - | | | |
         251 KYRRRHRKHSPQHTTTLSLSTLATPKRSGNN----NGSEPSDIIIPLR---TADSVFCPH 303
Db
         311 YEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qу
            304 YEKVSGDYGHPVYIVQEMPPQSPANIYYKV 333
Dh
RESULT 11
US-10-138-787-4
; Sequence 4, Application US/10138787
; Publication No. US20020172984A1
; GENERAL INFORMATION:
; APPLICANT: Holland, Sacha
  APPLICANT: Mbamalu, Geraldine
  APPLICANT: Pawson, Tony
  TITLE OF INVENTION: OLIGOMERIZED RECEPTORS WHICH AFFECT PATHWAYS REGULATED
  TITLE OF INVENTION: BY TRANSMEMBRANE LIGANDS FOR ELK-RELATED RECEPTOR
  TITLE OF INVENTION: TYROSINE KINASES
  FILE REFERENCE: 11757.23USWO
  CURRENT APPLICATION NUMBER: US/10/138,787
  CURRENT FILING DATE: 2002-05-03
  PRIOR APPLICATION NUMBER: US/09/214,631
  PRIOR FILING DATE: 1999-03-12
  PRIOR APPLICATION NUMBER: PCT/CA97/00473
  PRIOR FILING DATE: 1997-07-04
   PRIOR APPLICATION NUMBER: 60/021,272
  PRIOR FILING DATE: 1996-07-05
  NUMBER OF SEQ ID NOS: 13
  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
   LENGTH: 333
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-138-787-4
```

```
33.6%; Score 622.5; DB 13; Length 333;
 Best Local Similarity 40.9%; Pred. No. 2.3e-40;
 Matches 135; Conservative 54; Mismatches 128; Indels 13; Gaps
                                                                    6;
         14 GALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSS 73
QУ
                   : : |||:| ||:| :| | | || ||:||:||:
         14 GVLMVLCRTAISKSIVLEPIYMNSSNSKFLPGQGLVLYPQIGDKLDIICPKV---DSKTV 70
Db
         74 PNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHH 133
Qу
              ||:||:|:|
                                    71 GQYEYYKVYMVDKDQADRCTIKKENTPLLNCAKPDQDIKFTIKFQEFSPNLWGLEFQKNK 130
Db
        134 DYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQ-SPRGGAVPRKPVSEMP-MER-DR 190
QУ
            131 DYYIISTSNGSLEGLDNQEGGVCQTRAMKILMKVGQDASSAGSTPNKDPTRRPELEAGTN 190
Db
        191 GAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLLGVAGAGGAMC 250
Qу
            191 GRSSTTSPFVKPNPGSSTDGNSAGHSGNNILGSEVALFAGIASGCIIFIVIIITLVVLLL 250
Db
        251 WRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGGGAADPPFCPH 310
Qу
              : | | : : | | |
                                                          251 KYRRRHRKHSPQHTTTLSLSTLATPKRSGNN----NGSEPSDIIIPLR---TADSVFCPH 303
Db
        311 YEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qу
            304 YEKVSGDYGHPVYIVQEMPPQSPANIYYKV 333
RESULT 12
US-10-138-787-5
; Sequence 5, Application US/10138787
; Publication No. US20020172984A1
; GENERAL INFORMATION:
 APPLICANT: Holland, Sacha
  APPLICANT: Mbamalu, Geraldine
  APPLICANT: Pawson, Tony
  TITLE OF INVENTION: OLIGOMERIZED RECEPTORS WHICH AFFECT PATHWAYS REGULATED
  TITLE OF INVENTION: BY TRANSMEMBRANE LIGANDS FOR ELK-RELATED RECEPTOR
  TITLE OF INVENTION: TYROSINE KINASES
  FILE REFERENCE: 11757.23USWO
  CURRENT APPLICATION NUMBER: US/10/138,787
  CURRENT FILING DATE: 2002-05-03
  PRIOR APPLICATION NUMBER: US/09/214,631
  PRIOR FILING DATE: 1999-03-12
  PRIOR APPLICATION NUMBER: PCT/CA97/00473
  PRIOR FILING DATE: 1997-07-04
  PRIOR APPLICATION NUMBER: 60/021,272
  PRIOR FILING DATE: 1996-07-05
  NUMBER OF SEQ ID NOS: 13
  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
   LENGTH: 345
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-138-787-5
```

```
32.9%; Score 608.5; DB 13; Length 345;
 Best Local Similarity 38.7%; Pred. No. 3e-39;
 Matches 142; Conservative 50; Mismatches 116; Indels 59; Gaps 10;
          8 PGGVRVG----ALLLLGVLGLVSGL--SLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLL 61
Qу
           4 PGGRWLGKWLYAMVVWALCRLATPLAKNLEPVSWSSLNPKFLSGKGLVIYPKIGDKLDII 63
         62 CPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYS 121
Qy
           64 CPPAEAGRP----YEYYKLYLVRPEQAAACSTVLDPMVLVTCNRPEQEIRFTIKFQEFS 118
Db
        122 PNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPV 181
Qу
           119 PNYMGLEFKKHHDYYITSTSNGSLEGLENREGGVCRTRTMKIIMKVGQDPNAVTPEQLTT 178
Db
        182 SEMPMERDRGAAHSLE-PGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLA---- 236
Qу
           179 SRPSKEADNTVKMATQAPGSRGSLGDSDGKHETVNQEEKSGP-----GASGGSSGDPD 231
Db
        237 -----LLLLGVAGAGGA------MCWRRRRAKPSESRHPGPGSFGRGGSLGL 277
Qу
                232 GFFNSKVALFAAVGAGCVIFLLIIIFLTVLLLKLPKRHRKHTQ-----RAAALSL 281
Db
        278 ----GGGGGMGPREAEPGELGIALRGGGAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSP 333
Qy
                 282 STIASPKGGSGTAGTEPSDIIIPL---FTTENNYCPHYEKVSGDYGHPVYIVQEMPPQSP 338
Db
        334 PNIYYKV 340
Qу
           +++++
        339 ANIYYKV 345
Db
RESULT 13
US-09-862-179A-17
; Sequence 17, Application US/09862179A
; Patent No. US20020147306A1
; GENERAL INFORMATION:
  APPLICANT: Lin, Danny
  APPLICANT: Pawson, Anthony
  TITLE OF INVENTION: PEPTIDES THAT MODULATE THE INTERACTION OF B CLASS EPHRINS
; TITLE OF INVENTION: AND PDZ DOMAINS
 FILE REFERENCE: MTSI-P01-009
 CURRENT APPLICATION NUMBER: US/09/862,179A
  CURRENT FILING DATE: 2001-05-21
  NUMBER OF SEQ ID NOS: 44
 SOFTWARE: PatentIn version 3.1
; SEQ ID NO 17
   LENGTH: 89
   TYPE: PRT
   ORGANISM: Homo sapiens
US-09-862-179A-17
 Query Match 26.9%; Score 498; DB 9; Length 89; Best Local Similarity 100.0%; Pred. No. 2.4e-31;
 Matches 89; Conservative 0; Mismatches 0; Indels 0; Gaps
                                                                0;
```

```
252 RRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGGGAADPPFCPHY 311
Qу
            1 RRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGGGAADPPFCPHY 60
Db
         312 EKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qу
            61 EKVSGDYGHPVYIVQDGPPQSPPNIYYKV 89
Db
RESULT 14
US-10-138-787-13
; Sequence 13, Application US/10138787
; Publication No. US20020172984A1
; GENERAL INFORMATION:
  APPLICANT: Holland, Sacha
  APPLICANT: Mbamalu, Geraldine
  APPLICANT: Pawson, Tony
  TITLE OF INVENTION: OLIGOMERIZED RECEPTORS WHICH AFFECT PATHWAYS REGULATED
  TITLE OF INVENTION: BY TRANSMEMBRANE LIGANDS FOR ELK-RELATED RECEPTOR
  TITLE OF INVENTION: TYROSINE KINASES
  FILE REFERENCE: 11757.23USWO
  CURRENT APPLICATION NUMBER: US/10/138,787
  CURRENT FILING DATE: 2002-05-03
  PRIOR APPLICATION NUMBER: US/09/214,631
  PRIOR FILING DATE: 1999-03-12
  PRIOR APPLICATION NUMBER: PCT/CA97/00473
  PRIOR FILING DATE: 1997-07-04
  PRIOR APPLICATION NUMBER: 60/021,272
  PRIOR FILING DATE: 1996-07-05
  NUMBER OF SEQ ID NOS: 13
  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 13
   LENGTH: 89
   TYPE: PRT
   ORGANISM: Homo sapiens
US-10-138-787-13
                       26.9%; Score 498; DB 13; Length 89;
  Query Match
  Best Local Similarity 100.0%; Pred. No. 2.4e-31;
                                                                     0;
                                            0; Indels
                                                          0; Gaps
         89; Conservative 0; Mismatches
         252 RRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGGGAADPPFCPHY 311
QУ
            1 RRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGGGAADPPFCPHY 60
Db
         312 EKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qy
             61 EKVSGDYGHPVYIVQDGPPQSPPNIYYKV 89
Db
RESULT 15
US-09-864-761-48262
; Sequence 48262, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
```

```
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
 APPLICANT: Chen, Wensheng
  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES
USEFUL FOR
; TITLE OF INVENTION: GENE EXPRESSION ANALYSIS BY MICROARRAY
  FILE REFERENCE: Aeomica-X-1
  CURRENT APPLICATION NUMBER: US/09/864,761
  CURRENT FILING DATE: 2001-05-23
  PRIOR APPLICATION NUMBER: US 60/180,312
  PRIOR FILING DATE: 2000-02-04
  PRIOR APPLICATION NUMBER: US 60/207,456
  PRIOR FILING DATE: 2000-05-26
  PRIOR APPLICATION NUMBER: US 09/632,366
  PRIOR FILING DATE: 2000-08-03
  PRIOR APPLICATION NUMBER: GB 24263.6
  PRIOR FILING DATE: 2000-10-04
  PRIOR APPLICATION NUMBER: US 60/236,359
  PRIOR FILING DATE: 2000-09-27
  PRIOR APPLICATION NUMBER: PCT/US01/00666
  PRIOR FILING DATE: 2001-01-30
  PRIOR APPLICATION NUMBER: PCT/US01/00667
  PRIOR FILING DATE: 2001-01-30
  PRIOR APPLICATION NUMBER: PCT/US01/00664
  PRIOR FILING DATE: 2001-01-30
  PRIOR APPLICATION NUMBER: PCT/US01/00669
  PRIOR FILING DATE: 2001-01-30
  PRIOR APPLICATION NUMBER: PCT/US01/00665
  PRIOR FILING DATE: 2001-01-30
  PRIOR APPLICATION NUMBER: PCT/US01/00668
 PRIOR FILING DATE: 2001-01-30
  PRIOR APPLICATION NUMBER: PCT/US01/00663
  PRIOR FILING DATE: 2001-01-30
  PRIOR APPLICATION NUMBER: PCT/US01/00662
  PRIOR FILING DATE: 2001-01-30
  PRIOR APPLICATION NUMBER: PCT/US01/00661
  PRIOR FILING DATE: 2001-01-30
  PRIOR APPLICATION NUMBER: PCT/US01/00670
  PRIOR FILING DATE: 2001-01-30
  PRIOR APPLICATION NUMBER: US 60/234,687
  PRIOR FILING DATE: 2000-09-21
  PRIOR APPLICATION NUMBER: US 09/608,408
  PRIOR FILING DATE: 2000-06-30
  PRIOR APPLICATION NUMBER: US 09/774,203
  PRIOR FILING DATE: 2001-01-29
 NUMBER OF SEQ ID NOS: 49117
  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 48262
   LENGTH: 92
   TYPE: PRT
   ORGANISM: Homo sapiens
   OTHER INFORMATION: MAP TO AL136092.7
   OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 4.1
   OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 1.9
   OTHER INFORMATION: SWISSPROT HIT: P98172, EVALUE 4.00e-51
   OTHER INFORMATION: EST HUMAN HIT: BE562822.1, EVALUE 3.00e-50
```

US-09-864-761-48262

							Length	92;		
		Similarity								
Matches	52	2; Conserva	tive 1	5; Mi	smatches	24;	Indels	5;	Gaps	1;
Qу	42	FQAEGGYVLYP	QIGDRLDL	LCPRAR!	PPGPHSSP:	NYEFYKL	YLVGGAQ	RRCEAP	PAPNLL	101
		1: 1:	: : :	:	1				:	
Db	1	FLSGKGLVIYP:	KIGDKLDI	ICPRAE	AGRP	-YEYYKL	YLVRPEQA	AACSTV	LDPNVL	55
Qу	102	LTCDRPDLDLR	FTIKFQEY:	SPNLWG	HEFRSHHD	YYI 137				
		: : : ::	:		:	111				
Db	56	VTCNRPEQEIR:	FTIKFQEF:	SPNYMG	LEFKKHHD	YYI 91				

Search completed: April 13, 2004, 09:39:50

Job time: 32.0755 secs

GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

April 13, 2004, 09:22:17; Search time 50.0377 Seconds Run on:

(without alignments)

2143.906 Million cell updates/sec

Title: US-10-021-121-4

Perfect score: 1850

1 MGPPHSGPGGVRVGALLLLG.....PVYIVQDGPPQSPPNIYYKV 340 Sequence:

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

1017041 seqs, 315518202 residues Searched:

Total number of hits satisfying chosen parameters: 1017041

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

SPTREMBL 25:* Database :

1: sp archea:*

2: sp_bacteria:*

3: sp_fungi:*

4: sp_human:*

5: sp invertebrate:*

6: sp mammal:*

7: sp mhc:*

8: sp_organelle:*

9: sp_phage:*

10: sp_plant:*

11: sp rodent:*

12: sp virus:*

13: sp vertebrate:*

14: sp unclassified:*

15: sp_rvirus:*
16: sp_bacteriap:*

17: sp_archeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result Query

ક

Description No. Score Match Length DB ID

1	923	49.9	331	13	Q90Z31	Q90z31 brachydanio
2	919	49.7	327	13	Q9PT69	Q9pt69 xenopus lae
3	629.5	34.0	333	13	Q9PUJ4	Q9puj4 gallus gall
4	616	33.3	341	13	Q90Z33	Q90z33 brachydanio
5	605.5	32.7	334	13	Q90Z32	Q90z32 brachydanio
6	340	18.4	205	13	Q9 W 6H9	Q9w6h9 xenopus lae
7	214.5	11.6	237	5	Q9U3 M 2	Q9u3m2 caenorhabdi
8	198.5	10.7	279	5	Q9U474	Q9u474 caenorhabdi
9	182	9.8	652	5	Q9V4E1	Q9v4e1 drosophila
10	178.5	9.6	202	13	Q98TZ1	Q98tz1 gallus gall
11	168.5	9.1	205	4	Q8N578	Q8n578 homo sapien
12	167	9.0	205	11	Q9D7K8	Q9d7k8 mus musculu
13	163.5	8.8	206	11	Q9CZS8	Q9czs8 mus musculu
14	156	8.4	675	6	Q9N178	Q9n178 sus scrofa
15	155	8.4	229	13	093431	093431 brachydanio
16	153.5	8.3	217	13	Q7SY61	Q7sy61 xenopus lae
17	153.5	8.3	1691	11	Q9ESQ2	Q9esq2 mus musculu
18	151.5	8.2	1447	13	Q9IB91	Q9ib91 xenopus lae
19	149	8.1	325	5	017036	017036 caenorhabdi
20	149	8.1	569	5	Q17208	Q17208 bombyx mori
21	148.5	8.0	316	5	Q19111	Q19111 caenorhabdi
22	147	7.9	921	11	Q8BSQ4	Q8bsq4 mus musculu
23	147	7.9	2936	6	Q7YRK8	Q7yrk8 canis famil
24	146.5	7.9	888	11	Q8CCZ8	Q8ccz8 mus musculu
25	146.5	7.9	1140	11	Q61434	Q61434 mus musculu
26	146.5	7.9	1449	13	Q802B5	Q802b5 xenopus lae
27	146.5	7.9	1491	13	Q91718	Q91718 xenopus lae
28	146.5	7.9	1491	13	Q7ZTM4	Q7ztm4 xenopus lae
29	146	7.9	675	13	Q90800	Q90800 gallus gall
30	146	7.9	1669	11	Q9QZS0	Q9qzs0 mus musculu
31	145.5	7.9	305	5	017805	017805 caenorhabdi
32	145.5	7.9	308	5	Q94620	Q94620 meloidogyne
33	145	7.8	680	11	Q9D0D2	Q9d0d2 mus musculu
34	144.5	7.8	309	5	Q25466	Q25466 meloidogyne
35	144.5	7.8	1269	13	Q7T2Z7	Q7t2z7 gallus gall
36	144.5	7.8	1347	4	Q96QB3	Q96qb3 homo sapien
37	144.5	7.8	1420	13	Q90W37	Q90w37 gallus gall
38	143.5	7.8	775	16	Q9F342	Q9f342 streptomyce
39	143	7.7	445	5	Q8MZ49	Q8mz49 drosophila
40	143	7.7	1684	6	Q8HYC1	Q8hycl canis famil
41	143	7.7	1688	6	Q866Z2	Q866z2 canis famil
42	143	7.7	1747	5	Q26640	Q26640 strongyloce
43	142	7.7	1034	11	Q8K229	Q8k229 mus musculu
44	142	7.7	1497	11	Q7TMS0	Q7tms0 mus musculu
45	142	7.7	1835	13	Q9IAU4	Q9iau4 gallus gall

ALIGNMENTS

```
RESULT 1
Q90Z31

ID Q90Z31 PRELIMINARY; PRT; 331 AA.

AC Q90Z31;

DT 01-DEC-2001 (TrEMBLrel. 19, Created)

DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)

DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
```

```
DΕ
    Ephrin B3.
GN
    EFNB3.
    Brachydanio rerio (Zebrafish) (Danio rerio).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
OC
    Cyprinidae; Danio.
OC
ΟX
    NCBI TaxID=7955;
    [1]
RN
    SEQUENCE FROM N.A.
RP
    MEDLINE=21290827; PubMed=11397014;
RX
    Chan J., Mably J.D., Serluca F.C., Chen J.N., Goldstein N.B.,
RA
    Thomas M.C., Cleary J.A., Brennan C., Fishman M.C., Roberts T.M.;
RA
    "Morphogenesis of prechordal plate and notochord requires intact
RT
    eph/ephrin b signaling.";
RT
    Dev. Biol. 234:470-482(2001).
RL
    EMBL; AF375227; AAK64277.1; -.
DR
    ZFIN; ZDB-GENE-010618-3; efnb3.
DR
    GO; GO:0016020; C:membrane; IEA.
DR
    InterPro; IPR008972; Cupredoxin.
DR
    InterPro; IPR001799; Ephrin.
DR
    Pfam; PF00812; Ephrin; 1.
DR
    PRINTS; PR01347; EPHRIN.
DR
    ProDom; PD002533; Ephrin; 1.
DR
    PROSITE; PS01299; EPHRIN; 1.
DR
              331 AA; 35638 MW; 6A5EACD509A09818 CRC64;
SO
                       49.9%; Score 923; DB 13; Length 331;
 Query Match
                       54.8%; Pred. No. 7.9e-64;
 Best Local Similarity
                                                                    10;
                                                         40; Gaps
 Matches 190; Conservative 43; Mismatches 74; Indels
         10 GVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPG 69
Qу
            9 GLGILLIFLVDLLG-ITATNMEPIYWNSLNKRFSDDKGYVLYPQIGDRLDLICPSSDPPG 67
Db
         70 PHSSPNYEFYKLYLVGG-AQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHE 128
Qу
                            68 PRAPADYEYYKLYLVSSREQADRCEVTGAPNLLLTCDKPNSDMRFTIKFQEYSPNLWGHE 127
Db
         129 FRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRG-GAVPRKPVSEMPME 187
Qу
            128 FKTNHDYFIIATSDGTRQGLESMRGGVCATQGMKVVLKVGQSPYGLPAKSPKPDS---- 182
Db
         188 RDRGAAHSLEPGKENLPGDPTSNAT-----SRGAEGPLPPPSMPAVAGAAGGLALLL 239
Qv.
                      |: | | | |:|
                                         183 -----AGRINNPNPGTGNSTHPQIPPRGSGGENGPLPASNIAVIAGAAGGSAFLL 232
Db
         240 LGVAGAGGAMCWRRRRAKPSESRHPGPGSFG-----RGGSLGLGGGGGMGPREAEPGEL 293
Qу
                    :1:111 | 1 | 1 | 1 | 1 | 1
                                             1 1
         233 L-VTAVICVVCYRRRHAKHSESHHP-PLSLSSLTSPKRGCGGGVGGGNNNG---SEPSDI 287
Db
QУ
         294 GIALRGGGAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
                   288 IIPLR---TSDSAYCPHYEKVSGDYGHPVYIVQEMPPQSPANIYYKV 331
Db
```

```
327 AA.
               PRELIMINARY;
                               PRT;
ID
    09PT69
AC
    09PT69;
    01-MAY-2000 (TrEMBLrel. 13, Created)
DT
    01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
    Ephrin-B3 precursor.
DF.
    Xenopus laevis (African clawed frog).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Amphibia; Batrachia; Anura; Mesobatrachia; Pipoidea; Pipidae;
OC
    Xenopodinae; Xenopus.
OC
    NCBI TaxID=8355;
OX
RN
    [1]
    SEQUENCE FROM N.A.
RP
    TISSUE=Embryo;
RC
    MEDLINE=20099673; PubMed=10633856;
RX
    Helbling P.M., Saulnier D.M.E., Robinson V., Christiansen J.H.,
RA
    Wilkinson D.G., Brandli A.W.;
RA
    "Comparative analysis of embryonic gene expression defines potential
RT
    interaction sites for Xenopus EphB4 receptors with ephrin-B ligands.";
RT
    Dev. Dyn. 216:361-373(1999).
RL
    EMBL; AJ236866; CAB65511.1; -.
DR
    GO; GO:0016020; C:membrane; IEA.
DR
    GO; GO:0016491; F:oxidoreductase activity; IEA.
DR
    GO; GO:0008152; P:metabolism; IEA.
DR
DR
    InterPro; IPR002086; Aldehyde dehydr.
    InterPro; IPR008972; Cupredoxin.
DŘ
DR
    InterPro; IPRO01799; Ephrin.
DR
    Pfam; PF00812; Ephrin; 1.
    PRINTS; PR01347; EPHRIN.
DR
DR
    ProDom; PD002533; Ephrin; 1.
    PROSITE; PS00687; ALDEHYDE DEHYDR_GLU; 1.
DR
    PROSITE; PS01299; EPHRIN; \overline{1}.
DR
KW
    Signal.
                               POTENTIAL.
FT
    SIGNAL
                 1
                       24
               327 AA; 35913 MW; 4BB0FA39D4C22DCD CRC64;
SQ
    SEQUENCE
                        49.7%; Score 919; DB 13; Length 327;
  Query Match
  Best Local Similarity 60.4%; Pred. No. 1.6e-63;
                                                                       8;
  Matches 192; Conservative 30; Mismatches
                                                           14; Gaps
                                             82; Indels
          25 VSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSSPNYEFYKLYLV 84
QУ
             22 ISALSLDPIYWNSSNKRFEDTEGYVLYPQIGDRLDLLCPRSEPQGPFSSSPYEYYKLYLV 81
Db
          85 GGAOG-RRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHHDYYIIATSDG 143
Qу
                         82 GTKEEMSSCSILRTPNLLLTCDRPSQDLRFTIKFQEFSPNLWGHEFQSQRDYYIIATSDG 141
Db
         144 TREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPVSEMPMERDRGAAHSL-EPGKEN 202
Qу
             :| | : |: |
         142 TMDGIETLQGGVCETKGMKVTLKVGQSPNGATPPRRPSS---AGKDSGISPSVPNPDIPN 198
Db
         203 LPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLLGVAGAGGAMCWRRRRAKPSESR 262
Qγ
             199 V-GETSGNATKTGENGPLPISHVPLVAGAAGGAALLLL-VFGVVGWVCHRRRQAKHSDTR 256
Db
         263 HPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGGGAADPPFCPHYEKVSGDYGHPV 322
Qу
```

```
11::::
                                                 257 HP-PLSLGSITSPKRGGNN----NGHEPSDIIMPLRPSEAG--AFCPHYEKVSGDYGHPV 309
Db
        323 YIVQDGPPQSPPNIYYKV 340
Qу
            310 YIVQDMASQSPANIYYKV 327
Db
RESULT 3
Q9PUJ4
              PRELIMINARY; PRT;
                                    333 AA.
    Q9PUJ4
TD
AC
    09PUJ4;
    01-MAY-2000 (TrEMBLrel. 13, Created)
    01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
DE
    Ephrin-B2 precursor.
    Gallus gallus (Chicken).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC
OC
    Gallus.
OX
    NCBI TaxID=9031;
RN
    [1]
RP
    SEQUENCE FROM N.A.
RA
    Menzel P., Pasquale E.B.;
    "Coding sequence of chicken ephrin-B2.";
RT
    Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases.
RL
    EMBL; AF180729; AAD53948.1; -.
DR
    GO; GO:0016020; C:membrane; IEA.
DR
    InterPro; IPR008972; Cupredoxin.
DR
    InterPro; IPR001799; Ephrin.
DR
    Pfam; PF00812; Ephrin; 1.
DR
    PRINTS; PR01347; EPHRIN.
DR
    ProDom; PD002533; Ephrin; 1.
DR
    PROSITE; PS01299; EPHRIN; 1.
DR
KW
    Signal.
                             POTENTIAL.
                     27
FT
    SIGNAL
                1
                             EPHRIN-B2.
               28
                    333
FT
    CHAIN
             333 AA; 36761 MW; 4C28E8CB211B7783 CRC64;
SO
    SEQUENCE
                      34.0%; Score 629.5; DB 13; Length 333;
 Query Match
 Best Local Similarity 40.5%; Pred. No. 5.2e-41;
                                                                   6;
                                                       21; Gaps
 Matches 135: Conservative 52; Mismatches 125; Indels
         14 GALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSS 73
QУ
            16 GALMVLWRTALAKSIVLDPIYWNSSNPKFLPGQGLVLYPQIGDKLDIICPKV---DSKTV 72
Db
         74 PNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHH 133
Qy
              73 GQYEYYKVYMVDKDQADSCAIRKDNTPLLNCAKPDQDVKFTIKFQEFSPNLWGLEFQKNK 132
Db
         134 DYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPVSEMPMER---- 188
Qy
            133 DYYVISTSNGSLEGLNNQEGGVCQTKTMKILMKVGQDPNSAGLPR---STDPTKRPEQEA 189
Db
         189 -DRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLLGVAGAGG 247
Qу
```

```
190 GTNGKSSTTSPFVKDHSGSSTDG--SKAGHSSILGSEVALFAGIASGCIIFIVIIITLVV 247
Db
         248 AMCWRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGGGAADPPF 307
Qу
                                                  : | | :: | | |
                  111:
                         : |
                                     : 1
                               248 LLLKYRRRHRKHSPQHTTTLSLSTLATPKRSGNN----NGSEPSDIIIPLR---TADSVF 300
Db
         308 CPHYEKVSGDYGHPVYIVODGPPOSPPNIYYKV 340
QУ
             301 CPHYEKVSGDYGHPVYIVQEMPPQSPANIYYKV 333
Db
RESULT 4
Q90Z33
    Q90Z33
                                 PRT;
                                       341 AA.
                PRELIMINARY;
ID
AC
    Q90Z33;
    01-DEC-2001 (TrEMBLrel. 19, Created)
DT
    01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
DΕ
    Ephrin B1.
GN
    EFNB1.
    Brachydanio rerio (Zebrafish) (Danio rerio).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
OC
OC
    Cyprinidae; Danio.
    NCBI TaxID=7955;
ΟX
RN
    [1]
RP
    SEQUENCE FROM N.A.
RX
    MEDLINE=21290827; PubMed=11397014;
    Chan J., Mably J.D., Serluca F.C., Chen J.N., Goldstein N.B.,
RA
    Thomas M.C., Cleary J.A., Brennan C., Fishman M.C., Roberts T.M.;
RA
    "Morphogenesis of prechordal plate and notochord requires intact
RT
    eph/ephrin b signaling.";
RT
    Dev. Biol. 234:470-482(2001).
RL
    EMBL; AF375224; AAK64274.1; -.
DR
    ZFIN; ZDB-GENE-010618-2; efnb1.
    GO; GO:0016020; C:membrane; IEA.
DR
    InterPro; IPR008972; Cupredoxin.
DR
    InterPro; IPR001799; Ephrin.
DR
DR
    Pfam; PF00812; Ephrin; 1.
    PRINTS; PR01347; EPHRIN.
DR
    ProDom; PD002533; Ephrin; 1.
DR
    PROSITE; PS01299; EPHRIN; 1.
DR
    SEQUENCE 341 AA; 37849 MW; CB922F20E0D93E94 CRC64;
SO
                        33.3%; Score 616; DB 13; Length 341;
  Query Match
                        41.8%; Pred. No. 6e-40;
  Best Local Similarity
                                                                        11;
 Matches 141; Conservative 49; Mismatches 109; Indels
                                                            38; Gaps
          24 LVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSSPNYEFYKLYL 83
Qу
             - 1
Db
          23 LPAAKSLESVVWNSONPKFVSGKGLVIYPEIGDKLDIICPK----GDMGRP-YEFYKLYL 77
          84 VGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHHDYYIIATSDG 143
Qу
                          1
                   - 1
          78 VKKEQAESCSTILDPNVLVTCNKPEKDIKFTIKFQEFSPNYMGLEFKRFTNYYITSTSNG 137
Db
         144 TREGLESLQGGVCLTRGMKVLLRVGQSPRG----GAVPRKPVSEMPMERDRGAAHSLEP 198
Qу
```

```
|:|||::::|||
                                               : | : |
         138 TQEGLENREGGVCSTRSMKIIMKVGQDPNAPDPDLPDLPDRPYDNEIKDPTTSPSRKTER 197
Db
         199 GKEN-----LPGDPTSNATSR--GAEGPLPPPSMPAVAGAAG-GLALLLLGVAGAGG 247
Qу
                        198 GRENEVDGNGSKMPGKDTRNONNSPGSVEGIF--GSKPALFAAIGAGCVIFLLIIIILIV 255
Db
         248 AMCWRRRRAKPSESRHPGPGSFGRGGSL----GLGGGGGMGPREAEPGELGIALRGGGAA 303
Qу
                         : | | | | | | |
              : |:|:
                                                      : [ ] :: [ ] [ ]
         256 LLLKLRKRTR----KHSQP----RGGTALSLSTLATPKGAAQAGSEPSDIIIPLR---TT 304
Db
         304 DPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qу
             305 ENNYCPHYEKVSGDYGHPVYIVQEMPPQSPANIYYKV 341
Db
RESULT 5
Q90Z32
                PRELIMINARY;
                               PRT;
                                       334 AA.
   Q90Z32
ID
AC
    Q90Z32;
    01-DEC-2001 (TrEMBLrel. 19, Created)
    01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DТ
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
DE
    Ephrin B2b.
    EFNB2B.
GN
    Brachydanio rerio (Zebrafish) (Danio rerio).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
OC
    Cyprinidae; Danio.
OC
    NCBI TaxID=7955;
OX
RN
    [1]
    SEQUENCE FROM N.A.
RP
RX
    MEDLINE=21290827; PubMed=11397014;
    Chan J., Mably J.D., Serluca F.C., Chen J.N., Goldstein N.B.,
RA
    Thomas M.C., Cleary J.A., Brennan C., Fishman M.C., Roberts T.M.;
RA
    "Morphogenesis of prechordal plate and notochord requires intact
RT
    eph/ephrin b signaling.";
RT
    Dev. Biol. 234:470-482(2001).
RL
    EMBL; AF375226; AAK64276.1; -.
DR
    ZFIN; ZDB-GENE-010618-1; efnb2b.
DR
    GO; GO:0016020; C:membrane; IEA.
DR
    InterPro; IPR008972; Cupredoxin.
DR
DR
    InterPro; IPR001799; Ephrin.
DR
    Pfam; PF00812; Ephrin; 1.
    PRINTS; PR01347; EPHRIN.
DR
DR
    ProDom; PD002533; Ephrin; 1.
    SEOUENCE 334 AA; 36998 MW; 341497E0FE9473BD CRC64;
SO
  Query Match
                        32.7%; Score 605.5; DB 13;
                                                    Length 334;
  Best Local Similarity
                        41.0%; Pred. No. 3.9e-39;
  Matches 134; Conservative 45; Mismatches 113; Indels
                                                            35; Gaps
                                                                        8;
          30 LEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSSPNYEFYKLYLVGGAQG 89
Qy
                             || :|||::| :|
Db
          27 LESIYWNTSNTKFVPGRGVVLYPQIGDKMDIVCPRIK-PGSTEQTNIEYFRVYLVPKEQL 85
          90 RRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHHDYYIIATSDGTREGLE 149
Qу
```

```
: ||| ||:|| |::|| ||||:||||||
                                                     86 ETCHVTKSDMLLLNCDKPDQDVKFTFKFQEFSPNLWGLEFLRGKDYHIISTSNSTFEGLD 145
Db
         150 SLOGGVCLTRGMKVLLRVGOSPRGGAV----PRKPVSEMPMERDRGAAHSLEPGKENLPG 205
Qу
             146 NHHGGVCRSKSMKLVLRVGOSPTDSFSAKNHPTRNPPKYPENKDQNTF----SKENDVS 200
Db
         206 --DPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLLGVAGAGGAMCW------RR 253
Qу
                                     |:|| | || || ||:::
               201 QIDSMQNGESGGKSG-----ESVGSAGSDVALFAGV--ASGAVIFILIIIALVALLH 250
Db
         254 RRAKPSESRHPGPGSFGRGGSLGLGGGGGGMGPREAEPGELGIALRGGGAADPPFCPHYEK 313
Qу
                                            251 RRHQKHSAQCSGQLPLNTLPKRGSGASGGSNNNGSEPSDIIFPIRTSGSM---YCPHYEK 307
Db
         314 VSGDYGHPVYIVQDGPPQSPPNIYYKV 340
QУ
             308 VSGDYGHPVYIVQEMPPQNPANIYYKV 334
Db
RESULT 6
09W6H9
                                       205 AA.
               PRELIMINARY; PRT;
ΙD
    O9W6H9
AC
    09W6H9;
    01-NOV-1999 (TrEMBLrel. 12, Created)
DТ
    01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
DE
    Ephrin-B2 (Fragment).
    Xenopus laevis (African clawed frog).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Amphibia; Batrachia; Anura; Mesobatrachia; Pipoidea; Pipidae;
OC
OC
    Xenopodinae; Xenopus.
OX
    NCBI TaxID=8355;
RN
    [1]
RP
    SEQUENCE FROM N.A.
    MEDLINE=97411149; PubMed=9259557;
RX
    Smith A., Robinson V., Patel K., Wilkinson D.G.;
RA
    "The EphA4 and EphB1 receptor tyrosine kinases and ephrin-B2 ligand
RT
    regulate targeted migration of branchial neural crest cells.";
RT
    Curr. Biol. 7:561-570(1997).
RL
RN
    [2]
RP
    SEQUENCE FROM N.A.
RX
    MEDLINE=20099673;
    Helbling P.M., Saulnier D.M., Robinson V., Christiansen J.H.,
RA
    Wilkinson D.G., Brandli A.W.;
RA
    "Comparative analysis of embryonic gene expression defines potential
RT
RТ
    interaction sites for Xenopus EphB4 receptors with ephrin-B ligands.";
RL
    Dev. Dyn. 216:361-373(1999).
DR
    EMBL; AF128844; AAD32610.1; -.
DR
    GO; GO:0016020; C:membrane; IEA.
DR
    InterPro; IPR008972; Cupredoxin.
    InterPro; IPR001799; Ephrin.
DR
DR
    Pfam; PF00812; Ephrin; 1.
DR
    ProDom; PD002533; Ephrin; 1.
                       1
FT
    NON TER
                1
               205 AA; 22256 MW; 7DEDD34277260C87 CRC64;
SQ
    SEQUENCE
```

```
18.4%; Score 340; DB 13; Length 205;
 Query Match
 Best Local Similarity 37.0%; Pred. No. 9.6e-19;
 Matches 84; Conservative 35; Mismatches 72; Indels
                                                                    7;
                                                        36; Gaps
        128 EFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSP----RGGAVPRKPVS 182
Qу
                 1 EFORDKDYYIISTSNGSLEGVDNOEGGVCVTKAMKILMKVGQDPNFHNHRGASSTRRPDH 60
Db
         183 EMPM--ERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Qу
            61 ESGTNGKSSTTSPHVNGPEGSSTEGKNAGHSSILGSEVAL-----FAGIASGSIIFIV 113
Db
         241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLG------GGGGMGPREAEPGEL 293
Qу
                  : |||: :| :| :| :| :::
        114 IIITLVVLLLKYRRRHRKHSPQHT-----TLSLSTLATPKRSGNNNG---SEPSDI 161
Db
        294 GIALRGGGAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
QУ
             162 IIPLR---TAEGVFCPHYEKVSGDYGHPVYIVQEMPPQSPANIYYKV 205
Db
RESULT 7
09U3M2
               PRELIMINARY; PRT; 237 AA.
ID
    Q9U3M2
AC
    09U3M2;
    01-MAY-2000 (TrEMBLrel. 13, Created)
DТ
    01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
    C43F9.8 protein.
DE
    C43F9.8.
GN
    Caenorhabditis elegans.
OS
OC
    Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;
    Rhabditidae; Peloderinae; Caenorhabditis.
OC
    NCBI TaxID=6239;
OX
RN
RP
    SEQUENCE FROM N.A.
RA
    Mortimore B.J.;
    Submitted (NOV-1996) to the EMBL/GenBank/DDBJ databases.
RL
RN
    SEQUENCE FROM N.A.
RP
    MEDLINE=99069613; PubMed=9851916;
RX
RA
RT
    "Genome sequence of the nematode C.elegans: A platform for
RT
    investigating biology.";
    Science 282:2012-2018(1998).
RL
    EMBL; Z82262; CAB54195.1; -.
DR
DR
    PIR; T19914; T19914.
DR
    WormPep; C43F9.8; CE23593.
    GO; GO:0016020; C:membrane; IEA.
DR
    InterPro; IPR008972; Cupredoxin.
DR
    InterPro; IPR001799; Ephrin.
DR
    Pfam; PF00812; Ephrin; 1.
DR
    PRINTS; PR01347; EPHRIN.
DR
    ProDom; PD002533; Ephrin; 1.
SQ
    SEQUENCE 237 AA; 26748 MW; B9B2D9FCC71FE4FC CRC64;
 Query Match
                      11.6%; Score 214.5; DB 5; Length 237;
```

```
Best Local Similarity 25.7%; Pred. No. 6.5e-09;
 Matches 53; Conservative 41; Mismatches 83; Indels
                                                             29; Gaps
                                                                          6:
          11 VRVGALLLLGVLGLVS-GLSLEPVYWNSANKRFOAEG-GYVLYPOIGDRLDLLCPRARPP 68
QУ
             ::: :||: : : | |:| |
                                                 :|: ||||::
           1 MQIATFILLSLFPFIGWARKIPDINWISSNPIFDVSNTDHVISVHIGDRVSIRCPKSDET 60
Db
          69 GPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHE 128
Qу
                   Db
          61 G----KYEYSYIYMVSDEEYDHCFL-SKPRLVGACDNQTINASINIVFRSFTPTPGGFE 114
         129 FRSHHDYYIIA-----TSDGTREGLESLQGGVCLTRGMKVLLRVGQ 169
QУ
                                          115 FOPGKNYFLISKSEVDALIIYETANQIFPGTSDGTLEGIDRKKDGLCTAKQMKIKFEVGQ 174
Db
         170 SPRGGAVPRKPVSEMPMERDRGAAHS 195
Qу
               \mathbf{H}
                   1:
                        : :::|| | ||
         175 DRRGIENPK--FAARTLKKDRDAEHS 198
Dh
RESULT 8
Q9U474
                                        279 AA.
ID
    Q9U474
                PRELIMINARY;
                                 PRT;
AC
    09U474;
    01-MAY-2000 (TrEMBLrel. 13, Created)
DТ
    01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE
    VAB-2 (Hypothetical protein Y37E11AR.6).
GN
    VAB-2 OR Y37E11AR.6.
OS
    Caenorhabditis elegans.
    Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;
OC
    Rhabditidae; Peloderinae; Caenorhabditis.
OC
OX
    NCBI TaxID=6239;
RN
    [1]
RP
    SEQUENCE FROM N.A.
RC
    STRAIN=N2;
    MEDLINE=20084449; PubMed=10619431;
RX
    Chin-Sang I.D., George S.E., Ding M., Moseley S.L., Lynch A.S.,
RA
RA
    Chisholm A.D.;
    "The ephrin VAB-2/EFN-1 functions in neuronal signaling to regulate
RT
    epidermal morphogenesis in C. elegans.";
RT
RL
    Cell 99:781-790(1999).
RN
    [2]
    SEQUENCE FROM N.A.
RP
    STRAIN=Bristol N2;
RC
    MEDLINE=99069613; PubMed=9851916;
RX
RA
    None:
RT
    "Genome sequence of the nematode C. elegans: a platform for
RT
    investigating biology. The C. elegans Sequencing Consortium.";
RL
    Science 282:2012-2018(1998).
RN
    [3]
    SEQUENCE FROM N.A.
RP
RC
    STRAIN=Bristol N2;
    Miller N., Maggi L.;
RA
    "The sequence of C. elegans cosmid Y37E11AR.";
RT
RL
    Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN
     [4]
```

```
SEQUENCE FROM N.A.
RP
RC
    STRAIN=Bristol N2;
RA
    Waterston R.;
RT
    "Direct Submission.";
    Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RL
DR
    EMBL; AF201079; AAF25647.1; -.
    EMBL; AC024759; AAK68436.1; -.
DR
    WormPep; Y37E11AR.6; CE27606.
DR
DR
    GO; GO:0016020; C:membrane; IEA.
DR
    InterPro; IPR008972; Cupredoxin.
    InterPro; IPR001799; Ephrin.
DR
    Pfam; PF00812; Ephrin; 1.
DR
DR
    PRINTS; PR01347; EPHRIN.
    ProDom; PD002533; Ephrin; 1.
DR
    SEQUENCE 279 AA; 32068 MW; 8C291A92D97D39EF CRC64;
SQ
                        10.7%; Score 198.5; DB 5; Length 279;
 Query Match
                        27.8%; Pred. No. 1.4e-07;
 Best Local Similarity
 Matches 64; Conservative 35; Mismatches 90; Indels
                                                            41; Gaps
                                                                        8;
           1 MGPPHSGPGGVRVGALLLLGVLGLV--SGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRL 58
Qу
                     ::: :|| :| | | | | :|||| :
                                                             1 MHPP-----IKIQTILLF-ILTTVHCSAKRLPQIYWNSTNPLVER-----YAAIGDTL 47
Db
          59 DLLCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQ 118
Qу
                       :| :| : ||
                                                   48 DIVCPFF---DENSDELTEQSIIYRVTEEEYENCERRSKAKELGRCTQPYQEEKLKVAFR 104
Db
         119 EYSPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPR 178
Qу
                          111 | :: |
         105 LMSPNPSGLDYRPGVTYYFISTSTGSRKGLYNEQGGLCASHNLKMVIHI--TDRNG--- 158
Db
         179 KPVSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAV 228
Qу
                      |:
                                       11:11
                                                    159 -----TPKTIPPV 191
Dh
RESULT 9
09V4E1
    Q9V4E1
                                       652 AA.
ΙD
               PRELIMINARY;
                                PRT;
AC
    09V4E1;
    01-MAY-2000 (TrEMBLrel. 13, Created)
DT
    01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
    Ephrin protein (LD11109p).
DE
    EPHRIN OR CG1862 OR DSIM\EPHRIN; EPHRIN.
GN
OS
    Drosophila melanogaster (Fruit fly).
OC
    Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC
    Neoptera; Endopteryqota; Diptera; Brachycera; Muscomorpha;
OC
    Ephydroidea; Drosophilidae; Drosophila.
    NCBI TaxID=7227;
OX
RN
    [1]
    SEQUENCE FROM N.A.
RP
    Dai Y., Kunes S.;
RA
    "Isolation and Characterization of Drosophila Ephrin.";
RT
    Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RL
RN
```

```
RP
     SEQUENCE FROM N.A.
RC
     STRAIN=Berkeley;
    MEDLINE=20196006; PubMed=10731132;
RX
    Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA
     Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA
     George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA
     Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA
     Brandon R.C., Rogers Y.-H.C., Blazej R.G., Champe M., Pfeiffer B.D.,
RA
     Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,
RA
     Abril J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,
RA
     Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA
     Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
RA
     Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,
RA
     Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA
     Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA
     de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA
     Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA
     Durbin K.J., Evangelista C.C., Ferraz C., Ferriera S., Fleischmann W.,
RA
     Fosler C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA
RA
     Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
     Harris N.L., Harvey D., Heiman T.J., Hernandez J.R., Houck J.,
RA
     Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwam C.,
RA
     Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA
     Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,
RA
     Lasko P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,
RA
     Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,
RA
    Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA
RA
    Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
     Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,
RA
     Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA
     Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,
RA
     Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,
RA
     Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA
     Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA
     Wang Z .- Y., Wassarman D.A., Weinstock G.M., Weissenbach J.,
RA
     Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
RA
     Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA
     Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,
RA
RA
     Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
     "The genome sequence of Drosophila melanogaster.";
RT
     Science 287:2185-2195(2000).
RL
RN
     SEQUENCE FROM N.A.
RΡ
RC
     STRAIN=Berkley;
     Stapleton M., Brokstein P., Hong L., Agbayani A., Carlson J.,
RA.
     Champe M., Chavez C., Dorsett V., Dresnek D., Farfan D., Frise E.,
RA
     George R., Gonzalez M., Guarin H., Kronmiller B., Li P., Liao G.,
RA
     Miranda A., Mungall C.J., Nunoo J., Pacleb J., Paragas V., Park S.,
RA
     Patel S., Phouanenavong S., Wan K., Yu C., Lewis S.E., Rubin G.M.,
RA
     Celniker S.;
RA
     Submitted (MAR-2003) to the EMBL/GenBank/DDBJ databases.
RL
     EMBL; AF216287; AAF28394.1; -.
DR
     EMBL; AE003843; AAF59335.2; -.
DR
     EMBL; BT005199; AA061756.1; -.
DR
     FlyBase; FBgn0040324; Ephrin.
DR
     GO; GO:0016020; C:membrane; IEA.
DR
     InterPro; IPR008972; Cupredoxin.
DR
```

```
DR InterPro; IPR001799; Ephrin.
DR Pfam; PF00812; Ephrin; 1.
      PRINTS; PR01347; EPHRIN.
        ProDom; PD002533; Ephrin; 1.
DR
        SEQUENCE 652 AA; 72302 MW; 5BA2F02F15964594 CRC64;
SQ
                                              9.8%; Score 182; DB 5; Length 652;
   Query Match
   Best Local Similarity 22.9%; Pred. No. 7.2e-06;
   Matches 88; Conservative 50; Mismatches 136; Indels 110; Gaps 18;
                  33 VYWNSANKRFQAEG-GYVLYPQIG-----DRLDLLCPRARPPGPHSSPNYEFYKLYLVG 85
QУ
                         ::||::| |: : :: | | |:: ::|| || |:| |
                 219 MHWNTSNSIFRIDNTDHIIDVNKGNLAFEFDQVHIICP-VYEPGTFENET-EKYIIYNVS 276
Db
                  86 GAQGRRCEAPPA-PNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHHDYYIIATSDGT 144
Qу
                        : | | | | :: | | : | : | | : | | | : | : | | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : 
                 277 KVEYETCRITNADPRVIAICDKPQKLMFFTITFRPFTPQPGGLEFLPGNDYYFISTS--S 334
Db
                 145 REGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPVSEMPMERDRGAAHSL----EPG 199
Qy
                        :: | || || || || || :| :| :| :|
                 335 KDDLYRRIGGRCSTNNMKVVFKVCCAPEDNN-KTTALSNSKSVTDTGGAINVNIANNDES 393
Db
                 200 KENLPGDPTSNATSRGAEG-----PLPP-----P 223
QУ
                          | |: : |: | | |: |
                 394 HVNSHGNNIAIGTNIGINGGQIIGGPQSAGIPINPLSGNNNINGIPTTINSNIDQFNRIP 453
Db
                 224 SMPAVAGAAGGLALLLLGVAGAGGAMCWRRRRAKPSESRHPGPG-SFGRGGSLGLGGGGG 282
Qy
                            454 IOPNIIGNHVGTNAVGTGIVGGGGIIL-----TPGHAHGNINMLQPGRGGI 499
Db
                 283 MGPREAEPG----ELGIALRG-------GGAADPPFCPHYEKVSGDYGH 320
QУ
                        | | | | : | | :
                                                                                             500 NG---AYPGHHHIQTGIRINNVPTQHNYPSHKGNANSNINGNDDH---HHYNK-----H 547
Db
                 321 PVYIVQD-----GPPQSPPNIY 337
Qу
                    548 PNEVVKNEELTYNSGAATSDGNIF 571
Db
RESULT 10
Q98TZ1
      Q98TZ1 PRELIMINARY; PRT; 202 AA.
        098TZ1;
        01-JUN-2001 (TrEMBLrel. 17, Created)
        01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
        01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE
        Ephrin-A6 (Fragment).
OS
        Gallus gallus (Chicken).
        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
        Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC
        Gallus.
        NCBI_TaxID=9031;
OX
RN
        [1]
        SEQUENCE FROM N.A.
RP
        Menzel P., Valencia F., Godement P., Dodelet V.C., Pasquale E.B.;
RA
RT
        "Ephrin-A6, a new ligand for EphA receptors in the developing visual
RT
        system.";
```

```
Submitted (OCT-2000) to the EMBL/GenBank/DDBJ databases.
RL
    EMBL; AF317286; AAK00944.1; -.
DR
    GO; GO:0016020; C:membrane; IEA.
DR
    InterPro; IPR008972; Cupredoxin.
DR
    InterPro; IPR001799; Ephrin.
DR
DR
    Pfam; PF00812; Ephrin; 1.
    PRINTS; PR01347; EPHRIN.
DR
DR
    ProDom; PD002533; Ephrin; 1.
    PROSITE; PS01299; EPHRIN; 1.
DR
    NON TER 1
                      1
FT
    SEQUENCE 202 AA; 22624 MW; 91E2716FF91353F9 CRC64;
SQ
                       9.6%; Score 178.5; DB 13; Length 202;
 Query Match
  Best Local Similarity 27.5%; Pred. No. 3.4e-06;
 Matches 56; Conservative 27; Mismatches 84; Indels 37; Gaps
          33 VYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSSPNYEFYKLYLVGGAQGRRC 92
Qy
            25 VYWNGSNPRF-LQDDYSIQVSINDHLDIYCPHYSAPTPWA---ESFTLFMVDEEGYRGC 79
Db
          93 EAPPAPNLLLTCDR---PDLDLRFTIKFQEYSPNLWGHEFRSHHDYYIIAT-SDGTREGL 148
Qy
              80 SETPGAFKRWECNKPFAPFVPVRFSEKIQRFTPFSLGFEFRPGETYYYISVPTPGS---- 135
Db
         149 ESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPVSEMPMERDRGAAHSLEPGKENLPGDPT 208
Qу
                136 ----AGRCLKLRVSVCCR------ASTPEPLTEVPNSQPRGR------GGPE 171
Db
         209 SNATSRGAEGPLPPPSMPAVAGAA 232
Qу
             : | | | : | | : |
         172 GDAGSPRDAAPIPQRSRTRLVALA 195
Db
RESULT 11
Q8N578
              PRELIMINARY; PRT; 205 AA.
ID
    08N578
AC
    08N578;
    01-OCT-2002 (TrEMBLrel. 22, Created)
DT
    01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
DE
    Ephrin-A1.
    Homo sapiens (Human).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC
    NCBI TaxID=9606;
OX
RN
    [1]
     SEQUENCE FROM N.A.
RP
    TISSUE=Liver;
RC
RA
     Strausberg R.;
     Submitted (JUN-2002) to the EMBL/GenBank/DDBJ databases.
RL
     EMBL; BC032698; AAH32698.1; -.
DR
     GO; GO:0016020; C:membrane; IEA.
DR
     InterPro; IPR008972; Cupredoxin.
DR
     InterPro; IPR001799; Ephrin.
     InterPro; IPR001680; WD40.
DR
     Pfam; PF00812; Ephrin; 1.
DR
     PRINTS; PR01347; EPHRIN.
DR
```

```
ProDom; PD002533; Ephrin; 1.
DR
     PROSITE; PS01299; EPHRIN; 1.
DR
     PROSITE; PS00678; WD REPEATS 1; 1.
DR
     SEQUENCE 205 AA; 23785 MW; 4FE9A6D94C1251A9 CRC64;
SO
                           9.1%; Score 168.5; DB 4;
                                                       Length 205;
  Ouery Match
  Best Local Similarity 27.5%; Pred. No. 2.1e-05;
            52; Conservative 33; Mismatches 85;
                                                       Indels
                                                                19; Gaps
  Matches
           18 LLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSSPN-- 75
Qу
                             |:|||:|:|:|:|:|:|:|:|:|:|:|:|
            8 LLGLCCSLAAADRHTVFWNSSNPKFRNE-DYTIHVQLNDYVDIICPHYE---DHSVADAA 63
Db
           76 YEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDL---DLRFTIKFQEYSPNLWGHEFRSH 132
Qу
                                     : |:||
                                                 : : ||| ::|
                        :: |:
               1 1 1111
           64 MEQYILYLVEHEEYQLCQPQSKDQVRWQCNRPSAKHGPEKLSEKFQRFTPFTLGKEFKEG 123
Db
          133 HDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVP--RKPVSEMPMERD- 189
Qу
                                                        | :: :: | |
                                    11
                                        : | :: ||:
                          - 1
          124 HSYYYISKPIHQHEDR-----CLRLKVTVSGKITHSPQAHVNPQEKRLAADDPEVRVL 176
Db
          190 RGAAHSLEP 198
QУ
                 111 1
          177 HSIAHSAAP 185
Db
RESULT 12
09D7K8
                                   PRT;
                                          205 AA.
     Q9D7K8
                 PRELIMINARY;
ID
AC
     Q9D7K8;
     01-JUN-2001 (TrEMBLrel. 17, Created)
DT
     01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
DT
     01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
     Adult male tongue cDNA, RIKEN full-length enriched library,
DΕ
     clone:2310004J15, full insert sequence.
DE
GN
     EFNA1.
     Mus musculus (Mouse).
OS
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OC
 OX
     NCBI TaxID=10090;
 RN
      [1]
      SEOUENCE FROM N.A.
 RP
      STRAIN=C57BL/6J; TISSUE=Tongue;
 RC
     MEDLINE=21085660; PubMed=11217851;
 RX
      Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
 RA
      Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
 RA
      Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,
 RA
      Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
 RA
      Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
 RA
      Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
 RA
      Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,
 RA
      Schriml L.M., Staubli F., Suzuki R., Tomita M., Wagner L., Washio T.,
 RA
      Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
 RA
      Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
 RA
      Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
 RA
      Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,
 RA
      Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
 RA
```

```
Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
RA
     Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
RA
     Suzuki H., Toyo-oka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
RA
     Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohtsuki S.,
RA
     Hayashizaki Y.;
RA
     "Functional annotation of a full-length mouse cDNA collection.";
RT
     Nature 409:685-690(2001).
RL
     EMBL; AK009144; BAB26102.1; -.
DR
     MGD; MGI:103236; Efnal.
     GO; GO:0016020; C:membrane; IEA.
DR
     InterPro; IPR008972; Cupredoxin.
DR
     InterPro; IPR001799; Ephrin.
DR
     InterPro; IPR001680; WD40.
DR
     Pfam; PF00812; Ephrin; 1.
DR
     PRINTS; PR01347; EPHRIN.
DR
     ProDom; PD002533; Ephrin; 1.
DR
     PROSITE; PS01299; EPHRIN; 1.
DR
     PROSITE; PS00678; WD REPEATS_1; 1.
DR
                205 AA; 23772 MW; E37E55767459A4EC CRC64;
     SEQUENCE
SQ
                           9.0%; Score 167; DB 11; Length 205;
  Query Match
  Best Local Similarity 26.1%; Pred. No. 2.7e-05;
                                                 76; Indels
                                                                12; Gaps
           43; Conservative 34; Mismatches
  Matches
           18 LLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSSPNYE 77
Qу
                             1:111:1:1:1:1 1::1:1
            8 LLGLCCSLAAADRHIVFWNSSNPKFREE-DYTVHVQLNDYLDIICPHYEDDSV-ADAAME 65
Db
           78 FYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDL---DLRFTIKFQEYSPNLWGHEFRSHHD 134
QУ
                                                   :::||| ::| : | ||: |
                                    : 1:11
                       : |:
                1 11:1
            66 RYTLYMVEHQEYVACQPQSKDQVRWNCNRPSAKHGPEKLSVKFQRFTPFILGKEFKEGHS 125
 Db
           135 YYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRK 179
 QУ
                                       : | :: :|:
                                   : |
               || |:
           126 YYYISKPIYHQE-----SQCLKLKVTVNGKITHNPQAHVNPQE 163
 Db
 RESULT 13
 Q9CZS8
                                           206 AA.
                                    PRT;
                  PRELIMINARY;
      Q9CZS8
 TD
      Q9CZS8;
 AC
      01-JUN-2001 (TrEMBLrel. 17, Created)
 ידים
      01-JUN-2001 (TrEMBLrel. 17, Last sequence update)
 DT
      01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DT
      10 days embryo cDNA, RIKEN full-length enriched library,
      clone:2610529M21, full insert sequence.
 DΕ
      EFNA4.
 GN
      Mus musculus (Mouse).
 OS
      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC
      Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OC
      NCBI TaxID=10090;
 OX
      [1]
 RN
      SEQUENCE FROM N.A.
 RP
      STRAIN=C57BL/6J; TISSUE=Embryo;
 RC
      MEDLINE=21085660; PubMed=11217851;
 RX
      Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
 RA
      Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
 RA
```

```
Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,
RA
    Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
RA
    Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
RA
    Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
RA
    Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,
RA
    Schriml L.M., Staubli F., Suzuki R., Tomita M., Wagner L., Washio T.,
RA
    Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
RA
    Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,
RA
    Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
RA
    Gustincich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,
RA
    Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
RA
    Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
RA
     Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,
RA
     Suzuki H., Toyo-oka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,
RA
     Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohtsuki S.,
RA
RA
     Hayashizaki Y.;
     "Functional annotation of a full-length mouse cDNA collection.";
RT
     Nature 409:685-690(2001).
RL
     EMBL; AK012195; BAB28092.1; -.
DR
     MGD; MGI:106643; Efna4.
DR
     GO; GO:0016020; C:membrane; IEA.
DR
     InterPro; IPR008972; Cupredoxin.
DR
     InterPro; IPR001799; Ephrin.
DR
     Pfam; PF00812; Ephrin; 1.
DR
     PRINTS; PR01347; EPHRIN.
DR
     ProDom; PD002533; Ephrin; 1.
DR
     PROSITE; PS01299; EPHRIN; 1.
DR
              206 AA; 22859 MW; 675E32971D1C6EBC CRC64;
SQ
     SEQUENCE
                          8.8%; Score 163.5; DB 11; Length 206;
  Query Match
  Best Local Similarity 28.1%; Pred. No. 5.1e-05;
  Matches 61; Conservative 17; Mismatches 80; Indels
                                                                         10;
                                                             59; Gaps
           32 PVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSSPNYEFYKLYLVGGAQGRR 91
Qу
              29 PIYWNSSNPRL-LRGDAVVELGFNDYLDIFCPHYESPGPPEGP--ETFALYIVDWSGYEA 85
Db
           92 CEAPPAPNL-LLTCDRPDL---DLRFTIKFQEYSPNLWGHEFRSHHDYYIIATSDGTREG 147
Qу
                                   :||: | | |:| | 1 ||
                                                         | | | :
              | | | : | | |
           86 CTAEGANSFQRWNCSMPFAPFSPVRFSEKIQRYTPFPLGFEFLPGETYYYISVPTPESPG 145
Db
          148 -LESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPVSEMPMERDRGAAH-SLEPGKENLPG 205
 Qу
                                                    :: |::| | |
                  11 11
          146 RCLRLQVSVCC----VG 170
 Db
          206 DPTSNATS--RGAEGPLPPPSMPAVAGAAGGLALLLL 240
 QУ
               1:11 11 11 111
          171 SPGESGTSGWRGGHAPSP-----LCLLLL 194
 RESULT 14
 Q9N178
                                  PRT;
                                         675 AA.
                 PRELIMINARY;
     Q9N178
 ΙD
 AC
     Q9N178;
      01-OCT-2000 (TrEMBLrel. 15, Created)
 DT
      01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
 DT
      01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
 DT
```

```
Type X collagen.
DE
    COL10A1.
GN
    Sus scrofa (Pig).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
OC
    NCBI_TaxID=9823;
OX
RN
    [1]
    SEQUENCE FROM N.A.
RP
    MEDLINE=21015405; PubMed=11130976;
RX
    Nielsen V.H., Bendixen C., Arnbjerg J., Sorensen C.M., Jensen H.E.,
RA
    Shukri N.M., Thomsen B.;
    "Abnormal growth plate function in pigs carrying a dominant mutation
RT
    in type X collagen.";
RT
    Mamm. Genome 11:1087-1092(2000).
RL
    EMBL; AF222861; AAF37271.1; -.
DR
    InterPro; IPR001073; Clq.
DR
    InterPro; IPR008161; Clg helix.
DR
    InterPro; IPR008160; Collagen.
DR
    InterPro; IPR008983; TNF like.
DR
    Pfam; PF00386; Clq; 1.
DR
    Pfam; PF01391; Collagen; 8.
DR
    PRINTS; PR00007; COMPLEMNTC1Q.
DR
    ProDom; PD000007; Clg helix; 2.
DR
    SMART; SM00110; ClQ; 1.
DR
    PROSITE; PS01113; C1Q; 1.
DR
    Collagen.
ΚW
    SEQUENCE 675 AA; 65447 MW; 26397B10310383F9 CRC64;
SQ
                      8.4%; Score 156; DB 6; Length 675;
 Query Match
  Best Local Similarity 28.6%; Pred. No. 0.00078;
 Matches 106; Conservative 17; Mismatches 118; Indels 130; Gaps
                                                                 26;
          1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQI-GDR-L 58
QУ
                                          212 MGPP--GPPGV------GKR--GENGFPGQPGIKGDRGF 240
Db
         59 DLLCPRARPPGPHSSPNYEFYKLYLVGGAQGRR-CEAPPAPNLLLTCDRPDLDLRFTIKF 117
Qy
                 1 111 1 1 1 1 1 1 1 1 1 1 1 1 1
        241 PGESGPAGPPGPQGPP----- 278
Db
        118 QEYSPNLWGHEFRSHHDYYIIATSDGT----REGLESLQGGVCLTRGMKVLLRVGQSPRG 173
QУ
              279 ----PGTKGHPGAPG-----MAGPPGAPGFGKPGLPGLKG----QRG------PIG 315
Db
         174 GAVPRKPVSEMPMERDRG-AAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAA 232
Qу
              316 -- LPGAPGA----KGEQGPAGHPGEPGLTGPPG-----SRGPQGPKGIPGNNGVPGPK 362
Db
         233 GGLALLLLGVAGAGGAMCWRRRR---AKPSESRHPG-----PGSFGRGGSLGLGGGGG 282
QУ
            1: 1:11 1:11 1:11 1
         363 GEIG--LAGPAGFPGAKGERGPSGLDGKPGYPGEPGLNGPKGNPGLPGPKGDPGIGGPPG 420
Db
         283 M----GPREAE--PGELGIA-LRGG-----GAADPPFCPHYEKVSGDYGHPVYIVQDG 328
QУ
            421 LPGPVGPAGAKGVPGHNGEAGPRGAPGIPGTRGPIGPPGIPGFPGSKGDPGNP-----G 474
Db
         329 PPOSPPNIYYK 339
QУ
```

```
RESULT 15
093431
                             PRT:
                                     229 AA.
           PRELIMINARY;
    093431
ΙD
    093431;
AC
    01-NOV-1998 (TrEMBLrel. 08, Created)
DΤ
    01-NOV-1998 (TrEMBLrel. 08, Last sequence update)
DT
    01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DT
    Ephrin A-L1.
DE
    Brachydanio rerio (Zebrafish) (Danio rerio).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OS
OC
    Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
    Cyprinidae; Danio.
OC
    NCBI_TaxID=7955;
OX
RN
    [1]
    SEQUENCE FROM N.A.
RP
    Durbin L., Brennan C.H., Shiomi K., Cooke J.;
RA
     "Eph signalling is required for segmentation and differentiation of
RT
     the somites.";
RT
    Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases.
RL
     EMBL; AJ006838; CAA07264.1; -.
DR
    GO; GO:0016020; C:membrane; IEA.
DR
    InterPro; IPR008972; Cupredoxin.
DR
    InterPro; IPR001799; Ephrin.
DR
DR InterPro; IPR003006; Ig MHC.
DR Pfam; PF00812; Ephrin; 1.
DR PRINTS; PR01347; EPHRIN.
    ProDom; PD002533; Ephrin; 1.
DR
     PROSITE; PS01299; EPHRIN; 1.
DR
     PROSITE; PS00290; IG MHC; 1.
DR
     SEQUENCE 229 AA; 26115 MW; 8684462F67AF6F5C CRC64;
 SO
                        8.4%; Score 155; DB 13; Length 229;
  Query Match
  Best Local Similarity 27.2%; Pred. No. 0.00026;
                                                                     7;
                                                          34; Gaps
          56; Conservative 23; Mismatches
                                            93; Indels
           33 VYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSSPNYEFYKLYLVGGAQGRRC 92
 Qy
             25 VYWNSTNANFLWD-DYTVDVRINDYLDIICPH-YAHGEIASQEAERYVLYMVELEDYENC 82
 Db
           93 EAPPAPNLLLTCDR---PDLDLRFTIKFQEYSPNLWGHEFRSHHDYYIIATSDGTREGLE 149
 Qу
             83 KPHSFDQLRWECSRPFAPHAPEKFSEKFQRFTPFTLGKEFRQGESYYYIS-----K 133
 Db
          150 SL--QGGVCLTRGMKVLLRVGQSPRGGAVPRKPVSEMPMERDRGAAHSLEPGKENLPGDP 207
 Qу
              134 PLHHHGQECLRLKVDVV----GPHGSKNKKKMVEKVEEIEGKMAAGGVHNPSNRLPADD 188
 Db
          208 TSNATSRGAEGPLPPPSMPAVAGAAG 233
 Qу
                        | :|| :|
          189 -----PIAMIPVVQRSVG 201
 Db
```

Job time : 51.0377 secs

GenCore version 5.1.6 Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

April 13, 2004, 09:22:17 ; Search time 17.9623 Seconds Run on:

(without alignments)

985.614 Million cell updates/sec

US-10-021-121-4 Title:

Perfect score: 1850

1 MGPPHSGPGGVRVGALLLLG......PVYIVQDGPPQSPPNIYYKV 340 Sequence:

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

141681 seqs, 52070155 residues Searched:

Total number of hits satisfying chosen parameters: 141681

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

SwissProt 42:* Database :

> Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result		% Query				
No.	Score	_	Length	DB	ID	Description
1 2 3 4 5 6 7 8 9 10 11 12 13 14	1850 1780 637.5 632 629.5 628 626.5 613.5 608.5 600 185 179 176 175.5	100.0 96.2 34.5 34.2 34.0 33.9 33.9 33.2 32.9 32.4 10.0 9.7 9.5 9.5	340 340 336 346 333 334 332 345 345 327 195 238 209 213 200	1 1 1 1 1 1 1 1 1 1 1	EFB3_HUMAN EFB3_MOUSE EFB2_MOUSE EFB1_HUMAN EFB2_HUMAN EFB2_HCK EFB2_BRARE EFB1_MOUSE EFB1_RAT EFB1_XENLA EFA2_BRARE EFA3_HUMAN EFA2_MOUSE EFA2_HUMAN EFA2_HUMAN EFA2_CHICK	Q15768 homo sapien 035393 mus musculu P52800 mus musculu P98172 homo sapien P52799 homo sapien 073612 gallus gall 073874 brachydanio P52795 mus musculu P52796 rattus norv 013097 xenopus lae P79727 brachydanio P52797 homo sapien P52801 mus musculu 043921 homo sapien P52802 gallus gall
16 17	170.5 169.5	9.2 9.2	228 201	1 1	EFA5_CHICK EFA4_HUMAN	P52804 gallus gall P52798 homo sapien

```
P79728 brachydanio
P52794 xenopus lae
P52803 homo sapien
O08543 mus musculu
P97605 rattus norv
P20827 homo sapien
P97553 rattus norv
P52793 mus musculu
O08542 mus musculu
Q05306 mus musculu
Q05306 mus musculu
P04258 bos taurus
P17656 caenorhabdi
Q01955 homo sapien
P39061 mus musculu
P30754 riftia pach
P23206 bos taurus
P25940 homo sapien
P39060 homo sapien
P39060 homo sapien
P32017 gallus gall
P20849 homo sapien
P08125 gallus gall
P05997 homo sapien
P08125 gallus gall
P05997 homo sapien
P27658 nomo sapien
P27658 nomo sapien
P27658 nomo sapien
P27658 mus musculu
P27393 ascaris suu
P02461 homo sapien
P14282 oryctolagus
Q00780 mus musculu
                                      228 1 EFA5 BRARE
        169.5
                         9.2
18
        167.5
                         9.1
                                      216 1 EFA1 XENLA
19
                                      228 1 EFA5 HUMAN
        167.5
                         9.1
20
                                    228 1 EFA5_MOUSE
                     9.1
        167.5
21
        167.5 9.1
                                  228 1
                                                     EFA5 RAT
22
         166 9.0 205 1 EFA1 HUMAN
23
24 162.5 8.8 205 1 EFA1 RAT
                                    205 1 EFA1 MOUSE
                       8.7
25
         161
                                    206 1 EFA4 MOUSE
                       8.7
        160.5
26
                         8.7 206 1 EFA 10052

8.6 680 1 CA1A MOUSE

8.4 1049 1 CA13 BOVIN

8.2 301 1 CC02 CAEEL

8.0 1670 1 CA34 HUMAN
                       8.6
          159
27
         154.5
28
29
        151.5
30
        148.5
                         7.9 1774 1 CA1H MOUSE
31
        146.5
                         7.9 1027 1 CAFF RIFPA
32
          146
                        7.8
                                    674 1 CA1A BOVIN
            145
33
                       7.8 1745 1 CA35 HUMAN
            145
34
                       7.8 1516 1 CA1H_HUMAN
       144.5
35
                       7.8 1516 1 CATH_HOMAN
7.8 675 1 CA39_CHICK
7.8 921 1 CA19_HUMAN
7.7 674 1 CA1A_CHICK
7.7 1496 1 CA25_HUMAN
          144
36
            144
37
38
           143
39
         142.5
                                     744 1 CA18 HUMAN
                        7.7
40
          142
                        7.7 1029 1 CA26_MOUSE
7.7 1763 1 CA24_ASCSU
             142
41
42
           142
                         7.6 1466 1 CA13_HUMAN
7.6 744 1 CA18_RABIT
7.6 743 1 CA18_MOUSE
         141.5
43
         141
44
                                     743 1 CA18 MOUSE
       140.5 7.6
45
```

ALIGNMENTS

```
RESULT 1
EFB3 HUMAN
                                          340 AA.
                   STANDARD;
                                  PRT;
     EFB3 HUMAN
     Q15768; Q00680; Q8TBH7; Q92875;
АC
     01-NOV-1997 (Rel. 35, Created)
DT
     01-NOV-1997 (Rel. 35, Last sequence update)
DT
     15-MAR-2004 (Rel. 43, Last annotation update)
DT
     Ephrin-B3 precursor (EPH-related receptor tyrosine kinase ligand 8)
DE
     (LERK-8) (EPH-related receptor transmembrane ligand ELK-L3).
DE
     EFNB3 OR EPLG8 OR LERK8.
GN
     Homo sapiens (Human).
OS
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC
OX
     NCBI TaxID=9606;
RN
     [1]
RP
     SEQUENCE FROM N.A.
RA
     Cerretti D.P.;
     Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases.
RL
RN
RΡ
     SEQUENCE FROM N.A.
     TISSUE=Brain;
RC
     MEDLINE=97271551; PubMed=9126477;
RX
     Tang X.X., Pleasure D.E., Ikegaki N.;
RA
     "cDNA cloning, chromosomal localization, and expression pattern of
RT
```

```
EPLG8, a new member of the EPLG gene family encoding ligands of EPH-
     related protein-tyrosine kinase receptors.";
RТ
     Genomics 41:17-24(1997).
RL
RN
RP
     SEOUENCE FROM N.A.
     TISSUE=Brain cortex;
RC
    MEDLINE=96404527; PubMed=8808709;
RX
    Gale N.W., Flenniken A., Compton D.C., Jenkins N.A., Copeland N.G.,
RA
     Gilbert D.J., Davis S., Wilkinson D.G., Yancopoulos G.D.;
RA
     "Elk-L3, a novel transmembrane ligand for the Eph family of receptor
RT
     tyrosine kinases, expressed in embryonic floor plate, roof plate and
RT
RT
     hindbrain segments.";
     Oncogene 13:1343-1352(1996).
RL
RN
     SEQUENCE FROM N.A.
RP
RC
     TISSUE=Brain;
     MEDLINE=22388257; PubMed=12477932;
RX
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
     Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
     Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA
     Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA
     Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RA
     "Generation and initial analysis of more than 15,000 full-length
RT
     human and mouse cDNA sequences.";
RT
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RL
     -!- FUNCTION: May play a pivotal role in forebrain function. Binds to,
CC
         and induce the collapse of, commissural axons/growth cones in
CC
         vitro. May play a role in constraining the orientation of
CC
         longitudinally projecting axons (By similarity).
CC
     -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC
     -!- TISSUE SPECIFICITY: Highly expressed in brain; expressed in
CC
         embryonic floor plate, roof plate and hindbrain segments.
CC
     -!- SIMILARITY: Belongs to the ephrin family.
CC
     ______
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
     use by non-profit institutions as long as its content is in no way
CC
     modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
     or send an email to license@isb-sib.ch).
CC
CC
     EMBL; U57001; AAB05170.1; -.
DR
     EMBL; U66406; AAC51203.1; -.
DR
     EMBL; U62775; AAC50707.1; -.
 DR
```

```
EMBL; BC022499; AAH22499.1; -.
DR
    EMBL; BC042944; AAH42944.1; -.
DR
    Genew; HGNC:3228; EFNB3.
DR
    MIM; 602297; -.
DR
    GO; GO:0005887; C:integral to plasma membrane; TAS.
DR
    GO; GO:0005005; F:transmembrane-ephrin receptor activity; TAS.
DR
    GO; GO:0007267; P:cell-cell signaling; TAS.
DR
    GO; GO:0007399; P:neurogenesis; TAS.
DR
    InterPro; IPR008972; Cupredoxin.
DR
    InterPro; IPR001799; Ephrin.
DR
    Pfam; PF00812; Ephrin; 1.
DR
    PRINTS; PR01347; EPHRIN.
DR
    ProDom; PD002533; Ephrin; 1.
DR
    PROSITE; PS01299; EPHRIN; 1.
DR
    Developmental protein; Neurogenesis; Transmembrane; Glycoprotein;
KW
    Signal; Polymorphism.
KW
                              POTENTIAL.
                      27
    SIGNAL
                1
FT
                              EPHRIN-B3.
                28
                     340
    CHAIN
FT
                              EXTRACELLULAR (POTENTIAL).
               28
                     226
    DOMAIN
FT
                              POTENTIAL.
               227
                     247
FΨ
    TRANSMEM
                              CYTOPLASMIC (POTENTIAL).
                     340
    DOMAIN
               248
FT
                              PDZ RECOGNITION MOTIF (POTENTIAL).
               338
                     340
    DOMAIN
FT
                              BY SIMILARITY.
                62
                     104
FT
    DISULFID
                              BY SIMILARITY.
                     156
                92
FΤ
    DISULFID
                              N-LINKED (GLCNAC. . .) (POTENTIAL).
               210
                     210
FΤ
    CARBOHYD
                     166
                              R \rightarrow Q.
    VARIANT
               166
FΨ
                              /FTId=VAR 002356.
FT
              340 AA; 35834 MW; EDFF2A23C2FDE79F CRC64;
SO
    SEQUENCE
                       100.0%; Score 1850; DB 1; Length 340;
  Query Match
                       100.0%; Pred. No. 1.3e-112;
  Best Local Similarity
                                                                    0;
                                            0; Indels
                                                         0; Gaps
                            0; Mismatches
  Matches 340; Conservative
           1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Qу
            1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Db
          61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Qу
             61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Db
         121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
ΟV
             121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
Db
         181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Qу
             181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Db
         241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGMGPREAEPGELGIALRGG 300
Qу
             241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGMGPREAEPGELGIALRGG 300
Db
         301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qу
             301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Db
```

```
RESULT 2
EFB3 MOUSE
                                   PRT;
                                          340 AA.
     EFB3 MOUSE
                    STANDARD;
ΙD
AC
     035393;
     15-JUL-1999 (Rel. 38, Created)
DT
     15-JUL-1999 (Rel. 38, Last sequence update)
DT
     15-MAR-2004 (Rel. 43, Last annotation update)
DT
     Ephrin-B3 precursor.
DE
     EFNB3.
GN
     Mus musculus (Mouse).
OS
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
     NCBI TaxID=10090;
OX
RN
     SEQUENCE FROM N.A.
RP
RC
     TISSUE=Brain;
     MEDLINE=98143367; PubMed=9484836;
RX
     Bergemann A.D., Zhang L., Chiang M.-K., Brambilla R., Klein R.,
RA
     Flanagan J.G.;
RA
     "Ephrin-B3, a ligand for the receptor EphB3, expressed at the midline
RT
     of the developing neural tube.";
RT
     Oncogene 16:471-480(1998).
RL
RN
     [2]
     SEQUENCE FROM N.A.
RP
     STRAIN=C57BL/6; TISSUE=Brain;
RC
     MEDLINE=22388257; PubMed=12477932;
RX
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
     Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
     Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RΑ
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
      Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
      Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA
     Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA
      Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RA
      "Generation and initial analysis of more than 15,000 full-length
RT
      human and mouse cDNA sequences.";
RT
      Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RL
RN
      FUNCTION.
RΡ
      MEDLINE=20171264; PubMed=10704386;
RX
      Imondi R., Wideman C., Kaprielian Z.;
 RA
      "Complementary expression of transmembrane ephrins and their receptors
 RT
      in the mouse spinal cord: a possible role in constraining the
 RT
      orientation of longitudinally projecting axons.";
 RT
      Development 127:1397-1410(2000).
 RL
      -!- FUNCTION: May play a pivotal role in forebrain function. Binds to,
 CC
          and induce the collapse of, commissural axons/growth cones in
 CC
```

```
vitro. May play a role in constraining the orientation of
        longitudinally projecting axons.
CC
    -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC
    -!- TISSUE SPECIFICITY: Expressed on lateral floor plate cells,
CC
        specifically on commissural axon segments that have passed through
CC
        the floor plate. Expressed in cells of the retinal ganglion cell
CC
        layer during retinal axon guidance to the optic disk.
CC
    -!- DEVELOPMENTAL STAGE: Expressed in the floor plate throughout the
CC
        period of commissural axon pathfinding.
CC
    -!- SIMILARITY: Belongs to the ephrin family.
CC
    CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
CC
     EMBL; AF025288; AAC53537.1; -.
DR
     EMBL; BC052001; AAH52001.1; -.
DR
     EMBL; BC058617; AAH58617.1; -.
DR
    MGD; MGI:109196; Efnb3.
DR
    GO; GO:0007628; P:adult walking behavior; IMP.
DR
     GO; GO:0007411; P:axon guidance; IMP.
DR
     InterPro; IPR008972; Cupredoxin.
DR
     InterPro; IPR001799; Ephrin.
DR
     Pfam; PF00812; Ephrin; 1.
DR
     PRINTS; PR01347; EPHRIN.
DR
     ProDom; PD002533; Ephrin; 1.
DR
     PROSITE; PS01299; EPHRIN; 1.
DR
     Developmental protein; Neurogenesis; Transmembrane; Glycoprotein;
KW
KW
                                POTENTIAL.
                 1
                      27
FT
     SIGNAL
                                EPHRIN-B3.
                 28
                      340
FT
     CHAIN
                               EXTRACELLULAR (POTENTIAL).
                    227
                28
FT
     DOMAIN
                               POTENTIAL.
                    248
                228
FT
     TRANSMEM
                               CYTOPLASMIC (POTENTIAL).
                    340
                249
FT
     DOMAIN
                               PDZ RECOGNITION MOTIF (POTENTIAL).
                338
                      340
     DOMAIN
FT
               62 104
                                BY SIMILARITY.
     DISULFID
FТ
                92 156
                               BY SIMILARITY.
FT
     DISULFID
                                N-LINKED (GLCNAC. . .) (POTENTIAL).
               210
                    210
     CARBOHYD
FT
     SEQUENCE 340 AA; 35884 MW; 52F3D58FD209A6B8 CRC64;
SQ
                         96.2%; Score 1780; DB 1; Length 340;
  Query Match
  Best Local Similarity 95.6%; Pred. No. 4.3e-108;
Matches 325; Conservative 7; Mismatches 8; Indels 0; Gaps
                                                                         0;
  Matches 325; Conservative
            1 MGPPHSGPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Qу
              1 MGAPHFGPGGVQVGALLLLGFAGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDL 60
Db
           61 LCPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
QУ
              61 LCPRARPPGPHSSPSYEFYKLYLVEGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEY 120
Db
          121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
 Qу
```

```
121 SPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKP 180
Db
         181 VSEMPMERDRGAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
Qу
             181 VSEMPMERDRGAAHSAEPGRDTIPGDPSSNATSRGAEGPLPPPSMPAVAGAAGGMALLLL 240
Db
         241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGMGPREAEPGELGIALRGG 300
QУ
             241 GVAGAGGAMCWRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGMGPREAEPGELGIALRGG 300
Db
         301 GAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qу
             301 GTADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Db
RESULT 3
EFB2 MOUSE
                                       336 AA.
                                PRT;
                  STANDARD;
    EFB2 MOUSE
ID
    P52800;
AC
    01-OCT-1996 (Rel. 34, Created)
DT
     01-OCT-1996 (Rel. 34, Last sequence update)
ידת
    15-MAR-2004 (Rel. 43, Last annotation update)
DT
    Ephrin-B2 precursor (EPH-related receptor tyrosine kinase ligand 5)
DΕ
     (LERK-5) (HTK ligand) (HTK-L) (ELF-2).
DE
    EFNB2 OR EPLG5 OR LERK5 OR HTKL OR ELF2 OR EPL5.
GN
    Mus musculus (Mouse).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
     NCBI TaxID=10090;
OX
RN
     [1]
     SEQUENCE FROM N.A.
RP
     MEDLINE=96145238; PubMed=8559144;
RX
     Cerretti D.P., Vanden Bos T., Nelson N., Kozlosky C.J., Reddy P.,
RA
     Maraskovsky E., Park L.S., Lyman S.D., Copeland N.G.,
RA
     Gilbert D.J., Jenkins N.A., Fletcher R.A.;
RA
     "Isolation of LERK-5: a ligand of the eph-related receptor tyrosine
RT
     kinases.";
RT
     Mol. Immunol. 32:1197-1205(1995).
RL
RN
     SEQUENCE FROM N.A.
RP
     STRAIN=CB57BL/6J X SJL/J;
RC
     MEDLINE=95199254; PubMed=7534404;
RX
     Bennett B.D., Zeigler F.C., Gu Q., Fendly B., Goddard A.D.,
RA
RA
     Gillett N., Matthews W.;
     "Molecular cloning of a ligand for the EPH-related receptor protein-
RT
     tyrosine kinase Htk.";
RT
     Proc. Natl. Acad. Sci. U.S.A. 92:1866-1870(1995).
RL
RN
     [3]
     SEQUENCE FROM N.A.
RP
     STRAIN=ICR; TISSUE=Brain;
RC
     MEDLINE=95379837; PubMed=7651410;
RX
     Bergemann A.D., Cheng H.J., Brambilla R., Klein R., Flanagan J.G.;
RA
     "ELF-2, a new member of the Eph ligand family, is segmentally
RT
     expressed in mouse embryos in the region of the hindbrain and newly
RТ
     forming somites.";
 RT
     Mol. Cell. Biol. 15:4921-4929(1995).
 RL
```

```
RN
     [4]
     SEQUENCE FROM N.A.
RP
     STRAIN=C57BL/6; TISSUE=Brain;
RC
    MEDLINE=22388257; PubMed=12477932;
RX
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
     Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
     Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
    Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
    Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA.
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
    Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
     Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA
     Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA
     Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RA
     "Generation and initial analysis of more than 15,000 full-length
RT
     human and mouse cDNA sequences.";
RT
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RL
RN
     [5]
     FUNCTION.
RP
     MEDLINE=20171264; PubMed=10704386;
RX
     Imondi R., Wideman C., Kaprielian Z.;
RA
     "Complementary expression of transmembrane ephrins and their receptors
RT
     in the mouse spinal cord: a possible role in constraining the
RT
     orientation of longitudinally projecting axons.";
RΤ
     Development 127:1397-1410(2000).
RL
RN
     X-RAY CRYSTALLOGRAPHY (1.92 ANGSTROMS) OF 30-170.
RP
     MEDLINE=21563306; PubMed=11703926;
RX
     Toth J., Cutforth T., Gelinas A.D., Bethoney K.A., Bard J.,
RA
     Harrison C.J.;
RA
     "Crystal structure of an ephrin ectodomain.";
RT
     Dev. Cell 1:83-92(2001).
RL
RN
     X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 31-168 IN COMPLEX WITH
RΡ
     EPHB2.
RP
     MEDLINE=21638766; PubMed=11780069;
RX
     Himanen J.-P., Rajashankar K.R., Lackmann M., Cowan C.A.,
RA
     Henkemeyer M., Nikolov D.B.;
RA
     "Crystal structure of an Eph receptor-ephrin complex.";
RT
     Nature 414:933-938(2001).
RL
     -!- FUNCTION: Binds to the receptor tyrosine kinases EPHB2 and EPHB4.
CC
         May play a role in constraining the orientation of longitudinally
CC
         projecting axons.
CC
      -!- SUBUNIT: Binds to the receptor tyrosine kinase EPHB4.
CC
      -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC
      -!- TISSUE SPECIFICITY: Expressed on lateral floor plate cells,
CC
         specifically on commissural axon segments that have passed through
CC
          the floor plate. Expressed in cells of the retinal ganglion cell
CC
         layer during retinal axon guidance to the optic disk.
CC
      -!- DEVELOPMENTAL STAGE: Expressed in the floor plate throughout the
 CC
```

```
period of commissural axon pathfinding.
CC
    -!- PTM: Inducible phosphorylation of tyrosine residues in the
CC
        cytoplasmic domain (By similarity).
CC
    -!- SIMILARITY: Belongs to the ephrin family.
CC
    CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
    ______
CC
    EMBL; U16819; AAA99708.1; -.
DR
    EMBL; L38847; AAC42052.1; -.
DR
DR. EMBL; U30244; AAA82934.1; -.
DR EMBL; BC057009; AAH57009.1; -.
DR PIR; I49766; I49766.
DR PDB; 11KO; 15-MAY-02.
DR PDB; 1KGY; 28-MAY-02.
    MGD; MGI:105097; Efnb2.
DR
    InterPro; IPR008972; Cupredoxin.
DR
DR InterPro; IPR001799; Ephrin.
DR Pfam; PF00812; Ephrin; 1.
DR PRINTS; PR01347; EPHRIN.
   ProDom; PD002533; Ephrin; 1.
DR
   PROSITE; PS01299; EPHRIN; 1.
DR
     Developmental protein; Neurogenesis; Transmembrane; Glycoprotein;
KW
     Signal; Phosphorylation; 3D-structure.
KW
   SIGNAL 1 28 POTENTIAL.

CHAIN 29 336 EPHRIN-B2.

DOMAIN 29 232 EXTRACELLULAR (POTENTIAL).

TRANSMEM 233 253 POTENTIAL.

DOMAIN 254 336 CYTOPLASMIC (POTENTIAL).

DOMAIN 334 336 PDZ RECOGNITION MOTIF (POTENTIAL).
FT
FT
ТЧ
FT
FT
FT
               65 104
     DISULFID
FT
    DISULFID 92 156
CARBOHYD 39 39 N-LINKED (GLCNAC...).
CARBOHYD 142 142 N-LINKED (GLCNAC...) (POTENTIAL).
               92
FT
FT
FT
                            MISSING (IN REF. 3).
A -> T (IN REF. 1).
               3 4
177 177
FT
    CONFLICT
FT
     CONFLICT
     SEQUENCE 336 AA; 37202 MW; D08894996E399554 CRC64;
SQ
                        34.5%; Score 637.5; DB 1; Length 336;
  Query Match
  Best Local Similarity 42.1%; Pred. No. 1.9e-34;
  Matches 139; Conservative 49; Mismatches 129; Indels 13; Gaps
           14 GALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSS 73
Qу
                     : : |||:||:||:| :| | | || ||:||:||:
           17 GLLMVLCRTAISRSIVLEPIYWNSSNSKFLPGQGLVLYPQIGDKLDIICPKV---DSKTV 73
Db
           74 PNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHH 133
Qу
                74 GQYEYYKVYMVDKDQADRCTIKKENTPLLNCARPDQDVKFTIKFQEFSPNLWGLEFQKNK 133
Db
          134 DYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQ--SPRGGAVPRKPVSEMPMER-DR 190
Qу
```

```
134 DYYIISTSNGSLEGLDNQEGGVCQTRAMKILMKVGQDASSAGSARNHGPTRRPELEAGTN 193
Db
         191 GAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLLGVAGAGGAMC 250
Qу
             194 GRSSTTSPFVKPNPGSSTDGNSAGHSGNNLLGSEVALFAGIASGCIIFIVIIITLVVLLL 253
Db
         251 WRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGGGPREAEPGELGIALRGGGAADPPFCPH 310
Qy
               : | | ; : | | | |
                                                               254 KYRRRHRKHSPQHTTTLSLSTLATPKRGGNN----NGSEPSDVIIPLR---TADSVFCPH 306
Db
         311 YEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
Qу
             307 YEKVSGDYGHPVYIVQEMPPQSPANIYYKV 336
Db
RESULT 4
EFB1 HUMAN
                   STANDARD;
                                 PRT;
                                        346 AA.
   EFB1 HUMAN
    P98172;
AC
     01-OCT-1996 (Rel. 34, Created)
DT
     01-OCT-1996 (Rel. 34, Last sequence update)
DT
     15-MAR-2004 (Rel. 43, Last annotation update)
DT
     Ephrin-B1 precursor (EPH-related receptor tyrosine kinase ligand 2)
DΕ
     (LERK-2) (ELK ligand) (ELK-L).
DE
     EFNB1 OR EPLG2 OR LERK2 OR EFL-3.
GN
     Homo sapiens (Human).
OS
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC
     NCBI TaxID=9606;
OX
RN
     [1]
     SEQUENCE FROM N.A.
RP
     TISSUE=Placenta;
RC
     MEDLINE=94349923; PubMed=8070404;
RX
     Beckmann M.P., Cerretti D.P., Baum P., Vanden Bos T., James L.,
RA
     Farrah T., Kozlosky C., Hollingsworth T., Shilling H., Maraskovsky E.,
RA
     Fletcher F.A., Lhotak V., Pawson T., Lyman S.D.;
RA
     "Molecular characterization of a family of ligands for eph-related
RT
     tyrosine kinase receptors.";
RT
     EMBO J. 13:3757-3762(1994).
RL
RN
     [2]
     SEOUENCE FROM N.A.
RP
     Davis S., Gale N.W., Aldrich T.H., Maisonpierre P.C., Lhotak V.,
RA
     Pawson T., Goldfarb M., Yancopoulos G.D.;
RA
     Submitted (NOV-1994) to the EMBL/GenBank/DDBJ databases.
RL
RN
     [3]
     SEQUENCE FROM N.A.
RP
     Fletcher F.A., Huebner K., Shaffer L.G., Monaco A., Mueller U.,
     Kozlosky C., Druck T., Simoneaux D.K., Fairweather N., Chelly J.,
RA
     Cerretti D.P., Belmont J.W., Beckmann M.P., Lyman S.D.;
RA
     Submitted (JAN-1997) to the EMBL/GenBank/DDBJ databases.
RL
RN
     [4]
     SEQUENCE FROM N.A.
RP
     Howden P.;
RA
     Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RL
RN
     SEQUENCE FROM N.A.
RP
     TISSUE=Eye, and Skin;
RC
```

```
MEDLINE=22388257; PubMed=12477932;
RX
    Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
    Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
    Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
    Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
    Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
    Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
    Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
    Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
    Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
    Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
    Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
    Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
    Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
    Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
    Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA
    Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA
    Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RA
     "Generation and initial analysis of more than 15,000 full-length
RT
    human and mouse cDNA sequences.";
RT
    Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RL
     -!- FUNCTION: Binds to the receptor tyrosine kinases EPHB1 and EPHA1.
CC
         Binds to, and induce the collapse of, commissural axons/growth
CC
         cones in vitro. May play a role in constraining the orientation of
CC
         longitudinally projecting axons (By similarity).
CC
     -!- SUBUNIT: Binds GRIP1 and GRIP2.
CC
     -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC
     -!- TISSUE SPECIFICITY: Heart, placenta, lung, liver, skeletal muscle,
CC
CC
        kidney, pancreas.
CC
     -!- INDUCTION: By TNF-alpha.
     -!- PTM: Inducible phosphorylation of tyrosine residues in the
CC
         cytoplasmic domain (By similarity).
CC
     -!- SIMILARITY: Belongs to the ephrin family.
CC
     ______
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
     use by non-profit institutions as long as its content is in no way
CC
     modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
     or send an email to license@isb-sib.ch).
CC
     ______
CC
     EMBL; U09304; AAA53093.1; -.
DR
     EMBL; L37361; AAA52369.1; -.
DR
     EMBL; U09303; AAB41127.1; -.
DR
     EMBL; AL136092; -; NOT_ANNOTATED_CDS.
DR
     EMBL; BC016649; AAH16649.1; -.
DR
     EMBL; BC052979; AAH52979.1; -.
DR
     PIR; S46993; S46993.
DR
     Genew; HGNC: 3226; EFNB1.
DR
     MIM; 300035; -.
DR
     GO; GO:0005887; C:integral to plasma membrane; TAS.
DR
     GO; GO:0005625; C:soluble fraction; TAS.
DR
     GO; GO:0005108; F:transmembrane ephrin; TAS.
DR
     GO; GO:0007155; P:cell adhesion; TAS.
DR
     GO; GO:0007267; P:cell-cell signaling; TAS.
DR
     InterPro; IPR008972; Cupredoxin.
DR
```

```
InterPro; IPR001799; Ephrin.
DR
    Pfam; PF00812; Ephrin; 1.
DR
    PRINTS; PR01347; EPHRIN.
DR
    ProDom; PD002533; Ephrin; 1.
DR
    PROSITE; PS01299; EPHRIN; 1.
DR
    Developmental protein; Neurogenesis; Transmembrane; Glycoprotein;
KW
    Signal; Phosphorylation.
KW
                            POTENTIAL.
    SIGNAL
                    24
FT
              1
                           EPHRIN-B1.
              25
                    346
FT
    CHAIN
                          EXTRACELLULAR (POTENTIAL).

POTENTIAL.

CYTOPLASMIC (POTENTIAL).

PDZ RECOGNITION MOTIF (POTENTIAL).
                  237
    DOMAIN
              25
FT
             238 258
   TRANSMEM
FТ
   DOMAIN 259 346
FT
             344 346
   DOMAIN
FT
             64 101
                           BY SIMILARITY.
   DISULFID
\mathbf{FT}
             89 153 BY SIMILARITY.
139 139 N-LINKED (GLCNAC. . .) (POTENTIAL).
   DISULFID
FT
FT CARBOHYD
SQ SEQUENCE 346 AA; 38006 MW; 473DD2F1A5BF89DE CRC64;
                     34.2%; Score 632; DB 1; Length 346;
 Query Match
 Best Local Similarity 39.5%; Pred. No. 4.4e-34;
 Matches 145; Conservative 48; Mismatches 116; Indels 58; Gaps
          8 PGGVRVGALLLLGVLGLVSGL-----SLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLL 61
Qу
           4 PGQRWLGKWLVAMVVWALCRLATPLAKNLEPVSWSSLNPKFLSGKGLVIYPKIGDKLDII 63
Db
         62 CPRARPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYS 121
Qу
            64 CPRAEAGRP----YEYYKLYLVRPEQAAACSTVLDPNVLVTCNRPEQEIRFTIKFQEFS 118
Db
        122 PNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPV 181
Qу
            119 PNYMGLEFKKHHDYYITSTSNGSLEGLENREGGVCRTRTMKIIMKVGQDPNAVTPEQLTT 178
Db
        182 SEMPMERDRGAAHSLE-PGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLA---- 236
QУ
           179 SRPSKEADNTVKMATQAPGSRGSLGDSDGKHETVNQEEKSGP-----GASGGSSGDPD 231
Db
        237 -----LLLLGVAGAGGA------MCWRRRRAKPSESRHPGPGSFGRGGSLGL 277
Qу
             : | | | | : | : | : | : |
        232 GFFNSKVALFAAVGAGCVIFLLIIIFLTVLLLKLRKRHRKHTQQ------RAAALSL 282
Db
        278 ----GGGGGMGPREAEPGELGIALRGGGAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSP 333
Qу
                 283 STLASPKGGSGTAGTEPSDIIIPLR---TTENNYCPHYEKVSGDYGHPVYIVQEMPPQSP 339
Db
         334 PNIYYKV 340
Qy
            340 ANIYYKV 346
Db
RESULT 5
EFB2 HUMAN
    EFB2 HUMAN STANDARD; PRT; 333 AA.
ΤD
    P52799;
AC
    01-OCT-1996 (Rel. 34, Created)
DT
     01-OCT-1996 (Rel. 34, Last sequence update)
```

```
15-MAR-2004 (Rel. 43, Last annotation update)
    Ephrin-B2 precursor (EPH-related receptor tyrosine kinase ligand 5)
DE
    (LERK-5) (HTK ligand) (HTK-L).
DE
    EFNB2 OR EPLG5 OR LERK5 OR HTKL.
GN
    Homo sapiens (Human).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC
    NCBI TaxID=9606;
OX
RN
    [1]
    SEQUENCE FROM N.A.
RP
RC
    TISSUE=Brain;
    MEDLINE=96145238; PubMed=8559144;
RX
    Cerretti D.P., Vanden Bos T., Nelson N., Kozlosky C.J., Reddy P.,
RA
    Maraskovsky E., Park L.S., Lyman S.D., Copeland N.G., Gilbert D.J.,
RA
     Jenkins N.A., Fletcher R.A.;
RA
     "Isolation of LERK-5: a ligand of the eph-related receptor tyrosine
RT
    kinases.";
RT
    Mol. Immunol. 32:1197-1205(1995).
RL
RN
RP
    SEQUENCE FROM N.A.
     TISSUE=Brain;
RC
     MEDLINE=95199254; PubMed=7534404;
RX
     Bennett B.D., Zeigler F.C., Gu Q., Fendly B., Goddard A.D.,
RA
     Gillett N., Matthews W.;
RA
     "Molecular cloning of a ligand for the EPH-related receptor protein-
RT
RT
     tyrosine kinase Htk.";
     Proc. Natl. Acad. Sci. U.S.A. 92:1866-1870(1995).
RL
RN
     [3]
     SEQUENCE FROM N.A.
RP
     MEDLINE=98192220; PubMed=9533549;
RX
     Vogt T., Stolz W., Welsh J., Jung B., Kerbel R.S., Kobayashi H.,
RA
     Landthaler M., McClelland M.;
RA
     "Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for
RT
     increased tumorigenicity and metastatic potential in human malignant
RT
RT
     melanomas.";
     Clin. Cancer Res. 4:791-797(1998).
RL
     -!- FUNCTION: Binds to the receptor tyrosine kinases EPHB4 and EPHA3.
CC
         May play a role in constraining the orientation of longitudinally
CC
         projecting axons (By similarity).
CC
     -!- SUBUNIT: Binds to the receptor tyrosine kinases EPHB4 and EPHA3.
CC
     -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC
     -!- TISSUE SPECIFICITY: Lung and kidney.
CC
     -!- PTM: Inducible phosphorylation of tyrosine residues in the
CC
         cytoplasmic domain (By similarity).
CC
     -!- SIMILARITY: Belongs to the ephrin family.
CC
     ------
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
     use by non-profit institutions as long as its content is in no way
CC
     modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
     or send an email to license@isb-sib.ch).
CC
     _____
CC
     EMBL; U16797; AAA99707.1; -.
DR
     EMBL; L38734; AAC41752.1; -.
DR
     EMBL; U81262; AAD03786.1; -.
 DR
```

```
PIR; 184743; 184743.
DR
    Genew; HGNC:3227; EFNB2.
DR
    MIM; 600527; -.
DR
    GO; GO:0005887; C:integral to plasma membrane; TAS.
DR
    GO; GO:0005106; F:ephrin; TAS.
DR
    GO; GO:0005108; F:transmembrane ephrin; TAS.
DR
    GO; GO:0007267; P:cell-cell signaling; TAS.
DR
    GO; GO:0007397; P:histogenesis and organogenesis; TAS.
DR
    InterPro; IPR008972; Cupredoxin.
DR
    InterPro; IPR001799; Ephrin.
DR
    Pfam; PF00812; Ephrin; 1.
DR
    PRINTS; PR01347; EPHRIN.
DR
    ProDom; PD002533; Ephrin; 1.
DR
    PROSITE; PS01299; EPHRIN; 1.
DR
    Developmental protein; Neurogenesis; Transmembrane; Glycoprotein;
KW
    Signal; Phosphorylation.
KW
                              POTENTIAL.
                     27
    SIGNAL
                1
FT
                     333
                              EPHRIN-B2.
                28
    CHAIN
FT
                              EXTRACELLULAR (POTENTIAL).
                28
                     229
    DOMAIN
FΤ
                              POTENTIAL.
    TRANSMEM
               230
                     250
FT
                              CYTOPLASMIC (POTENTIAL).
                     333
               251
    DOMAIN
FT
                              PDZ RECOGNITION MOTIF (POTENTIAL).
                    333
               331
FT
    DOMAIN
                              BY SIMILARITY.
                    101
                62
FΤ
    DISULFID
                              BY SIMILARITY.
                89
                     153
FT
    DISULFID
                              N-LINKED (GLCNAC. . .) (POTENTIAL).
               36
                     36
FT
    CARBOHYD
                              N-LINKED (GLCNAC. . .) (POTENTIAL).
                    139
              139
    CARBOHYD
FT
              333 AA; 36923 MW; 6D9932A632626AEA CRC64;
    SEQUENCE
SQ
                       34.0%; Score 629.5; DB 1; Length 333;
  Query Match
  Best Local Similarity 40.9%; Pred. No. 6.2e-34;
  Matches 135; Conservative 52; Mismatches 130; Indels
                                                                    5;
                                                         13; Gaps
          14 GALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSS 73
Qy
                    14 GVLMVLCRTAISKSIVLEPIYWNSSNSKFLPGQGLVLYPQIGDKLDIICPKV---DSKTV 70
Db
          74 PNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHH 133
QУ
                                    11:11:1:1
          71 GQYEYYKVYMVDKDQADRCTIKKENTPLLNCAKPDQDIKFTIKFQEFSPNLWGLEFQKNK 130
Db
         134 DYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQ--SPRGGAVPRKPVSEMPMER-DR 190
Qу
             131 DYYIISTSNGSLEGLDNQEGGVCQTRAMKILMKVGQDASSAGSTRNKDPTRRPELEAGTN 190
Db
         191 GAAHSLEPGKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLLGVAGAGGAMC 250
Qу
             191 GRSSTTSPFVKPNPGSSTDGNSAGHSGNNILGSEVALFAGIASGCIIFIVIIITLVVLLL 250
Db
         251 WRRRRAKPSESRHPGPGSFGRGGSLGLGGGGGMGPREAEPGELGIALRGGGAADPPFCPH 310
Qу
                                             1
                               : |
         251 KYRRRHRKHSPQHTTTLSLSTLATPKRSGNN----NGSEPSDIIIPLR---TADSVFCPH 303
Db
         311 YEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
QУ
             304 YEKVSGDYGHPVYIVQEMPPQSPANIYYKV 333
Db
```

```
RESULT 6
EFB1 CHICK
                               PRT; 334 AA.
    EFB1 CHICK
                STANDARD;
AC
    073612;
    15-JUL-1999 (Rel. 38, Created)
DT
    15-JUL-1999 (Rel. 38, Last sequence update)
DT
    15-MAR-2004 (Rel. 43, Last annotation update)
DT
    Ephrin-B1 precursor (CEK5 ligand) (CEL5-L).
DΕ
GN
    EFNB1.
    Gallus gallus (Chicken).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC
OC
    Gallus.
    NCBI TaxID=9031;
OX
RN
    [1]
    SEOUENCE FROM N.A.
RP
    MEDLINE=97223524; PubMed=9070326;
RX
    Holash J.A., Soans C., Chong L.D., Shao H., Dixit V.M.,
RA
    Pasquale E.B.;
RA
    "Reciprocal expression of the Eph receptor Cek5 and its ligand(s) in
RT
    the early retina.";
RT
    Dev. Biol. 182:256-269(1997).
RL
    -!- SUBUNIT: Binds to the receptor tyrosine kinase EPHB2.
CC
    -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC
    -!- PTM: Inducible phosphorylation of tyrosine residues in the
CC
CC
        cytoplasmic domain (By similarity).
    -!- SIMILARITY: Belongs to the ephrin family.
CC
    _____
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
     or send an email to license@isb-sib.ch).
CC
     ______
CC
     EMBL; U72394; AAC07986.1; -.
DR
     InterPro; IPR008972; Cupredoxin.
DR
     InterPro; IPR001799; Ephrin.
DR
     Pfam; PF00812; Ephrin; 1.
DR
     PRINTS; PR01347; EPHRIN.
DR
     ProDom; PD002533; Ephrin; 1.
DR
     PROSITE; PS01299; EPHRIN; 1.
DR
     Developmental protein; Neurogenesis; Transmembrane; Glycoprotein;
KW
KW
     Signal; Phosphorylation.
     SIGNAL
                               POTENTIAL.
FT
                 1
                      25
                 26
                      334
                               EPHRIN-B1.
FT
     CHAIN
                26 231
                               EXTRACELLULAR (POTENTIAL).
FT
     DOMAIN
               232 252
                              POTENTIAL.
     TRANSMEM
FT
               253 334
                              CYTOPLASMIC (POTENTIAL).
FT
     DOMAIN
                              PDZ RECOGNITION MOTIF (POTENTIAL).
                332
                     334
FT
     DOMAIN
               60
                      97
                               BY SIMILARITY.
FT
     DISULFID
                85
                      149
                               BY SIMILARITY.
FT
     DISULFID
                     135
                               N-LINKED (GLCNAC. . .) (POTENTIAL).
               135
FT
     CARBOHYD
     SEQUENCE 334 AA; 36858 MW; 48AF556E9ED56CD5 CRC64;
SO
```

```
Best Local Similarity 39.7%; Pred. No. 7.7e-34;
 Matches 146; Conservative 50; Mismatches 100; Indels 72; Gaps 13;
          8 PGGVR--VGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRA 65
Qу
           4 PRGGRWLLGVLLALCRLAAPLAKSLEPVSWSAGNPKFMSGKGLVIYPEIGDKLDIICPKA 63
Dh
         66 RPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLW 125
Qу
                                      | ||:|:||:||: ::|||||||
                   1::11111
            1 1
         64 EPSKP----YDYYKLYLVKKDQADACSTVMDPNVLVTCNRPEQEIRFTIKFQEFSPNYM 118
Db
        126 GHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPVSEMP 185
QУ
                  119 GLEFKRQQDYFITSTSNGTLDGLENREGGVCQTRSMKIVMKVGQDP-NAVIPEQLTTSRP 177
Db
        186 MER-----DRGAAHSL----EPGKENLPGDPTSNA--TSRGAEGPLPPPSMPAVAGA 231
Qу
                                          : |: ||||
        178 SKEADNTVKIVTQSPRHKVPTVEEPGK---PGSVNQNGQETQGPSDGFL--SSKVAVFAA 232
Db
        232 AGG-----PGPGSFGRG 272
QУ
                                      |:| | :: |
                                                         1 1
                        1:11::
            233 IGAGCVIFILIIIFLVVLLIKI-----RKRHRKHTQQRAAALSLSTLASPKCSGNA 283
Db
        273 GSLGLGGGGGMGPREAEPGELGIALRGGGAADPPFCPHYEKVSGDYGHPVYIVQDGPPQS 332
Qу
                         11
        284 GS-----EPSDIIIPLR---TTENNYCPHYEKVSGDYGHPVYIVQEMPPQS 326
Db
        333 PPNIYYKV 340
QУ
            1 11111
        327 PANIYYKV 334
Db
RESULT 7
EFB2 BRARE
                              PRT; 332 AA.
    EFB2 BRARE
                 STANDARD;
ID
    073874;
AC
    15-JUL-1999 (Rel. 38, Created)
DT
    15-JUL-1999 (Rel. 38, Last sequence update)
DT
    15-MAR-2004 (Rel. 43, Last annotation update)
DT
    Ephrin-B2 precursor (Ephrin B2a).
DE
    EFNB2 OR EFNB2A.
GN
    Brachydanio rerio (Zebrafish) (Danio rerio).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
OC
OC
     Cyprinidae; Danio.
OX
    NCBI TaxID=7955;
RN
     [1]
     SEQUENCE FROM N.A.
RP
     MEDLINE=98438455; PubMed=9765210;
RX
     Durbin L., Brennan C., Shiomi K., Cooke J., Barrios A.,
RA
     Shanmugalingam S., Guthrie B., Lindberg R., Holder N.;
RA
     "Eph signaling is required for segmentation and differentiation of
RT
     the somites.";
RT
     Genes Dev. 12:3096-3109(1998).
RL
RN
     SEQUENCE FROM N.A.
RP
     MEDLINE=21290827; PubMed=11397014;
RX
```

```
Chan J., Mably J.D., Serluca F.C., Chen J.N., Goldstein N.B.,
RA
    Thomas M.C., Cleary J.A., Brennan C., Fishman M.C., Roberts T.M.;
RA
    "Morphogenesis of prechordal plate and notochord requires intact
RT
    eph/ephrin b signaling.";
RT
    Dev. Biol. 234:470-482(2001).
RL
    -!- SUBUNIT: Binds to the receptor tyrosine kinase EPHB4.
CC
    -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC
    -!- PTM: Inducible phosphorylation of tyrosine residues in the
CC
        cytoplasmic domain (By similarity).
CC
    -!- SIMILARITY: Belongs to the ephrin family.
CC
    ______
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
CC
    EMBL; AJ004863; CAA06168.1; -.
DR
    EMBL; AF375225; AAK64275.1; -.
DR
    ZFIN; ZDB-GENE-990415-67; efnb2a.
DR
    InterPro; IPR008972; Cupredoxin.
DR
    InterPro; IPR001799; Ephrin.
DR
    Pfam; PF00812; Ephrin; 1.
DR
    PRINTS; PR01347; EPHRIN.
DR
    ProDom; PD002533; Ephrin; 1.
DR
    PROSITE; PS01299; EPHRIN; 1.
DR
    Developmental protein; Neurogenesis; Transmembrane; Glycoprotein;
KW
    Signal; Phosphorylation.
KW
                               POTENTIAL.
                1
                      2.4
FT
    SIGNAL
                               EPHRIN-B2.
    CHAIN
                25
                      332
FT
                     225
                               EXTRACELLULAR (POTENTIAL).
FT
    DOMAIN
                25
                              POTENTIAL.
               226 246
    TRANSMEM
FT
                             CYTOPLASMIC (POTENTIAL).
              247 332
FT
    DOMAIN
                              PDZ RECOGNITION MOTIF (POTENTIAL).
                     332
               330
FT
    DOMAIN
               59
                     98
                              BY SIMILARITY.
FT
    DISULFID
                              BY SIMILARITY.
               86
                    150
FT
    DISULFID
                     20
                              N-LINKED (GLCNAC. . .) (POTENTIAL).
               20
FT
    CARBOHYD
                      33
                               N-LINKED (GLCNAC. . .) (POTENTIAL).
               33
FT
    CARBOHYD
                              N-LINKED (GLCNAC. . .) (POTENTIAL).
                      136
FT
               136
    CARBOHYD
                            N-LINKED (GLCNAC. . .) (POTENTIAL).
                     211
               211
FT
    CARBOHYD
    SEQUENCE 332 AA; 36724 MW; 189ED82372C71C8B CRC64;
SO
                        33.9%; Score 626.5; DB 1; Length 332;
  Query Match
  Best Local Similarity 42.2%; Pred. No. 9.6e-34;
  Matches 145; Conservative 54; Mismatches 106; Indels 39; Gaps
                                                                      12;
          14 GALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSS 73
Qу
             11 GVLVIACKVNLSRALILDSIYWNTTNTKFVPGQGLVLYPQIGDKMDIVCPRVE---GGSM 67
Db
          74 PNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSHH 133
QУ
                68 EGVEYYKLYMVPLEQLKSCQVTKADTPLLNCVKPDQDVKFTLKFQEFSPNLWGLEFFRGK 127
Db
         134 DYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRK-PVSEMPMERDRGA 192
QУ
```

```
128 DYYIISTSNGTMEGLDNQEGGVCKTKSMKIIMKVGQNPSDPISPKDYPTSYPPKHPDLGG 187
Db
         193 AHS----LEP----GKENLPGDPTSNATSRGAEGPLPPPSMPAVAGAAGGLALLLLGV 242
Qу
              | |:| |:: |: |:| | ::: ::::::
         188 KDSKSNEVLKPDASPHGEDK--GDGNKSSSVIGSEVAL----FACIASASVIVIIIIIML 241
Db
         243 AGAGGAMCWRRRRAKPSESRHPGPGSFG----RGGSLGLGGGGGMGPREAEPGELGIA 296
Qу
                   :: | | | | | | | | | | |
                                             242 VFL--LLKYRRRHRKHS-PQHATTLSLSTLATPKRGGS----GGNNNG---SEPSDIIIP 291
Db
         297 LRGGGAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYKV 340
QУ
                  292 LR---TADSVFCPHYEKVSGDYGHPVYIVQEMPPQSPANIYYKV 332
Db
RESULT 8
EFB1 MOUSE
                               PRT;
                                       345 AA.
                   STANDARD;
    EFB1 MOUSE
ID
AC
    P52795;
    01-OCT-1996 (Rel. 34, Created)
DT
    01-OCT-1996 (Rel. 34, Last sequence update)
DT
    15-MAR-2004 (Rel. 43, Last annotation update)
DT
    Ephrin-B1 precursor (EPH-related receptor tyrosine kinase ligand 2)
DΕ
    (LERK-2) (ELK ligand) (ELK-L) (STRA1 protein) (CEK5 receptor ligand)
DE
DE
     (CEK5-L).
    EFNB1 OR EPLG2 OR LERK2 OR STRA1 OR EPL2.
GN
OS
    Mus musculus (Mouse).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
    NCBI TaxID=10090;
OX
RN
     [1]
RP
     SEQUENCE FROM N.A.
RC
     STRAIN=129/Sv;
    MEDLINE=95203867; PubMed=7896266;
RX
     Fletcher F.A., Renshaw B., Hollingsworth T., Baum P., Lyman S.D.,
RA
     Jenkins N.A., Gilbert D.J., Copeland N.G., Davison B.L.;
RA
     "Genomic organization and chromosomal localization of mouse Eplg2, a
RT
     gene encoding a binding protein for the receptor tyrosine kinase
RT
RT
     elk.";
     Genomics 24:127-132(1994).
RL
RN
     [2]
RP
     SEQUENCE FROM N.A.
     MEDLINE=95377533; PubMed=7649373;
RX
     Bouillet P., Oulad-Abdelghani M., Vicaire S., Garnier J.M.,
RA
     Schuhbaur B., Dolle P., Chambon P.;
RA
     "Efficient cloning of cDNAs of retinoic acid-responsive genes in P19
RT
     embryonal carcinoma cells and characterization of a novel mouse gene,
RΤ
RT
     Stral (mouse LERK-2/Eplg2).";
RL
     Dev. Biol. 170:420-433(1995).
RN
     [3]
     SEQUENCE FROM N.A.
RP
RC
     TISSUE=Brain;
     MEDLINE=95014510; PubMed=7929389;
RX
     Shao H., Lou L., Pandey A., Pasquale E.B., Dixit V.M.;
RA
     "cDNA cloning and characterization of a ligand for the Cek5 receptor
RT
     protein-tyrosine kinase.";
RT
```

```
J. Biol. Chem. 269:26606-26609(1994).
RL
RN
RΡ
    SEQUENCE FROM N.A.
    STRAIN=FVB/N; TISSUE=Mammary gland;
RC
    MEDLINE=22388257; PubMed=12477932;
RX
    Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
    Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
    Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
    Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
    Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
    Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
    Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
    Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
    Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
    Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
    Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
    Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
    Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
    Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
    Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA
    Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA
    Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RA
     "Generation and initial analysis of more than 15,000 full-length
RT
    human and mouse cDNA sequences.";
RT
     Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RL
RN
     [5]
RP
     FUNCTION.
    MEDLINE=20171264; PubMed=10704386;
RX
     Imondi R., Wideman C., Kaprielian Z.;
RA
     "Complementary expression of transmembrane ephrins and their receptors
RT
     in the mouse spinal cord: a possible role in constraining the
RT
     orientation of longitudinally projecting axons.";
RT
     Development 127:1397-1410(2000).
RL
     -!- FUNCTION: Binds to the receptor tyrosine kinases EPHB1 and EPHA1.
CC
         Binds to, and induce the collapse of, commissural axons/growth
CC
         cones in vitro. May play a role in constraining the orientation of
CC
         longitudinally projecting axons.
CC
     -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC
     -!- TISSUE SPECIFICITY: Expressed on lateral floor plate cells,
CC
         specifically on commissural axon segments that have passed through
CC
         the floor plate. Expressed in cells of the retinal ganglion cell
CC
         layer during retinal axon guidance to the optic disc.
CC
     -!- DEVELOPMENTAL STAGE: Expressed in the floor plate throughout the
CC
         period of commissural axon pathfinding.
CC
     -!- PTM: Inducible phosphorylation of tyrosine residues in the
CC
         cytoplasmic domain.
CC
     -!- SIMILARITY: Belongs to the ephrin family.
CC
     ______
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
     use by non-profit institutions as long as its content is in no way
CC
     modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
     or send an email to license@isb-sib.ch).
CC
     ______
CC
     EMBL; U07602; AAC53247.1; -.
DR
```

```
EMBL; U07598; AAC53247.1; JOINED.
DR
    EMBL; U07599; AAC53247.1; JOINED.
DR
    EMBL; U07600; AAC53247.1; JOINED.
DR
    EMBL; Z48781; CAA88695.1; -.
DR
    EMBL; U12983; AAA53231.1; -.
DR
    EMBL; BC006797; AAH06797.1; -.
DR
    PIR; I48780; I48780.
DR
    MGD; MGI:102708; Efnb1.
DR
    GO; GO:0045121; C:lipid raft; IDA.
DR
    GO; GO:0007411; P:axon guidance; IMP.
DR
    InterPro; IPR008972; Cupredoxin.
DR
    InterPro; IPR001799; Ephrin.
DR
    Pfam; PF00812; Ephrin; 1.
DR
    PRINTS; PR01347; EPHRIN.
DR
    ProDom; PD002533; Ephrin; 1.
DR
    PROSITE; PS01299; EPHRIN; 1.
DR
    Developmental protein; Neurogenesis; Transmembrane; Glycoprotein;
KW
    Signal; Phosphorylation.
KW
                            POTENTIAL.
    SIGNAL
              1 24
FT
               25
                   345
                           EPHRIN-B1.
    CHAIN
FT
                           EXTRACELLULAR (POTENTIAL).
              25 236
    DOMAIN
FT
              237 257
                           POTENTIAL.
    TRANSMEM
FΤ
             258 345
                           CYTOPLASMIC (POTENTIAL).
    DOMAIN
FT
             343 345
                           PDZ RECOGNITION MOTIF (POTENTIAL).
    DOMAIN
FT
             64 101
89 153
                           BY SIMILARITY.
FT
    DISULFID
                            BY SIMILARITY.
    DISULFID
FT
                           N-LINKED (GLCNAC. . .) (POTENTIAL).
    CARBOHYD 139 139
FT
                   90
                           S \rightarrow T (IN REF. 2).
             90
FT
    CONFLICT
    SEQUENCE 345 AA; 37859 MW; 8C96FD3DC5CBC405 CRC64;
SO
                     33.2%; Score 613.5; DB 1; Length 345;
 Query Match
 Best Local Similarity 38.2%; Pred. No. 6.9e-33;
 Matches 138; Conservative 51; Mismatches 107; Indels 65; Gaps
                                                                10;
         15 ALLLLGVLGLVSGL--SLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHS 72
QУ
           15 AMVVLTLCRLATPLAKNLEPVSWSSLNPKFLSGKGLVIYPKIGDKLDIICPRAEAGRP-- 72
Db
         73 SPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSH 132
Qy
              73 ---YEYYKLYLVRPEQAAACSTVLDPNVLVTCNKPHQEIRFTIKFQEFSPNYMGLEFKKY 129
Db
        133 HDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPVSEMPMERDRGA 192
Qу
            130 HDYYITSTSNGSLEGLENREGGVCRTRTMKIVMKVGQDP-NAVTPEQLTTSRPSKESDNT 188
Db
        193 AHSLEPGKENLPGDPTSNATSRGAEGP-----LPPPSMPAVAGAAGG-----LA 236
Qу
                        : | ||::|
        189 VKT-----ATQAPGRGSQGDSDGKHETVNQEEKSGPGAGGGGSGDSDSFFNSK 236
Db
        237 LLLLGVAGAGGA-----GG 279
Qу
            : | | | | |
                         : |:| | ::
                                             | :| |
        237 VALFAAVGAGCVIFLLIIIFLTVLLLKLRKRHRKHTQQ-----RAAALSLSTLASP 287
Db
        280 GGGMGPREAEPGELGIALRGGGAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYK 339
QУ
                   288 KGGSGTAGTEPSDIIIPLR---TTENNYCPHYEKVSGDYGHPVYIVQEMPPQSPANIYYK 344
Db
```

```
340 V 340
Qy
        345 V 345
Db
RESULT 9
EFB1 RAT
                                PRT: 345 AA.
                   STANDARD;
ID
    EFB1 RAT
AC
    P52796;
    01-OCT-1996 (Rel. 34, Created)
DΤ
    01-OCT-1996 (Rel. 34, Last sequence update)
DT
    15-MAR-2004 (Rel. 43, Last annotation update)
    Ephrin-B1 precursor (EPH-related receptor tyrosine kinase ligand 2)
DΕ
    (LERK-2) (ELK ligand) (ELK-L).
DE
    EFNB1 OR EPLG2 OR LERK2.
GN
    Rattus norvegicus (Rat).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
OC
OX
    NCBI TaxID=10116;
    [1]
RN
    SEQUENCE FROM N.A.
RP
RC
    TISSUE=Brain;
    MEDLINE=95022634; PubMed=7936648;
RX
    Fletcher F.A., Carpenter M., Shilling H., Baum P., Ziegler S.,
RA
    Gimpel S., Hollingsworth T., Vanden Bos T., Davison B.L.,
RA
     Lyman S.D., Beckmann M.P.;
RA
     "LERK-2, a binding protein for the receptor-tyrosine kinase ELK, is
RT
     evolutionarily conserved and expressed in a developmentally regulated
RT
RT
     pattern.";
     Oncogene 9:3241-3248(1994).
RL
    -!- FUNCTION: Binds to the receptor tyrosine kinases EPHB3
CC
         (preferred), EPHB1 and EPHA1. Binds to, and induce the collapse
CC
         of, commissural axons/growth cones in vitro. May play a role in
CC
         constraining the orientation of longitudinally projecting axons
CC
        (By similarity).
CC
     -!- SUBUNIT: Binds to the receptor tyrosine kinases EPHB3 (preferred),
CC
         EPHB1 and EPHB2.
CC
     -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC
     -!- PTM: Inducible phosphorylation of tyrosine residues in the
CC
         cytoplasmic domain (By similarity).
CC
     -!- SIMILARITY: Belongs to the ephrin family.
CC
     _____
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
     use by non-profit institutions as long as its content is in no way
CC
     modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
CC
     or send an email to license@isb-sib.ch).
CC
     EMBL; U07560; AAA53092.1; -.
DR
     PIR; I58406; I58406.
DR
     InterPro; IPR008972; Cupredoxin.
DR
     InterPro; IPR001799; Ephrin.
DR
     Pfam; PF00812; Ephrin; 1.
```

PRINTS; PR01347; EPHRIN.

DR

```
ProDom; PD002533; Ephrin; 1.
    PROSITE; PS01299; EPHRIN; 1.
DR
    Developmental protein; Neurogenesis; Transmembrane; Glycoprotein;
KW
    Signal; Phosphorylation.
KW
                            POTENTIAL.
               1
FT
    SIGNAL
                            EPHRIN-B1.
                    345
               25
FT
    CHAIN
                            EXTRACELLULAR (POTENTIAL).
                    236
              2.5
FT
    DOMAIN
                            POTENTIAL.
                   257
              237
FT
    TRANSMEM
                            CYTOPLASMIC (POTENTIAL).
                  345
              258
FT
    DOMAIN
                            PDZ RECOGNITION MOTIF (POTENTIAL).
              343 345
    DOMAIN
_{
m FT}
                            BY SIMILARITY.
             64
                    101
    DISULFID
              89 153
                           BY SIMILARITY.
FT
    DISULFID
                           N-LINKED (GLCNAC. . .) (POTENTIAL).
                   139
    CARBOHYD
             139
FT
    SEQUENCE 345 AA; 37951 MW; 1B3045C5C7358F7E CRC64;
SQ
                     32.9%; Score 608.5; DB 1; Length 345;
 Query Match
 Best Local Similarity 38.0%; Pred. No. 1.4e-32;
 Matches 137; Conservative 52; Mismatches 107; Indels 65; Gaps 10;
         15 ALLLLGVLGLVSGL--SLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHS 72
Qγ
            15 AMVVLTLCRLATPLAKNLEPVSWSSLNPKFLSGKGLVIYPKIGDKLDIICPRAEAGRP-- 72
Db
         73 SPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLWGHEFRSH 132
Qу
             73 ---YEYYKLYLVRPEQAAACSTVLDPNVLVTCNKPQQEIRFTIKFQEFSPNYMGLEFKKY 129
Db
        133 HDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPVSEMPMERDRGA 192
QУ
            130 HDYYITSTSNGSLEGLENREGGVCRTRTMKIVMKVGQDP-NAVTPEQLTTSRPSKESDNT 188
Db
        193 AHSLEPGKENLPGDPTSNATSRGAEGP------LPPPSMPAVAGAAGG-----LA 236
Qу
                                   | | |: |
                        : | ||::|
        189 VKT----ATQAPGRGSQGDSDGKHETVNQQEKSGPGAGGSGSGDTDSFFNSK 236
Db
        237 LLLLGVAGAGGA-----GG 279
Qy
                            : |:| | :: | :| |
            : | | | | |
        237 VALFAAVGAGCVIFLLIIIFLTVLLLKLRKRHRKHTQQ-----RAAALSLSTLASP 287
Db
        280 GGGMGPREAEPGELGIALRGGGAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSPPNIYYK 339
QУ
                   288 KGDSGTAGTEPSDIIIPLR---TTENNYCPHYEKVSGDYGHPVYIVQEMPPQSPANIYYK 344
Db
         340 V 340
Qу
         345 V 345
Db
RESULT 10
EFB1 XENLA
                STANDARD; PRT; 327 AA.
     EFB1 XENLA
ID
АC
     013097;
     01-NOV-1997 (Rel. 35, Created)
DT
     01-NOV-1997 (Rel. 35, Last sequence update)
 DT
     15-MAR-2004 (Rel. 43, Last annotation update)
 DT
     Ephrin-B1 precursor (EPH-related receptor tyrosine kinase ligand 2)
 DE
     (LERK-2) (ELK ligand) (ELK-L) (XLERK).
 DE
```

```
EFNB1 OR EPLG2 OR LERK2.
GN
    Xenopus laevis (African clawed frog).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Amphibia; Batrachia; Anura; Mesobatrachia; Pipoidea; Pipidae;
OC
    Xenopodinae; Xenopus.
OC
    NCBI TaxID=8355;
OX
RN
    [1]
    SEQUENCE FROM N.A.
RP
    MEDLINE=97316777; PubMed=9174051;
RX
    Jones T.L., Karavanova I., Chong L., Zhou R.P., Daar I.O.;
RA
    "Identification of XLerk, an Eph family ligand regulated during
RT
    mesoderm induction and neurogenesis in Xenopus laevis.";
RT
    Oncogene 14:2159-2166(1997).
RL
    -!- FUNCTION: May have a role in the developing mesenchymal and
CC
        nervous tissue.
CC
    -!- SUBCELLULAR LOCATION: Type I membrane protein.
CC
    -!- TISSUE SPECIFICITY: In the adult, expressed at low levels in most
CC
        adult tissues with increased levels observed in the kidney,
CC
        oocytes, ovary and testis.
CC
     -!- PTM: Inducible phosphorylation of tyrosine residues in the
CC
        cytoplasmic domain (By similarity).
CC
     -!- SIMILARITY: Belongs to the ephrin family.
CC
    ______
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
     or send an email to license@isb-sib.ch).
CC
     CC
    EMBL; U31427; AAC35995.1; -.
DR
    InterPro; IPR008972; Cupredoxin.
DR
    InterPro; IPR001799; Ephrin.
    Pfam; PF00812; Ephrin; 1.
DR
    PRINTS; PR01347; EPHRIN.
DR
     ProDom; PD002533; Ephrin; 1.
DR
     PROSITE; PS01299; EPHRIN; 1.
DR
     Developmental protein; Neurogenesis; Transmembrane; Glycoprotein;
KW
     Signal; Phosphorylation.
KW
                               POTENTIAL.
                      20
                 1
FT
     SIGNAL
                              EPHRIN-B1.
                      327
                21
     CHAIN
FT
                              EXTRACELLULAR (POTENTIAL).
                21 225
     DOMAIN
FT
                              POTENTIAL.
               226 246
 FT
     TRANSMEM
               247 327
                              CYTOPLASMIC (POTENTIAL).
 FT
     DOMAIN
                    327
                              PDZ RECOGNITION MOTIF (POTENTIAL).
               325
 FT
     DOMAIN
                               BY SIMILARITY.
                      93
     DISULFID
                57
 FT
                81 145
                               BY SIMILARITY.
     DISULFID
 FT
                               N-LINKED (GLCNAC. . .) (POTENTIAL).
     CARBOHYD
              131 131
 FT
                              N-LINKED (GLCNAC. . .) (POTENTIAL).
                     202
 FT
     CARBOHYD
               202
     SEQUENCE 327 AA; 36621 MW; 71230CE7F6BE5974 CRC64;
 SQ
                        32.4%; Score 600; DB 1; Length 327;
  Query Match
   Best Local Similarity 39.8%; Pred. No. 4.8e-32;
  Matches 146; Conservative 43; Mismatches 100; Indels 78; Gaps
                                                                       12;
```

QУ

```
3 GLRRLLGLLLVLYRLCSALGKNLEPVTWNSQNPRFISGKGLVLYPEIGDRLDIICPKGLF 62
Db
         66 RPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDLDLRFTIKFQEYSPNLW 125
Qу
                63 QP-----YEYYKLYMVRRDQLEACSTVIDPNVLVTCNQPGKEYRFTIKFQEFSPNYM 114
Db
        126 GHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPVSEMP 185
Qу
            115 GLEFRRNQDYYITSTSNSTLQGLENREGGVCQTRSMKIIMKVGQDP--NAVPPEQLT--- 169
Db
        186 MERDRGAAHSLEPGKENLPGDPTSNATSRGA-EGPLPPP----SMPAVAGAAGGLA 236
Qy
                   : | | | : | | | : | | |
        170 -----TTRPSKE---ADNTGKIATFGPWNGPVQNPGKSDTNLSDKPTGRWGVDGFF 217
Db
        237 LLLLGVAGAGGAMC------WRRRRAKPSE----SRHPGPGSFGRGG 273
Qу
                                      |:| | ::
                                                    : | 1 | 1 | 1
        218 NSKIAVFAAIGAGCVIFILIIIFLVVLLIKIRKRHRKHTQQAAALSLSTLASPKCSGNAG 277
Db
        274 SLGLGGGGGMGPREAEPGELGIALRGGGAADPPFCPHYEKVSGDYGHPVYIVQDGPPQSP 333
Qу
                        1
        278 S-----EPSDIIIPLR---TTENNYCPHYEKVSGDYGHPVYIVQEMPPQSP 320
Db
        334 PNIYYKV 340
QУ
            321 ANIYYKV 327
Db
RESULT 11
EFA2 BRARE
                STANDARD; PRT; 195 AA.
    EFA2 BRARE
ID
    P79727;
AC
    01-NOV-1997 (Rel. 35, Created)
DT
    01-NOV-1997 (Rel. 35, Last sequence update)
DT
     15-MAR-2004 (Rel. 43, Last annotation update)
DT
    Ephrin-A2 precursor (EPH-related receptor tyrosine kinase ligand 6)
DE
     (LERK-6) (ELF-1) (ZFEPHL3).
DE
    EFNA2 OR EPLG6 OR LERK6.
GN
     Brachydanio rerio (Zebrafish) (Danio rerio).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC.
    Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
OC
     Cyprinidae; Danio.
OC
     NCBI TaxID=7955;
OX
RN
     [1]
     SEQUENCE FROM N.A.
RP
     TISSUE=Embryo;
RC
     MEDLINE=97195707; PubMed=9043080;
     Brennan C., Monschau B., Lindberg R., Guthrie B., Drescher U.,
RA
     Bonhoeffer F., Holder N.;
RA
     "Two Eph receptor tyrosine kinase ligands control axon growth and may
RT
     be involved in the creation of the retinotectal map in the
RT
     zebrafish.";
RT
     Development 124:655-664(1997).
RL
     -!- FUNCTION: Control axon growth and may be involved in the creation
CC
        of the retino-tectal map.
CC
     -!- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor
CC
        (Potential).
CC
```

```
-!- TISSUE SPECIFICITY: Widespread expression in the embryo.
    -!- DEVELOPMENTAL STAGE: Expressed in the presumptive midbrain of
CC
       developing embryos from the six-somite stage. By 24 hours,
CC
       expressed throughout the midbrain including the region of the
CC
       presumptive tectum. At later stages, expressed in a graded fashion
CC
       throughout the tectum.
CC
    -!- SIMILARITY: Belongs to the ephrin family.
CC
    .
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
    ______
CC
    EMBL; Y09668; CAA70863.1; -.
DR
    ZFIN; ZDB-GENE-990415-66; efna2.
    InterPro; IPR008972; Cupredoxin.
DR
    InterPro; IPR001799; Ephrin.
DR
    Pfam; PF00812; Ephrin; 1.
DR
    PRINTS; PR01347; EPHRIN.
DR
    ProDom; PD002533; Ephrin; 1.
DR
    PROSITE; PS01299; EPHRIN; 1.
DR
    Developmental protein; Neurogenesis; Glycoprotein; Lipoprotein;
KW
    Membrane; GPI-anchor; Signal.
KW
                          POTENTIAL.
    SIGNAL
                1
                     16
FT
                             EPHRIN-A2.
                    174
    CHAIN
               17
FT
    PROPEP 175 195 REMOVED IN MATURE FORM (POTENTIAL).
DISULFID 57 97 BY SIMILARITY.
LIPID 174 174 GPI-anchor amidated cysteine (Potential).
CARBOHYD 32 32 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT
FT
FT
FT
    SEQUENCE 195 AA; 22688 MW; 9EE284FEB61D0C42 CRC64;
                       10.0%; Score 185; DB 1; Length 195;
  Query Match
  Best Local Similarity 29.9%; Pred. No. 1.6e-05;
  Matches 63; Conservative 21; Mismatches 71; Indels 56; Gaps
          33 VYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRARPPGPHSSPNYEFYKLYLVGGAQGRRC 92
QУ
             29 VYWNSSNSRFW-QGEYTVAVSINDYLDVYCPYYESPQPHS--RMERYILFMVNHDGYLTC 85
Db
          93 EAPPAPNLLLTCDR---PDLDLRFTIKFQEYSPNLWGHEFRSHHDYYIIATSDGTREGLE 149
Qу
                      86 EHRMRGFKRWECNRPQSPDGPLRFSEKFQLFTPFSLGFEFRPGHEYYYISSPHPNHAGKP 145
Db
         150 SLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPVSEMPMERDRGAAHSLEPGKENLPGDPTS 209
Qy
                              :||:
         146 CLK-------KPTSS------GYESPEPFLTD 169
Db
         210 NATSRGAEGPLPPPSMPAVAGAAGGLALLLL 240
QУ
             : ||:||
         170 QSQRCGADGPC-----LAVLML 186
 Db
```

```
238 AA.
                                   PRT;
                    STANDARD;
    EFA3 HUMAN
ID
    P52797;
AC
     01-OCT-1996 (Rel. 34, Created)
DΤ
     01-OCT-1996 (Rel. 34, Last sequence update)
DT
     15-MAR-2004 (Rel. 43, Last annotation update)
DT
     Ephrin-A3 precursor (EPH-related receptor tyrosine kinase ligand 3)
DΕ
     (LERK-3) (EHK1 ligand) (EHK1-L).
DE
     EFNA3 OR EPLG3 OR LERK3 OR EFL2.
GN
     Homo sapiens (Human).
OS
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC
     NCBI TaxID=9606;
OX
RN
     [1]
     SEQUENCE FROM N.A.
RΡ
     MEDLINE=95140419; PubMed=7838529;
RX
     Kozlosky C.J., Maraskovsky E., McGrew J.T., Vanden Bos T.,
RA
     Teepe M., Lyman S.D., Srinivasan S., Fletcher F.A., Gayle R.B. III,
RA
     Cerretti D.P., Beckmann M.P.;
RA
     "Ligands for the receptor tyrosine kinases hek and elk: isolation of
RT
     cDNAs encoding a family of proteins.";
RT
     Oncogene 10:299-306(1995).
RL
RN
     SEQUENCE FROM N.A.
RP
     MEDLINE=95063919; PubMed=7973638;
RX
     Davis S., Gale N.W., Aldrich T.H., Maisonpierre P.C., Lhotak V.,
RA
     Pawson T., Goldfarb M., Yancopoulos G.D.;
RA
     "Ligands for EPH-related receptor tyrosine kinases that require
RΤ
     membrane attachment or clustering for activity.";
RT
     Science 266:816-819(1994).
RL
RN
     [3]
RΡ
     SEQUENCE FROM N.A.
     TISSUE=Duodenum;
RC
     MEDLINE=22388257; PubMed=12477932;
RX
     Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA
     Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA
     Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA
     Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA
     Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA
     Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA
     Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA
     Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA
     Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA
     Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA
     Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA
     Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A.,
RA
     Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA
     Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA
      Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA
      Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
 RA
      Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
 RA
      "Generation and initial analysis of more than 15,000 full-length
 RT
      human and mouse cDNA sequences.";
 RT
      Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RL
      -!- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor.
 CC
      -!- TISSUE SPECIFICITY: Expressed in brain, skeletal muscle, spleen,
 CC
          thymus, prostate, testis, ovary, small intestine, and peripheral
 CC
          blood leukocytes.
 CC
```

```
-!- SIMILARITY: Belongs to the ephrin family.
    ______
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
    entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
    or send an email to license@isb-sib.ch).
CC
    ______
CC
    EMBL; U14187; AAC50078.1; -.
DR
    EMBL; L37360; AAA52368.1; -.
DR
    EMBL; BC017722; AAH17722.1; -.
DR
    PIR; I38849; I38849.
DR
    Genew; HGNC:3223; EFNA3.
DR
    MIM; 601381; -.
DR
    GO; GO:0005887; C:integral to plasma membrane; TAS.
DR
    GO; GO:0005005; F:transmembrane-ephrin receptor activity; TAS.
    GO; GO:0007267; P:cell-cell signaling; TAS.
DR
    InterPro; IPR008972; Cupredoxin.
DR
    InterPro; IPR001799; Ephrin.
DR
    Pfam; PF00812; Ephrin; 1.
DR
    PRINTS; PR01347; EPHRIN.
DR
    ProDom; PD002533; Ephrin; 1.
DR
    PROSITE; PS01299; EPHRIN; 1.
    Glycoprotein; Lipoprotein; Membrane; GPI-anchor; Signal.
KW
                     22 POTENTIAL.
    SIGNAL
              1
FT
                             EPHRIN-A3.
               23 214
    CHAIN
FT
                             REMOVED IN MATURE FORM (POTENTIAL).
               215 238
    PROPEP
FT
             63 110 BY SIMILARITY.

214 214 GPI-anchor amidated glycine (Potential).

38 38 N-LINKED (GLCNAC. . .) (POTENTIAL).

67 67 N-LINKED (GLCNAC. . .) (POTENTIAL).

100 100 N-LINKED (GLCNAC. . .) (POTENTIAL).

71 74 MISSING (IN REF. 2).
    DISULFID
FT
    LIPID
FT
    CARBOHYD
FΤ
    CARBOHYD
\operatorname{FT}
FT
    CARBOHYD
    CONFLICT
FT
    SEQUENCE 238 AA; 26350 MW; 8EFD6AE8FE33FDDA CRC64;
SO
                        9.7%; Score 179; DB 1; Length 238;
  Query Match
  Best Local Similarity 28.4%; Pred. No. 4.8e-05;
         65; Conservative 24; Mismatches 80; Indels 60; Gaps
                                                                    12;
           7 GPGGVRVGALLLLGVLGLVSGLSLEPVYWNSANKRFQAEGGYVLYPQIGDRLDLLCP--R 64
QУ
             24 GPG-----GALG----NRHAVYWNSSNQHLRRE-GYTVQVNVNDYLDIYCPHYN 67
Db
          65 ARPPGPHSSP----NYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDL---DLRFTIKF 117
QУ
            68 SSGVGPGAGPGPGGGAEQYVLYMVSRNGYRTCNASQGFK-RWECNRPHAPHSPIKFSEKF 126
 Db
         118 QEYSPNLWGHEFRSHHDYYIIATSDGTREGLESLQGGVCLTRGMKVLLRVGQSPRGGAVP 177
 QУ
             127 QRYSAFSLGYEFHAGHEYYYISTPTHNLH------WKCLR--MKVFVCCASTSHSG--- 174
 Db
         178 RKPVSEMP------MERDRGAAHSLE-----PGKENLP 204
 Qу
             175 EKPVPTLPQFTMGPNVKINVLEDFEGENPQVPKLEKSISGTSPKREHLP 223
 Db
```

```
RESULT 13
EFA2 MOUSE
                  STANDARD; PRT; 209 AA.
   EFA2 MOUSE
AC
    P52801;
    01-OCT-1996 (Rel. 34, Created)
DT
    01-OCT-1996 (Rel. 34, Last sequence update)
DT
    15-MAR-2004 (Rel. 43, Last annotation update)
DT
    Ephrin-A2 precursor (EPH-related receptor tyrosine kinase ligand 6)
DΕ
    (LERK-6) (ELF-1) (CEK7-ligand) (CEK7-L).
DΕ
    EFNA2 OR EPLG6 OR LERK6 OR ELF1 OR EPL6.
GN
OS
    Mus musculus (Mouse).
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OC
    NCBI TaxID=10090;
OX
RN
    [1]
    SEQUENCE FROM N.A.
RP
    STRAIN=Swiss Webster; TISSUE=Brain;
RC
    MEDLINE=95007776; PubMed=7522971;
RX
    Cheng H.J., Flanagan J.G.;
RA
     "Identification and cloning of ELF-1, a developmentally expressed
RT
     ligand for the Mek4 and Sek receptor tyrosine kinases.";
RT
    Cell 79:157-168(1994).
RL
RN
    [2]
     SEQUENCE FROM N.A.
RP
     TISSUE=Brain;
RC
    MEDLINE=95181289; PubMed=7876076;
RX
     Shao H., Lou L., Pandey A., Verderame M.F., Siever D.A., Dixit V.M.;
RA
     "cDNA cloning and characterization of a Cek7 receptor
RT
     protein-tyrosine kinase ligand that is identical to the ligand
RT
     (ELF-1) for the Mek-4 and Sek receptor protein-tyrosine kinases.";
RT
     J. Biol. Chem. 270:3467-3470(1995).
RL
     -!- SUBUNIT: Binds to the receptor tyrosine kinases EPHA3, EPHA4 and
CC
CC
        EPHA5.
     -!- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor
CC
         (Potential).
CC
     -!- SIMILARITY: Belongs to the ephrin family.
CC
     _____
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
     use by non-profit institutions as long as its content is in no way
CC
     modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
     or send an email to license@isb-sib.ch).
CC
     CC
     EMBL; U14941; AAA53636.1; -.
DR
     EMBL; U14752; AAA68520.1; -.
DR
     PIR; A54984; A54984.
DR
     MGD; MGI:102707; Efna2.
DR
     InterPro; IPR008972; Cupredoxin.
DR
     InterPro; IPR001799; Ephrin.
DR
     Pfam; PF00812; Ephrin; 1.
DR
     PRINTS; PR01347; EPHRIN.
 DR
     ProDom; PD002533; Ephrin; 1.
 DR
     PROSITE; PS01299; EPHRIN; 1.
 DR
     Glycoprotein; Lipoprotein; Membrane; GPI-anchor; Signal.
 KW
```

```
20
                             POTENTIAL.
                1
FT
    SIGNAL
              21 184
185 209
69 110
                              EPHRIN-A2.
FT
    CHAIN
                              REMOVED IN MATURE FORM (POTENTIAL).
    PROPEP
FT
                              BY SIMILARITY.
    DISULFID
    DISULFID 69 110
LIPID 184 184
FT
                              GPI-anchor amidated asparagine
FT
                               (Potential).
FT
                               N-LINKED (GLCNAC. . .) (POTENTIAL).
                     38
               38
    CARBOHYD
FT
    CARBOHYD 170 170
CARBOHYD 184 184
                              N-LINKED (GLCNAC. . .) (POTENTIAL).
FT
                    184 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT
    SEQUENCE 209 AA; 23586 MW; F1997545F25B9ABC CRC64;
SQ
                       9.5%; Score 176; DB 1; Length 209;
 Query Match
 Best Local Similarity 29.3%; Pred. No. 6.6e-05;
 Matches 58; Conservative 19; Mismatches 69; Indels 52; Gaps 7;
          33 VYWNSANKRFQAE----GGYVLYPQIGDRLDLLCPRARPPGPHSSPNYEFYKLYLVGGA 87
Qу
             1111:1 111 111:1 11:1 11:1 1
          35 VYWNRSNPRFQVSAVGDGGGYTVEVSINDYLDIYCPHYGAPLP-PAERMERYILYMVNGE 93
Db
          88 QGRRCEAPPAPNLLLTCDRPDL---DLRFTIKFQEYSPNLWGHEFRSHHDYYIIATSDGT 144
QУ
                94 GHASCDHRQRGFKRWECNRPAAPGGPLKFSEKFQLFTPFSLGFEFRPGHEYYYISATP-- 151
Db
         145 REGLESLQGGVCLTRGMKVLLRVGQSPRGGAVPRKPVSEMPMERDRGAAHSLEPGKENLP 204
QУ
         Db
         205 GDP----TSNATSRGAEG 218
Qу
             | | | | | | | |
         175 EAPEPIFTSNSSCSGLGG 192
Dh
RESULT 14
EFA2 HUMAN
                 STANDARD; PRT; 213 AA.
    EFA2 HUMAN
TD
     043921; 076020;
AC
     15-DEC-1998 (Rel. 37, Created)
DT
     15-JUL-1999 (Rel. 38, Last sequence update)
DT
     15-MAR-2004 (Rel. 43, Last annotation update)
DT
     Ephrin-A2 precursor (EPH-related receptor tyrosine kinase ligand 6)
DE
     (LERK-6) (HEK7-ligand) (HEK7-L).
     EFNA2 OR EPLG6 OR LERK6.
GN
     Homo sapiens (Human).
OS
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
     Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC
     NCBI TaxID=9606;
OX
     [1]
RN
     SEQUENCE FROM N.A.
RP
     MEDLINE=98126446; PubMed=9465306;
RX
     Cerretti D.P., Nelson N.;
RA
     "Characterization of the genes for mouse LERK-3/Ephrin-A3 (Epl3),
RT
     mouse LERK-4/Ephrin-A4 (Epl4), and human LERK-6/Ephrin-A2 (EPLG6):
RT
     conservation of intron/exon structure.";
RT
     Genomics 47:131-135(1998).
RL
RN
     SEQUENCE FROM N.A.
RΡ
     Lamerdin J.E., McCready P.M., Skowronski E., Adamson A.W.,
RA
```

```
Burkhart-Schultz K., Gordon L., Kyle A., Ramirez M., Stilwagen S.,
RA
    Phan H., Velasco N., Garnes J., Danganan L., Poundstone P.,
RA
    Christensen M., Georgescu A., Avila J., Liu S., Attix C., Andreise T.,
RA
    Trankheim M., Amico-Keller G., Coefield J., Duarte S., Lucas S.,
RA
    Bruce R., Thomas P., Quan G., Kronmiller B., Arellano A.,
RA
    Montgomery M., Ow D., Nolan M., Trong S., Kobayashi A., Olsen A.O.,
RA
    Carrano A.V.;
RA
    Submitted (MAR-1998) to the EMBL/GenBank/DDBJ databases.
RL
RN
RP
    SEQUENCE FROM N.A.
    TISSUE=Brain;
RC
    MEDLINE=99045414; PubMed=9826538;
RX
    Aasheim H.C., Pedeutour F., Grosgeorge J., Logtenberg T.;
RA
    "Cloning, chromosal mapping, and tissue expression of the gene
RT
    encoding the human Eph-family kinase ligand ephrin-A2.";
RT
    Biochem. Biophys. Res. Commun. 252:378-382(1998).
RL
    -!- SUBUNIT: Binds to the receptor tyrosine kinases EPHA3, EPHA4 and
CC
CC
        EPHA5.
    -!- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor
CC
        (Potential).
CC
    -!- SIMILARITY: Belongs to the ephrin family.
CC
CC
    This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
    between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
    the European Bioinformatics Institute. There are no restrictions on its
CC
    use by non-profit institutions as long as its content is in no way
CC
    modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
     or send an email to license@isb-sib.ch).
CC
     CC
     EMBL; U92896; AAC39577.1; -.
DR
     EMBL; U92893; AAC39577.1; JOINED.
DR
     EMBL; U92894; AAC39577.1; JOINED.
DR
     EMBL; AC004258; AAC04896.1; -.
     EMBL; AJ007292; CAA07435.1; -.
DR
     PIR; JE0322; JE0322.
DR
     Genew; HGNC: 3222; EFNA2.
DR
DR
     MIM; 602756; -.
     GO; GO:0005106; F:ephrin; TAS.
DR
     GO; GO:0007267; P:cell-cell signaling; TAS.
DR
     InterPro; IPR008972; Cupredoxin.
DR
     InterPro; IPR001799; Ephrin.
DR
     Pfam; PF00812; Ephrin; 1.
DR
     PRINTS; PR01347; EPHRIN.
DR
     ProDom; PD002533; Ephrin; 1.
DR
     PROSITE; PS01299; EPHRIN; 1.
DR
     Glycoprotein; Lipoprotein; Membrane; GPI-anchor; Signal.
KW
                                POTENTIAL.
                 1
                       24
FT
     SIGNAL
                                 EPHRIN-A2.
     CHAIN
                 25
                       188
FT
                                REMOVED IN MATURE FORM (POTENTIAL).
                189 213
     PROPEP
FT
                73 114
                                BY SIMILARITY.
     DISULFID
FT
                188 188
                                GPI-anchor amidated asparagine
FT
     LIPID
                                 (Potential).
FT
                                N-LINKED (GLCNAC. . .) (POTENTIAL).
                42
                       42
     CARBOHYD
FT
                               N-LINKED (GLCNAC. . .) (POTENTIAL).
                       174
     CARBOHYD 174
FT
                                N-LINKED (GLCNAC. . .) (POTENTIAL).
     CARBOHYD 188 188
FT
                                R \rightarrow A (IN REF. 3).
                 6
                       6
     CONFLICT
FT
```

```
25 26 RA -> PP (IN REF. 3).
29 30 AA -> RR (IN REF. 3).
FT
   CONFLICT
    CONFLICT
FT
    SEQUENCE 213 AA; 23878 MW; 33C9FB1A8168B2D0 CRC64;
SQ
                       9.5%; Score 175.5; DB 1; Length 213;
 Ouery Match
 Best Local Similarity 36.8%; Pred. No. 7.2e-05;
          43; Conservative 14; Mismatches 51; Indels 9; Gaps
                                                                       3;
 Matches
          33 VYWNSANKRFQA----EGGYVLYPQIGDRLDLLCPRARPPGPHSSPNYEFYKLYLVGGA 87
QУ
            39 VYWNRSNPRFHAGAGDDGGGYTVEVSINDYLDIYCPHYGAPLP-PAERMEHYVLYMVNGE 97
Db
          88 QGRRCEAPPAPNLLLTCDRPDL---DLRFTIKFQEYSPNLWGHEFRSHHDYYIIATS 141
Qу
             98 GHASCDHRQRGFKRWECNRPAAPGGPLKFSEKFQLFTPFSLGFEFRPGHEYYYISAT 154
Db
RESULT 15
EFA2 CHICK
                 STANDARD; PRT; 200 AA.
    EFA2 CHICK
ID
    P52802;
AC
    01-OCT-1996 (Rel. 34, Created)
DT
    01-OCT-1996 (Rel. 34, Last sequence update)
DT
    15-MAR-2004 (Rel. 43, Last annotation update)
DT
    Ephrin-A2 precursor (EPH-related receptor tyrosine kinase ligand 6)
DE
    (LERK-6) (ELF-1).
    EFNA2 OR EPLG6 OR LERK6 OR ELF1.
GN
    Gallus gallus (Chicken).
OS
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC
    Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC
OC
    Gallus.
    NCBI TaxID=9031;
OX
RN
     [1]
     SEQUENCE FROM N.A.
RP
     MEDLINE=95360981; PubMed=7634327;
RX
     Cheng H.J., Nakamoto M., Bergemann A.D., Flanagan J.G.;
RA
     "Complementary gradients in expression and binding of ELF-1 and Mek4
RT
     in development of the topographic retinotectal projection map.";
RT
     Cell 82:371-381(1995).
RL
     -!- SUBUNIT: Binds to the receptor tyrosine kinases EPHA3, EPHA4 and
CC
        EPHA5 (By similarity).
CC
     -!- SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor
CC
        (Potential).
CC
     -!- TISSUE SPECIFICITY: Expressed in a gradient across the tectum
CC
        being more strongly expressed at the posterior pole.
CC
     -!- SIMILARITY: Belongs to the ephrin family.
CC
     ______
CC
     This SWISS-PROT entry is copyright. It is produced through a collaboration
CC
     between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC
     the European Bioinformatics Institute. There are no restrictions on its
CC
     use by non-profit institutions as long as its content is in no way
CC
     modified and this statement is not removed. Usage by and for commercial
CC
     entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC
     or send an email to license@isb-sib.ch).
CC
CC
     EMBL; L40932; AAC42229.1; -.
DR
     InterPro; IPR008972; Cupredoxin.
```

```
InterPro; IPR001799; Ephrin.
DR
    Pfam; PF00812; Ephrin; 1.
    PRINTS; PR01347; EPHRIN.
DR
    ProDom; PD002533; Ephrin; 1.
DR
    PROSITE; PS01299; EPHRIN; 1.
    Glycoprotein; Lipoprotein; Membrane; GPI-anchor; Signal.
KW
                               POTENTIAL.
                     22
    SIGNAL
                1
FT
                               EPHRIN-A2.
                      175
                23
    CHAIN
FT
                              REMOVED IN MATURE FORM (POTENTIAL).
               176 200
FT
    PROPEP
               61 101
175 175
                              BY SIMILARITY.
FT
    DISULFID
                               GPI-anchor amidated asparagine
    LIPID
FT
                               (Potential).
FT
                               N-LINKED (GLCNAC. . .) (POTENTIAL).
    CARBOHYD 36 36
FT
                    N-LINKED (GLCNAC. . .) (POTENTIAL).
N-LINKED (GLCNAC. . .) (POTENTIAL).
    CARBOHYD 161 161
FT
    CARBOHYD
              175
FT
    SEQUENCE 200 AA; 23049 MW; 8FAB1AE5E45EED96 CRC64;
SQ
                        9.3%; Score 172; DB 1; Length 200;
  Query Match
  Best Local Similarity 35.3%; Pred. No. 0.00011;
 Matches 49; Conservative 16; Mismatches 58; Indels 16; Gaps
                                                                       5;
          15 ALLLLGVLGLVSGLSLEP------VYWNSANKRFQAEGGYVLYPQIGDRLDLLCPRA 65
Qy
             7 AALLAAIVG-VCVWSDDPGKVISDRYAVYWNRSNPRFH-RGDYTVEVSINDYLDIYCPHY 64
Db
          66 RPPGPHSSPNYEFYKLYLVGGAQGRRCEAPPAPNLLLTCDRPDL---DLRFTIKFQEYSP 122
Qу
                                                         |:|: ||| ::|
               | | : | | | | : | : | : |
                                                1:111
          65 EEPLP--AERMERYVLYMVNYEGHASCDHRQKGFKRWECNRPDSPSGPLKFSEKFQLFTP 122
Db
         123 NLWGHEFRSHHDYYIIATS 141
Qу
               | | | | | | | | | | | | | |
         123 FSLGFEFRPGHEYYYISAS 141
Db
```

Search completed: April 13, 2004, 09:25:56 Job time: 18.9623 secs